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Abstract 
Obesity is an epidemic health problem worldwide associated with 
increased risk of cardiovascular disease, metabolic syndrome, and cancer. Its 
incidence increased in pregnant women in the last two decades as well as 
observed in the general population. Maternal obesity is related to offspring 
obesity, and there is an increased risk of adverse outcomes for both mother and 
child. Visceral adipose tissue (VAT) is an important risk factor for metabolic 
imbalance in human subjects, also during pregnancy. So, our aim was to study 
epigenetic regulation and proteomic signature of obesity in morbid obese 
women with and without pregnancy. The first aim of this study was to 
investigate the miRNA-expression profile and the proteomic signature in VAT 
from obese women to identify miRNA/protein target pairs associated with 
obesity. Notably, most miRNAs were down-expressed in obese tissues, 
whereas most of the proteins from the investigated spots were up-expressed. 
Bioinformatics integration of miRNA expression and proteomic data 
highlighted two potential miRNA/protein target pairs: miR-141/YWHAG 
(tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, 
gamma polypeptide) and miR-520e/RAB11A (Ras-related protein RAB-11A); 
the functional interaction between these miRNAs and their target sequences on 
the corresponding mRNAs was confirmed by luciferase assays. Both RAB11A 
and YWHAG proteins are involved in glucose homeostasis; YWHAG is also 
involved in lipid metabolism. Hence, the identified miRNA/protein target pairs 
are potential players in the obese phenotype. The second aim of this study was 
to investigate the effects of maternal pre-pregnancy obesity in placental tissue 
and in human amniotic mesenchymal stem cells (hA-MSCs) from morbidly 
obese women to highlight differential expression patterns to correlate with the 
obese phenotype. The miRNA-expression profile was studied in amnion from 
obese and control women. Seven miRNAs were expressed only in amnion from 
obese women, whereas 13 miRNAs were up-expressed and 12 miRNAs down-
expressed in amnion from obese women compared to controls. Target genes of 
these miRNAs and miRNA-regulated pathways were predicted by 
bioinformatics. MiRNAs significantly down-regulated the neurotrophin, 
cancer/ErbB, mammalian target of rapamycin, insulin, adipocytokine, actin 
cytoskeleton and mitogen-activated protein kinase signaling pathways. In 
conclusion, this study shows that the miRNA profile is altered in amnion 
during obesity and we hypothesize that this could affect pathways important 
for placental growth and function, thereby contributing to an increase in the 
newborn’s risk of future metabolic diseases. In hA-MSCs from obese (Ob-) 
and non-obese (Co-) pregnant women were studied both the miRNA and 
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protein expression profiles to highlight differential expression patterns to 
correlate with the obese phenotype. Among the tested miRNAs 11 were up-
expressed and 14 were down-expressed in Ob- compared to Co-hA-MSCs. 
Interestingly, 7 miRNAs were obesity-specific, being expressed only in Ob-
hA-MSCs. Bioinformatics showed that differently expressed miRNAs 
significantly regulated genes belonging to several metabolic pathways, i.e. 
MAPK signalling, actin cytoskeleton, focal adhesion, axon guidance, insulin 
signaling, etc. Proteomic signature showed 40 differently expressed protein 
spots, 62% were increased and 38% were decreased in Ob- compared to Co-
hA-MSCs. Globally, a total of 41 proteins were identiﬁed in these spots. They 
were involved into 5 pathways: Focal adhesion, Processing in endoplasmic 
reticulum, Metabolic pathways, Regulation of actin cytoskeleton, MAPK 
signaling. Further investigations are needed to validate proteomic data and to 
identify miRNA/protein target pairs in hA-MSCs. In conclusion, these data 
highlight in Ob-hA-MSCs altered pathways that were relevant for both 
metabolic function and structural integrity. Interestingly, these pathways were 
previously found to be altered in whole placenta or in adipose tissue from 
obese women, so supporting that cellular dysfunctions are present in utero 
during obesity and likely contribute to increase the newborns’ risk for 
metabolic diseases in adult life. 
 
KEYWORDS: obesity, pregnancy, visceral adipose tissue, miRNAs, 2D-DIGE 
 
 
 
 
 
 
 
 
 
 
6 
 
1. BACKGROUND 
Obesity definition and epidemiology 
Obesity is currently considered an epidemic in developed and 
developing countries causing a major health concern that has a priority in 
public health policies (Pardo et al. 2012). More than one in three adults is 
obese in the United States, Mexico, and New Zealand, and more than one in 
four in Australia, Canada, and Chile. Rates grew rapidly in some countries 
since the 1990s, while they grew slower in other countries. A positive note is 
that the overweight rate has almost stabilized in Italy in the past ten years 
(Figure 1). However, in Italy, more than 30% of 15-year-olds are overweight or 
obese (OECD obesity update, 2014). Obesity is responsible for 1% to 3% of 
total health expenditure in most countries (5% to 10% in the USA) (OECD 
obesity update, 2014). This phenomenon is worrying, since it implies an 
increased risk of premature death from related disease, such as diabetes, 
cardiovascular disease, and certain forms of cancer (Pardo et al. 2012). A 
growing number of countries have adopted policies to prevent obesity from 
spreading further (OECD obesity update. 2014). 
 
Figure 1. Obesity rates. Since 1990s rates grew rapidly in Australia, England and United States, while in other 
countries they grew slowly (from OECD obesity update 2014). 
Obesity insurgence is characterized by an increased body weight due to 
an altered imbalance between energy intake and energy expenditure. The 
energy balance is regulated by a physiological complex, including afferent and 
efferent signals to the central nervous system (Woods and D’Alessio 2008). 
The signals coming from the periphery are constituted by gastrointestinal 
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hormones (ghrelin, GLP-1, Peptide Y, cholecystokinin, pancreatic polypeptide, 
etc.), and peptidic products released from adipose tissue and hormones, such as 
insulin, produced by other tissues. 
One of the major players in body weight regulation is leptin. This 
protein was the first to be identified among a long series of products secreted 
by adipose tissue that today is considered a true endocrine organ. The 
molecules synthesized and secreted by adipose tissue are called ’adipokines’. 
Different cell types contribute to the secretion of these molecules; for example, 
a considerable number of adipokines related to inflammation was found in the 
vascular-stromal fraction and in the matrix of adipose tissue, which is rich in 
cells of the immune system.  
Leptin produces the major peripheral signals that regulate the sense 
of satiety by acting on the melanocortin circuit. Leptin acts through its 
receptors (ObRb) in two different subpopulations of neurons in the arcuate 
nucleus. One of this expresses both orexigenic neuropeptides: Neuripeptide Y 
(NPY) and Agouti Related Protein (AgRP), whose expression is reduced by 
leptin (Schwartz et al. 2000); the other population expresses both anorexigenic 
neuropeptides: Cocaine and Amphetamine Related Transcript (CART) and α-
melanocyte stimulating hormone (α-MSH), derived from the proteolytic 
processing of the POMC gene (pro-opiomelanocortin), operated by enzymes 
pro-convertasi (PC1 and PC2). The expression of POMC is induced by leptin 
(Schwartz et al. 2000). AgRP and α-MSH compete, at hypothalamic level, to 
binding to melanocortin receptors (MC-Rs), in particular for subtype 4 
(MC4R). Under normal conditions, the interaction between the central circuits 
and peripheral signals produces a coordinated response to any change in 
nutritional status. Generally, monogenic obesity in humans is associated with 
mutations in POMC, PC1, PC2, and MC4R genes (Bellisari  2008, Chen and 
Garg 1999, Farooqi et al. 2000, Krude et al. 1998, Raffin-Sanson et al. 2003, 
Echwald et al. 1999, Challis et al. 2002, Miraglia del Giudice et al. 2001). 
These observations suggest that this pathway is important for energy 
homeostasis and that it is strictly regulated. In parallel, leptin also acts on the 
central nervous system, by inducing release of noradrenaline. Noradrenaline 
exerts its action on adipose tissue by binding to β3-adrenergic receptors, 
activating lipolysis and thermogenesis in the adipose tissue. The latter 
mechanism is responsible for the increase in energy expenditure. 
Serum leptin concentration and its expression in adipose tissue are 
directly proportional to the levels of adiposity and changes in body weight, 
making the hormone a good indicator of the deposits of fat in the body 
(Vázquez-Vela et al. 2008).  
Adiponectin is another protein secreted from adipose tissue. It is a 
protein of 30 kDa secreted by adipocytes whose circulating levels are 
decreased in presence of obesity and insulin resistance. Adiponectin is present 
in the blood in different isoforms: trimeric (low-molecular weight LMW), 
hexameric (two homotrimers), and multimeric (from 12 to 18 monomers, high 
molecular weight-HMW) which have different biological functions. The HMW 
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form has an insulin-sensitizing effect, while the LMW form exerts its effects 
centrally (Galic et al. 2010).  
Adiponectin binds to its receptors ubiquitously expressed, AdipoR1 
and AdipoR2, so activating AMP dependent kinase. The first receptor is 
expressed primarily in skeletal muscle, the second is more expressed in the 
liver, both are also present in the hypothalamus where they co-localize with the 
leptin receptor. In hypothalamus, adiponectin has opposite effects to leptin, 
through the activation of orexigenic genes and the silencing of anorexigenic 
ones. At the peripheral level, the adiponectin is involved in the phosphorylation 
of the insulin receptor and its substrate, a necessary mechanism for the 
translocation of GLUT4 transporter to the cell membrane of muscles and liver 
(Vázquez-Vela et al. 2008). In humans, adiponectin levels inversely correlate 
with insulin resistance and the metabolic syndrome and are also decreased in 
the presence of obesity. Adiponectin also counteracts the effects of TNF- 
(Tumor necrosis factor-), a pro-inflammatory molecule, inhibiting the 
expression of adhesion molecules in endothelial cells, thereby diminishing the 
atherogenic risk (Galic et al. 2010). 
The grade of obesity is evaluated by the body mass index (BMI), 
defined as the weight in kilograms divided by the height in square meters 
(kg/m2). It is the most used index from the World Health Organization (WHO). 
This classification provides that a person is overweight when the BMI is 
greater or equal to 25 and obese when the BMI is greater or equal to 30 (WHO. 
Fact sheet No 311. 2011). BMI is a strong predictor of overall mortality; above 
the optimum BMI range of about 22.5–25 kg/m² the progressive excess 
mortality is due to vascular disease (Huda et al. 2010; Lievense et al. 2002).  
Obesity is a multifactorial disease that involves interactions between 
environmental and genetic factors. Studies of families, twins, and adopted 
children, indicate that obesity is in part heritable (Miller et al. 2004). 
Monogenic form of obesity results from mutations in genes involved in the 
central pathways of food intake regulation, such as leptin and POMC (pro-
opiomelanocortin) genes (Clement and Ferrè 2003). These cases are few 
exceptions because obesity is a complex disease, and inter-individual variations 
of this phenotype are due to the action of multiple genes and environmental 
factors (Bellisari et al. 2008). The environmental/behavioral component is 
believed to affect the etiopathogenesis of obesity for the 60-70%, while the 
remaining 30-40% is due to alteration in the genetic counterpart. Studies in 
children and adolescents showed that the obesity insurgence is mostly the 
result of periods if overfeeding rather than a defect in basal energy expenditure 
(Clement and Ferrè 2003). While stored fat served as an energy reservoir 
during times of famine, in the modern commercialized world of continuous and 
ubiquitous food abundance and persistent physical inactivity, the energy 
conserving function of these genes has become a liability by promoting 
continuous fat storage (Bellisari et al. 2008).  
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Adipose tissues  
 
In mammals, it is possible recognize two distinct adipose tissues: 
white adipose tissue (White Adipose Tissue, WAT) and brown adipose tissue 
(Brown Adipose Tissue, BAT). 
WAT contains adipocytes characterized by the presence within the cell 
cytoplasm a single large vacuole of lipids, which occupies about 80% of the 
cell volume, confining the nucleus and the other organelles to the periphery of 
the cell. BAT instead contains adipocytes characterized by the presence within 
cells of numerous lipid droplets of small size and several mitochondria.  
WAT contains in addition to mature adipocytes, several multipotent 
mesenchymal stem cells (MSCs) and pre-adipocytes. The increase of the 
deposits of triglycerides (TG), in conditions of positive caloric balance, 
produces a hypertrophy of the adipose cell. When these cells reach a critical 
volume, the differentiation of mesenchymal cells is subsequently stimulated 
(adipogenesis). Adipocyte differentiation is an important component of 
hyperplasia of adipose tissue (Vázquez-Vela et al. 2008). WAT has key 
functions in the control of the metabolism through energy homeostasis, 
adipocyte diﬀerentiation, and insulin sensitivity. Besides, it aﬀects 
inﬂammation, through a control mechanism mediated by anti-inﬂammatory 
molecules and the activation of anti-inﬂammatory metabolic and immune 
pathways (Balistreri  et al. 2010). 
BAT provides energy expenditure from non-oxidative phosphorylation 
in form of heat largely for cold adaptation. The uncoupling of phosphorylation 
in BAT is due to the activity of uncoupling protein-1, expressed on the internal 
mitochondrial membrane, which by creating a proton leak exhausts the 
electrochemical gradient needed for oxidative phosphorylation. As 
consequence, BAT aﬀects energy use by producing heat from uncoupled 
oxidative phosphorylation (Balistreri  et al.2010). 
Based on the localization of WAT, it is possible to identify a subcutaneous 
adipose tissue (SAT) and a visceral adipose tissue (VAT).  
SAT deposits cover the whole body surface: in women they are particularly 
developed in gluteal-femoral region and breast, while in men they are present 
mainly in the abdomen and around the muscles of the limbs. VAT is largely 
localized in the mesenteric and omental regions, while smaller deposits are also 
present in the epicardial region and in the mediastinum. VAT represents up to 
10−20% of total fat in men and 5−8% in females. In both genders, the amount 
of visceral fat increases with age (Ibrhaim 2010). 
The risk of morbidity associated with obesity is related more to body fat 
distribution rather than total body fat. Fat accumulated in VAT is the major risk 
factor for obesity-related disorders. Because of its anatomical position, visceral 
fat venous blood is drained directly to the liver through the portal vein. This 
characteristic allows the direct access of the free fatty acids and adipokines 
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released from fat to the liver. Adipokines activate hepatic immune mechanisms 
with production of inﬂammatory mediators such as C-reactive protein (CRP). 
There are biological diﬀerences between VAT and SAT. In fact, compared 
with SAT, VAT contains more large and insulin-resistant adipocytes and 
inﬂammatory cells such as macrophages that secrete pro-inﬂammatory 
cytokines (TNF-α, IL-6, and CRP). Visceral adipocytes are more metabolically 
active and have a greater lipolytic activity than SAT adipocytes. VAT is more 
sensible to the catecholamine-induced lipolysis and less to the anti-lipolytic 
action of insulin. VAT shows a higher insulin-stimulated glucose uptake 
compared with SAT (Ibrhaim 2010). 
In addition, adipose tissues show selective gene expression patterns. 
Characterization of differences in gene expression between human 
subcutaneous adipose tissue and visceral adipose tissue also suggest genetic 
developmental heterogeneity. Particularly, they show different expression of 
genes involved in embryonic development that could play potentially important 
roles in adipocyte development and fat distribution (Gesta et al. 2006). 
 
Obesity in pregnancy 
 
The prevalence of obesity in women of child-bearing age (20-34 years 
old) has reached 28.6% in the United States population and continues to 
increase (Ma et al. 2010).  
Maternal obesity is associated with adverse consequences, both in 
mother and child (Catalano et al. 2007, Huda et al. 2010) because obesity and 
pregnancy are independently associated with insulin resistance and 
inflammation status, which may be exacerbated when combined. 
All women increase maternal fat stores during pregnancy irrespective of 
pre-pregnancy adiposity. Obese women, who have more saturated 
subcutaneous fat stores, accumulate fat more centrally than lean women. This 
visceral adiposity appears correlated more strongly to adverse metabolic 
outcomes in pregnancy including gestational diabetes mellitus, gestational 
hypertension, and preeclampsia (Huda  et al. 2010; Bartha et al. 2007). 
Maternal obesity is also accompanied by alterations in glucose 
metabolism and by perturbation in inflammatory markers, adipokines, and 
vascular dysfunction.  
In normal pregnancies, insulin secretion increases, while insulin sensitivity 
is unchanged to facilitate provision of fuel substrate for the fetus. The ability of 
insulin to suppress lipolysis is also reduced during late pregnancy, contributing 
to greater postprandial increases in free fatty acids, increased gluconeogenesis, 
and insulin-resistance (IR). Obese women are four times more likely to develop 
gestational diabetes mellitus than lean women, because they have a loss of the 
reduction in fasting glucose in early pregnancy and significant enhancement of 
peripheral and hepatic IR. In this mechanism are potentially implicated the 
release of inflammatory mediators, such as TNF-, the low release of  
adiponectin, an insulin-sensitizing hormone, and reduction in the lipogenic 
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transcription factor peroxisome proliferator activated receptor- (PPAR- 
resulting in reduced adipose tissue insulin sensitivity and increased lipolysis 
(Huda et al. 2010). 
Recently reports showed that at birth, term infants of overweight and obese 
women have increased fat mass in comparison with those of lean weight 
women (Sewell et al. 2006). The fetuses of the obese mothers were more 
insulin resistant than the fetuses of lean mothers and there was also a positive 
correlation between foetal insulin resistance and foetal adiposity (Catalano et 
al, 2009). Moreover, the risk of childhood obesity is quadrupled if the mother 
was obese before pregnancy, which suggests that the in utero environment is 
obesogenic (Li et al. 2005). The mechanisms whereby maternal obesity and 
nutrient excess in utero increased risk for future metabolic disease are poorly 
understood, but likely include changes in foetal nutrient supply in combination 
with genetic and epigenetic mechanism. The in utero environment can modify 
the gene expression of foetal genome and exerts stimulatory and inhibitory 
effects on foetal growth and adiposity (Heerwagen et al. 2010). The primary 
mechanisms that could contribute to foetal programming of obesity are 
neuronal regulation of appetite and food intake, adipose tissue physiology, and 
inflammation (Figure 2).   
During fetus development, the nucleus accumbens and the hypothalamus are 
the two areas in the brain established to link maternal diet and offspring 
feeding behavior. Animal studies showed that maternal obesity affects the 
expression of hypothalamic neuropeptides in offspring and also disrupts the 
development of hypothalamic neural projections important for the regulation of 
energy homeostasis. However additional research is needed to elucidate these 
mechanisms (Sen et al. 2012). 
Maternal over-nutrition affects the expression of genes involved in 
adipogenesis, particularly PPAR- and AMP-activated protein kinase (AMPK). 
PPAR- is a transcription factor that enhances the adipocyte differentiation; 
AMPK is a key enzyme in biosynthesis of fatty acids and represses the 
transcriptional activity of PPAR-. Animal studies showed that in adipose 
tissue from rats and sheep of obese mothers, PPAR- is increased and AMPK 
activity is repressed. These evidences suggest a role of PPAR- and AMPK in 
the increased adiposity reported in offspring of obese mother.  
The inflammatory state of obese mothers could contribute to greater 
offspring adiposity as showed in studies on pregnant rats treated with TNF-α 
and IL-6. Body weight and fat mass were increased  in their offspring respect 
to control animals. Maternal obesity also induces macrophage accumulation 
and increased inflammatory cytokine expression in placenta. The role of these 
inflammatory mediators in the programming of obesity is not fully understood 
and remains to be established how the in utero environment induces long term 
changes predisposing the offspring of obesity (Sen et al. 2012). 
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Figure 2. Mechanisms involved in transgestational obesity. The molecular mechanisms that contribute to in utero 
programming of obesity are complex and not yet fully understood. The primary mechanisms are neuronal regulation of 
appetite and food intake, adipose tissue physiology, altered energy metabolism and inflammation (from Sen et al. 
2012). 
 
Epigenetics: MicroRNAs 
The term epigenetic refers to heritable changes in gene expression that 
cannot be explained by changes in DNA sequence. There is evidence on the 
impact of different nutrients, environmental compounds, and metabolic 
situations on the epigenome. Recently studies demonstrated that maternal 
undernutrition and overnutrition can alter the foetal epigenome. 
As epigenetic changes are modulated by environmental exposures, 
epigenetics is considered the interface between genetics and the environment. 
In this sense, only environmental factors, including nutritional habits are able 
to explain the phenotypical and epigenetic differences reported in monozygotic 
twins. In fact, epigenetic mechanisms are good candidates for explaining the 
role of the diet and other environmental conditions of parents and grandparents, 
or the influence of perinatal dietary exposures as determinants of later health 
outcomes. Altered epigenetic marks are extensively studied in cancer and in 
chronic non-communicable metabolic diseases such as obesity, diabetes and 
cardiovascular diseases (Milagro et al. 2013). 
Epigenetic processes play a crucial role in determining when and where 
specific genes are expressed. Alteration in these mechanisms could lead to 
profound changes in phenotype. The principal epigenetic mechanisms are: 
DNA methylation, histone modification, and microRNAs (miRNAs).  
A common modification in mammalian genomes is the methylation at 
the 5’ position of cytosine in DNA CpG dinucleotide. Hypermethylation of 
these regions is associated with transcriptional repression, whereas their 
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hypomethylation is associated with transcriptional activation. DNA 
methylation is a stable epigenetic mark that is transmitted through DNA 
replication and cell division.  
Histone modification, such as acetylation, methylation, 
phosphorylation, occurs by histone-modifying enzymes that acts on amino acid 
residues in the histone N-terminals.  
Acetylation of histones is generally associated with active gene 
transcription. Consequently, removal of acetyl group from a histone residue by 
histone deacetylases (HDACs) represses gene transcription. The precise mode 
of action of the modified histone tails is not yet known. However, positive 
charges of lysine tails are neutralized by acetylation causing the attraction 
between DNA and histones resulting in opening of chromatin structure. An 
alternative hypothesis to the functionality of histone tail modifications is that 
specific proteins recognize and interact with the histone modifications. Other 
modifications of histones, such as methylation, can be either activating or 
repressing depending on degree of modification and specific site of the 
modification (Milagro et al. 2013). 
Among the known epigenetic mechanisms, microRNAs have recently 
emerged as an important class mRNA expression regulators. MiRNAs are 
found in all multicellular organisms, from plants to humans, and in many 
instances are highly conserved through evolution. For this reason, they are 
likely to be important for normal cellular function.  
MiRNAs have a peculiar biogenesis (Figure 3) a primary miRNA of 
several thousands of bases long is transcribed by RNA polymerase II, which is 
cleaved in the nucleus by a protein complex containing the enzyme Drosha to 
give a precursor miRNA of around 70 nucleotides in a stem-loop structure. 
This is then transported into the cytoplasm and further processed by the 
enzyme Dicer to give a short double-stranded miRNA complex, which contains 
the mature miRNA strand and a passenger strand (miRNA*), which is 
normally degraded. The mature miRNA is incorporated the RNA-induced 
silencing complex (miRISC) by associating with the Argonaute subfamily. In 
this complex, the mature miRNA is able to regulate gene expression, binding 
through partial complementary generally, for the most part to the 3’- 
untranslated region (3’-UTR) of target mRNAs, and leading at the same time to 
some degree of mRNA degradation and translation inhibition (Inui et al. 2010). 
The most stringent requirement for this interaction is a contiguous and perfect 
Watson-Crick basepairing of the miRNA 5’nucleotides 2-8, representing the 
“seed region” nucleating the interaction (Rottiers and Naar 2012). 
MiRNAs are likely to be predominantly fine tuners of gene 
expression, but there is some evidence that on reaching a critical threshold, 
they may highly repress protein production, and in so doing act as ‘switches’. 
Each miRNA may fine-tune the expression of hundreds or even 
thousands of proteins, and it is estimated that over 60% of mammalian mRNAs 
are conserved targets for miRNAs. Additionally, each mRNA may be targeted 
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by many miRNAs. This system therefore potentially has enormous regulatory 
capacity, but also possesses a complexity that can make it difficult to clarify. 
MiRNAs act as node of signaling networks essential for wide array 
of biological processes involved in regulation of a variety of biological 
processes, including appetite regulation, adipocyte differentiation, and insulin 
secretion (Heneghan et al. 2010; Ortega et al. 2010).  
 
 
 
Figure 3. Biogenesis of microRNAs. MicroRNAs (miRNAs) are transcribed as precursor RNAs from intergenic, 
intronic or polycistronic genomic loci by RNA polymerase II (Pol II). The primary miRNA (pri-miRNA) transcript 
forms a stem–loop structure that is recognized and processed by the Drosha/DGCR8 complex or the spliceosome in the 
nucleus. The precursor (pre-miRNA) hairpins from both canonical and non-canonical miRNA pathways are then 
transported by an exportin 5 and RAN-GTP-dependent process to the cytosol, where they are processed by the 
Dicer/TRBP RNase III enzyme complex to form the mature double-stranded ~22‑nucleotide miRNA. Argonaute 
proteins unwind the miRNA duplex and facilitate incorporation of the miRNA-targeting strand into the AGO-
containing RNA-induced silencing complex (RISC). The RISC–miRNA assembly is then guided to specific target 
sequences in mRNAs (Image from Mol Cell Biol 2012). 
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Placenta 
 
The placenta is generally recognized for important functions such as 
nutrition, respiration, and excretion as well as maintenance of feto-maternal 
tolerance. It maintains foetal homeostasis by carrying out a wide range of 
physiological functions. Therefore, placental perturbations, by affecting one or 
more aspects of placental structure and function, may determine long-term 
health outcomes into adulthood (Murphy et al. 2010). For example, placental 
weight correlates with foetal weight, and since foetal growth is related to adult 
outcomes, placental weight and low birth weight could predict adult diseases as 
obesity, diabetes 2, and hypertension (Barker 2005, Godfrey 2002, Osmond 
and Barker 2000, Lewis et al. 2006). In addition, changes in placental structure 
(thicker placental exchange barrier and increased placental vascular resistance) 
are directly involved in the foetal programming of cardiovascular diseases 
(Thornburg and Louey 2010). The placenta could act as a nutrient sensor, in 
fact it could modify nutrient and hormone availability to foeto-placental tissues 
in relation to environmental conditions in a manner that maximizes foetal 
growth (Jansson and Powell 2007). 
 The term placenta is discoid in shape with a diameter of 15–20 cm and 
a thickness of 2–3 cm. From the margins of chorionic disc extend the foetal 
membrane, amnion and chorion, and the endometrial decidua (Parolini et al. 
2008). The foetal component includes the amniotic and chorionic foetal 
membranes which separates fetus from the endometrium, enclosing the fetus in 
the amniotic cavity. The amnio-chorionic membrane forms the outer limits of 
the sac that encloses the foetus, while the innermost layer of the sac is the 
amniotic membrane (AM). The AM thickness varies from 0.02 mm to 0.5 mm 
and consists of an epithelial monolayer, a thick basement membrane, and an 
avascular stroma (Figure 4).  
The layer nearest to the foetus is the amniotic epithelium and consists of 
a single layer of cells uniformly arranged on the basement membrane. The 
basement membrane is one of the thickest membranes found in all human 
tissue. The support provided to the foetus by the basement membrane 
throughout gestation stands testimony to the structural integrity of this 
remarkable membrane. The compact layer of stromal matrix adjacent to the 
basement membrane forms the main fibrous skeleton of the AM. The collagens 
of the compact layer are secreted by mesenchymal cells situated in the 
fibroblast layer. Interstitial collagens (types I and III) predominate and form 
parallel bundles that maintain the mechanical integrity of AM. Collagens type 
V and VI form filamentous connections between interstitial collagens and the 
epithelial basement membrane. The intermediate layer (spongy layer or zona 
spongiosa) of the stromal matrix sits adjacent to the chorionic membrane. Its 
abundant content of proteoglycans and glycoproteins produces a spongy 
appearance in histologic preparations, and it contains a non fibrillar meshwork 
of mostly type III collagen. The spongy layer is loosely connected to the 
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chorionic membrane; hence, the AM is easily separated from the chorion by 
means of blunt dissection. AM is not just a simple avascular structure (no 
blood vessels or nerves); it has multiple metabolic functions, such as the 
transport by diffusion out of the amniotic fluid and/or from the underlining 
decidua of water and soluble materials and the production of bioactive factors, 
including vasoactive peptides, growth factors, and cytokines. The AM provides 
protection to the developing embryo against desiccation and an environment of 
suspension, in which the embryo can grow free from pressures of the structures 
that surround its body (NiKnejad et al. 2008). Foetal membranes facilitate gas 
and waste exchange and play a critical role as defensive barriers. AM also has 
an important role during birth, because the substances produced by the 
epithelium of AM allow the initiation and maintenance of uterine contractility. 
 
Figure 4. Structure of foetal membrane at term. Amniotic membrane consists of a foetal (chorion plate) and 
maternal (deciduas) component. In the figure are reported the extracellular matrix component of each layer (from 
NiKnejad et al. 2008). 
Amniotic mesenchymal stem cells (hA-MSCs) 
Human placenta draws great interest because represent a reserve of stem 
cells. Current source of stem cells are embryonic stem cells and adult type stem 
cells, but these pose many ethically and technically problems. The use of 
placenta as source of mesenchymal stem cell does not raise ethical problems 
and also has many advantages, as placenta is a tissue readily available, easily 
accessible, large number of cells can be isolated from the membranes (Mihu et 
al. 2009). The plasticity, self-renewal, and multi-lineage potential of 
mesenchymal stem cells have generated growing interest in their use in a 
constantly expanding variety of experimental regenerative applications (Klein 
and Fauza 2011). Four regions of placenta can be distinguished: amniotic 
epithelial, amniotic mesenchymal, chorionic mesenchymal, and chorionic 
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trophoblastic. From each region, different cell populations are isolated: from 
the amniotic mesenchymal region of foetal placenta are isolated:  human 
amniotic mesenchymal stromal cells (hA-MSC) (Parolini et al. 2008). Cells 
from each layer demonstrate variable plasticity. Because of their plasticity, the 
term stem cell has been used in the literature to describe a number of cells 
isolated from placenta. Self- renewal and “hierarchy”, which are normally 
considered a hallmark of stem cells, have not been clearly demonstrated in the 
different placenta derived cell types, and therefore the term “stem cell” at this 
time is not always appropriate. However, it may be interesting to mention that 
recent reports propose an alternative stem cell concept whereby plasticity is 
essential to define stemness, and self-renewal and hierarchy are optional 
characteristics (Parolini et al. 2008). According to criteria recently proposed by 
Dominici et al. for bone marrow-derived mesenchymal stromal cells (Parolini 
et al. 2008), mesenchymal cells isolated from foetal membranes should be 
termed mesenchymal stromal cells (hA-MSC). Minimal criteria for defining 
hA-MSCs are the following: 
- Adherence to plastic; 
- Formation of fibroblast colony-forming units; 
- A particular pattern of surface antigen expression; 
- Capacity to differentiate in more lineages, such as osteogenic, 
adipogenic, chondrogenic, and vascular/endhotelial; 
- Foetal origin. 
 
The hA-MSCs are isolated from the mesoderm of the amnion; the isolation 
is generally performed from term amnion dissected from the deflected part of 
the foetal membrane to minimize the presence of maternal cells. The surface 
markers expressed by hA-MSC are specific markers for mesehncymal stem 
cells such as  CD90, CD29, CD105, CD73, CD49e, but they don’t express 
hematopoietic (CD45 and CD34) and monocyte markers (CD14) (Parolini et 
al. 2008). Mihu  and colleagues had characterized them phenotipically and 
genotipically. They have observed that hA-MSC expressed Oct-3/4, SSEA-4, 
Nanog and Sox-2. Oct-3/4 and Nanog are markers of pluripotency and self-
regeneration capacity and they are essential in the formation of internal cell 
mass. SSEA-4 is a glycoprotein expressed in early embryonic development and 
it plays a role in maintenance of the non-differentiation state of stem cells. 
Another important characteristic, with crucial implication in the immunological 
tolerance of maternal organism towards the foetal organism, is the absence of 
HLA-DR transcript (Mihu et al. 2009).     
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2. AIMS OF THE STUDY 
 Etiopathogenesis of obesity is still poorly known, thus, recent evidence 
suggests that epigenetic mechanisms could play a key role in its insurgence. 
Our aim was to study both epigenetic regulation and proteomic signature of 
VAT and foetal component of placenta in morbid obese women, in order to 
identify different metabolic pattern compared to control women. 
 Particularly, the first aim of this study was to investigate miRNA and 
protein signatures in VAT from obese women, to identify metabolic pathways 
miRNA-regulated during obesity. For this purpose, the objectives are: 
1) To identify differently expressed miRNAs in VAT from obese patients 
compared with non-obese patients and to find predicted targets using 
bioinformatic tools; 
2) To identify differently expressed proteins in VAT from obese patients 
compared with non-obese patients using 2D-DIGE (Two-Dimensional 
Fluorescence Diﬀerence Gel Electrophoresis) followed by tandem mass 
spectrometry; 
3) To integrate data obtained by transcriptomic and proteomic approaches, to 
highlight miRNA-regulated proteins. 
 The second aim of this research project is to investigate, the role of 
epigenetic mechanisms of gene regulation in obese pregnant women, as risk 
factors in foetal programming of obesity. For this purpose, the objectives are 
the following:  
1) To identify differently expressed miRNAs in amnion from obese pregnant 
women compared with non-obese pregnant women and to find predicted 
targets using bioinformatics;  
2) To identify metabolic pathways that could be silenced or switched on by a 
miRNA-mediated mechanism (using bioinformatics); 
3) To identify differently expressed miRNAs in Ob-hA-MSCs compared with 
Co-hA-MSCs and to find predicted targets using bioinformatic tools; 
4) To identify differently expressed proteins in Ob-hA-MSCs compared to CO-
hA-MSCs using 2D-DIGE (Two-Dimensional Fluorescence Diﬀerence Gel 
Electrophoresis) followed by tandem mass spectrometry. 
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3. MATERIALS AND METHODS 
Obese women 
Fifteen obese women (age range: 19−65 years old, BMI [mean ±SEM] 
42.2 ± 1.6 kg/m2) and ten non-obese women (age range: 19−57 years old, BMI 
[mean ± SEM] 23.7 ± 1.2 kg/m2) were enrolled in the study. During surgery 
(gastric banding or laparoscopic cholecystectomy for obese and non-obese 
women, respectively), VAT biopsy samples were collected and frozen in liquid 
nitrogen until their use. The main anamnestic, clinical, and general 
characteristics of the enrolled subjects were recorded at admission. The day 
before surgery, a fasted blood sample was collected from all subjects and tested 
for the main biochemical parameters (glucose, cholesterol, triglycerides, AST, 
ALT, ALP, GGT) by routine methods. Written informed consent was obtained 
from all recruited subjects, and the study was approved by the Ethics 
Committee of the Faculty of Medicine of the “Federico II” University of 
Naples (Italy) . 
Obese pregnant women  
Sixteen obese (age range: 26–39 years old) and seven control pregnant 
women (age range: 26–38 years old), pre-pregnancy BMI (mean/SEM) 
40.3/1.8 kg/m2 and 22.4/1.0 kg/m2, respectively) have been recruited at the 
Dipartimento of Neuroscienze and Scienze Riproduttive and 
Odontostomatologiche, University of Naples Federico II. The exclusion criteria 
were neoplasia, viral infection, diabetes, and drug assumption. The clinical, 
personal, and family histories of the twenty three women were recorded during 
a medical interview conducted by an expert upon hospitalization. Data relative 
to each pregnancy follow-up and delivery were also recorded. The general 
characteristics of the newborn and clinical data (birth weight, length, head 
circumference, Apgar score) were recorded at birth. All patients and controls 
gave their informed consent to the study and both parents gave consent for 
their newborns. The study was performed according to the Helsinki II 
Declaration and was approved by the Ethics Committee of our Faculty. Two 
fasting peripheral blood samples were collected at delivery from all enrolled 
pregnant women. One blood sample was used for DNA extraction, whereas the 
other was centrifuged at 2,500 rpm for 15 min was stored at -80°C until 
processing. At delivery, placentas were collected by C-section from each 
enrolled women and immediately processed.  
Biochemical evaluations  
The main serum biochemical parameters were evaluated by routine 
assays. Leptin and adiponectin were measured in maternal serum and in cord 
plasma with Luminex xMAP Technology on a BioRad Multiplex Suspension 
Array System (Bio-Rad, Hemel Hempstead, Herts., UK), in compliance with 
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the manufacturer’s instructions. The ratio leptin/adiponectin (L/A) was also 
calculated. 
Cell isolation from placenta tissue 
Placentas were collected and immediately processed, following Parolini 
et al. After removal of the maternal decidua, the amnion was manually 
separated from the chorion and extensively washed 5 times in 40 mL of 
phosphate-buffered saline (PBS) containing 100 U/mL penicillin, 100 μg/mL 
streptomycin and 250 μg/mL amphotericin B (all from Sigma-Aldrich) after 
which it was mechanically minced into small pieces (Parolini et al. 2008). 
Amnion fragments were digested overnight at 4°C in ACCUMAX® reagent 
(Innovative Cell Technology, San Diego), a combination of DNase, protease, 
and collagenolytic enzymes, containing 100 U/mL penicillin, 100 μg/mL 
streptomycin, and 250 μg/mL amphotericin B. The next day, digestion 
enzymes were inactivated with complete culture medium constituted by low 
glucose D-MEM (Sigma-Aldrich) supplemented with 10% of heat-inactivated 
bovine serum (FBS), 1% of non-essential amino acids and 2% of 
Ultraglutamine (all from Lonza, Basel, Switzerland). After centrifugation at 
300g for 10 min, cell pellets and digested tissue fragments were seeded in a 
cell culture dish (BD Falcon, New York) in complete culture medium and 
incubated at 37°C in 5% CO2. One week later, digested tissue pieces were 
removed from the dish and discarded, and isolated cells formed distinct 
fibroblast colony-forming units. When the colonies reached 70% confluence, 
they were washed with PBS and detached with trypsin/EDTA (Sigma-Aldrich), 
counted, and reseeded in complete medium for expansion at a concentration of 
about 5,000/cm2 (Parolini et al. 2008). 
Cell preparation  
hA-MSCs were expanded for several passages. Absence of mycoplasma 
contamination was assessed as described previously (Mariotti et al. 2008). The 
population-doubling level was calculated for each subcultivation with the 
following equation: population doubling= [log10 (NH) ─ log10 (NI)]/ log10 
(2), where NI is the cell inoculum number and NH is cell harvest number 
(Bieback et al. 2004). The increase in population doubling was added to the 
population doubling levels of the previous passages, to yield the cumulative 
population doubling level. When 70%-80% confluent cultures had reached 
about 4 population doublings, they were detached with trypsin/EDTA, 
resuspended in PBS with 10% FBS, and processed for flow cytometry, and 
DNA, RNA, and protein extraction. Cellular viability was assessed by both 
Trypan blue dye exclusion and the analysis of light scatter proprieties in flow 
cytometry, and it was never lower than 90%.  
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DNA typing  
The foetal origin of both amnion and hA-MSCs was verified by DNA 
typing. Genomic DNA was extracted from the mother’s peripheral blood, from 
amnion samples and from hA-MSCs using the Nucleon BACC2 extraction kit 
(Illustra DNA Extraction Kit BACC2, GE Healthcare, Calfont St. Giles, Bucks, 
UK). DNA concentration was evaluated using the NanoDrop® ND-1000 UV-
Vis spectrophotometer (NanoDrop Technologies, Wilmington, DE). Genomic 
DNA (1 ng) was amplified in a final volume of 25 µL using the AmpFlSTR® 
Identifiler™ PCR Amplification Kit (Applied Biosystems, Foster City). The 
AmpFlSTR® Identifiler™ PCR Amplification Kit is a short tandem repeat 
(STR) multiplex assay that amplifies 15 repeat loci and the Amelogenin gender 
determining marker in a single PCR amplification using a primer set labeled 
with four fluorescent molecules. The amplification was performed with the 
GeneAmp PCR System 9700 (Applied Biosystems) instrument. PCR products 
were then analyzed by capillary electrophoresis on the ABI Prism 3130 
Genetic Analyzer (Applied Biosystems) together with an allelic ladder,which 
contained all the most common alleles for the analyzed loci that were present 
in Caucasian populations and both a negative- and a positive-quality control 
sample. Typically, 1µL of each sample was diluted in 18.7µL of deionized 
formamide; each sample was supplemented with 0.3µL of an internal size 
standard (LIZ 500 Applied Biosystems) labeled with an additional fluorophore. 
The samples were denatured at 95 °C for 4 min and then placed in the auto 
sampler tray (maximum of 96 samples) on the ABI Prism 3130 for automatic 
injection in the capillaries. The data were analyzed with the Gene Mapper 
Software (Applied Biosystems). 
Immunophenotyping of hA-MSCs by flow cytometry 
The expression of 38 hematopoietic, mesenchymal, endothelial, 
epithelial, and no-lineage membrane antigens was analyzed on the surface of 
hA-MSCs by four-color flow cytometry (Table 1). All monoclonal antibodies 
(MoAbs) were from Becton Dickinson (San José) except anti-CD338-APC, 
which was from R&D (Minneapolis), anti-CD-133-PE and anti-CD271-APC 
MoAbs, which were from Milenyi Biotec (Bergisch Gladbach, Germany). For 
all antibody staining experiments, at least 1x105 hA-MSCs isolated from each 
placenta sample were incubated at 4°C for 20 min with the appropriate amount 
of MoAbs, washed twice with PBS, and finally analyzed with an unmodified 
Becton-Dickinson FACSCanto II flow cytometer (Becton-Dickinson, San 
Jose), that was set up according to published guidelines (Perfetto et al. 2006). 
For each sample, the respective control was prepared in order to determine the 
level of background cellular autofluorescence without antibody staining. 
CaliBRITE beads (Becton-Dickinson) were used as quality controls across the 
study according to the manufacturer’s instructions. Daily control of CaliBRITE 
intensity showed no change in instrument sensitivity throughout the study. The 
relative voltage range for each detector was assessed una tantum at the 
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beginning of the study, using the “eight-peak” technology (Rainbow 
Calibration Particles, Becton-Dickinson, catalog no. 559123). Compensation 
was set in the FACS-DiVa (Becton-Dickinson) software, and compensated 
samples were analyzed. Samples were acquired immediately after staining 
using the FACSCanto II instrument, and at least 10,000 events were recorded 
for each monoclonal combination. Levels of CD antigen expression were 
displayed as median fluorescence intensity (MFI). The FACS-DiVa software 
(Becton-Dickinson) was used for cytometric analysis. 
RNA isolation 
  
Total RNA (including miRNAs) was purified from VAT, amnion, and hA-
MSCs using the mirVanaTM miRNA isolation kit (Ambion).  RNA 
concentration was evaluated by NanoDrop® ND-1000 UV-Vis 
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The 
total RNA isolated from VAT, amnion and hA-MSCs from non-obese females 
was pooled to serve as control in the comparison of the miRNA expression 
proﬁles of the obese females. 
 
MiRNAs expression profile  
 
TaqMan low density arrays (TLDA) micro-fluidic cards were used to 
detect and quantify mature miRNAs according to manufacturer’s instructions. 
Each TLDA Human MicroRNA Panel v1.0 card contained 365 preloaded 
human miRNA targets and two endogenous controls (small nucleolar RNAs: 
RNU48 and RNU44). TLDAs were prepared in two-steps. In the first step, 640 
ng of total RNA were reverse transcribed in eight multiplex reverse 
transcriptase (RT) reaction pools using stem loop RT primers specific for 
mature miRNA species. Then, each of the resulting eight cDNA pools was 
diluted, mixed with TaqMan Universal PCR master mix, and loaded into one of 
the eight fill ports on the TLDA microfluidic card. The card was centrifuged 
for 2 min at 1200 rpm to distribute samples to the multiple wells of the fill 
ports and sealed to prevent well-to-well contamination. Finally, the cards were 
processed on a 7900 HT Real-Time PCR System (Applied Biosystems). The 
miRNA expression values were normalized to RNU48 (endogenous control), 
and relative expression values were obtained using the ΔΔCT method (Relative 
Quantification, RQ=2-ΔΔCT) with Sequence Detection System (SDS) v2.3 and 
RQ Manager 1.2 software (Applied Biosystems). To normalize the miRNA 
data and to reduce inter-individual variability, were considered differently 
expressed miRNAs whose mean RQ levels were < 0.5 (down-expressed) or > 
2.0 (up-expressed) in most of the samples from obese compared to normal 
weight women.   
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Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) of 
miRNAs and mRNAs  
 
The expression levels of some selected miRNAs in VAT (miR-141, 
miR-200c, miR-520e, and miR-520d),  and some selected miRNAs in amnion 
(miR-422b, miR-23b, miR-338, miR-449bb, and miR-139) were also validated 
by TaqMan miRNA assays (Applied Biosystems), in accordance with the 
manufacturer’s instructions on the 7900 HT real-time PCR system (Applied 
Biosystems). The expression of one of these selected miRNAs in VAT, 
namely, miR-141, was preliminarily tested in each non-obese control, and after 
ensuring that the expression was comparable among these individuals, we 
pooled their RNAs to obtain a control against which to compare miRNA levels 
in obese women.  
The expression levels of the selected miRNAs were ﬁrst normalized to 
the endogenous control (RNU48), and then the relative expression values were 
obtained versus the non-obese control pool, using the ΔΔCT method (relative 
quantiﬁcation, RQ = 2−ΔΔCT) with SDS v2.3 and RQ Manager 1.2 software 
(Applied Biosystems). 
Real-time RT-PCR of RAB11A and YWHAG mRNAs was performed 
using gene-speciﬁc primers (RAB11a, forward: 
AACATCAGCATATTATCGTGGA and reverse: 
GATCACTCTTATTGCCCACA; YWHAG, forward: 
AGACCCAGCCCCGCGAAGAT and reverse: 
TCTGTCACGTTCTTCATGGCCGC), the Power SYBR Green PCR Master 
Mix (Applied Biosystems), and the PRISM 7900HT sequence detection system 
(Applied Biosystems).  
 
Preparation of Protein Extracts  
hA-MSCs isolated from placentas of obese women were pooled in 
group of two, so we have 6 samples of Ob-hA-MSCs and 6 samples of Co-hA-
MSCs. 
Protein extracts from hA-MSCs samples were prepared using a lysis 
buffer containing 7M urea, 2M thiourea, 4% CHAPS (3-[(3-
cholamidopropyl)dimethylammonium]-1-propane sulfonate) in 30mM Tris-
HCl, and the GeHealthcare cocktail of protease inhibitors. The suspensions 
were solubilized by sonicator. Then, the samples were centrifuged at max 
speed for 45 min at 4 °C. The clear interface of each sample was recovered and 
was transferred to a clean tube. The samples were precipitated using the 2D-
Clean-up kit (Amersham) according to the manufacturer’s instructions. Briefly, 
equal amount (300 µl) of precipitant and co-precipitant were added to each 
sample. The samples were mixed well for 15 minutes and then centrifuged at 
maximum speed for 5 minutes to obtain the pellet. The supernatant was 
removed from each sample and 25µl of de-ionized water was added on top of 
each pellet. The samples were rapidly vortexed, after 1mL of cool wash buffer 
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and 5µl of wash additive were added on each sample. The pellets were 
incubated at -20°C ON. The day after, the samples were centrifuged at 
maximum speed at 4°C for 30 minutes. The supernatant were carefully 
removed and each pellet was solubilized in 300 µl of lysis buffer. The pH of 
each samples were adjusted to 8.5 using 1M NaOH.  
Protein extracts from VAT samples were prepared using a lysis buﬀer 
containing 2% SDS, 10% glycerol, 6.25 mM Tris-HCl pH 6.8, 0.5 mM EDTA, 
20 mM NaF, 1 mM Na3VO4 (Santa Cruz Biotechnology, Santa Cruz, CA), and 
the Sigma-Aldrich cocktail of protease inhibitors. The suspensions were shaken 
in Tissue Lyser II (Qiagen) for 4 min at maximum frequency. After 30 min on 
ice, samples were centrifuged at 15000g for 10 min at 4 °C. The clear interface 
of each sample was recovered and was transferred to a clean tube. 
Protein concentrations were determined after precipitation by using 
BioRad protein reagent. Proteins extracted from VAT samples used for 
proteomic analysis were precipitated for 16 h at −20 °C with 9 volumes of a 
mix composed of acetone and methanol (9:1) and then centrifuged at 15000g 
for 30 min at 4 °C. Then, protein pellets were solubilized in a buﬀer, UTC, 
containing 7 M urea, 2 M thiourea, 4% CHAPS (3-
[(3cholamidopropyl)dimethylammonium]-1-propane sulfonate) in 30 mM Tris-
HCl. Protein concentrations were re-determined after precipitation by using 
BioRad protein reagent. 
 
Two-Dimensional Fluorescence Diﬀerence Gel Electrophoresis (2D-DIGE) 
 
Protein extracts were labeled with 240 pmol of Cy3 or Cy5 ﬂuorescent 
dye on ice, in the dark, for 30 min. To exclude preferential binding of a label to 
a set of proteins, the samples were dye-swapped. The internal standard 
containing equal amounts of proteins from each sample was labeled with Cy2. 
The same internal standard was run in all gels to normalize the experiments 
and to reduce gel-to-gel variations. Labeling reactions were stopped by adding 
1 mM lysine. Sample pairs labeled with Cy3 and Cy5 and the internal standard 
were combined and used to passively hydrate individual strips as follows: each 
mix of labeled samples was diluted in UTC solution containing 130 mM DTT, 
2% IPG Buﬀer pH 3−10 NL (GE Healthcare, Buckinghamshire, UK), 2.8% 
DeStreak reagent (GE Healthcare) in a ﬁnal volume of 400 μL. The mixtures 
were used to hydrate 24 cm IPG strips pH 3−10NL required for protein 
separation in the ﬁrst dimension. Isoelectric focusing (IEF) was run in an 
IPGphor II apparatus (GE Healthcare) according to this voltage protocol: 300 
V for 3 h, linear gradient to 600 V in 3 h, linear gradient to 1000 V in 3 h, 
linear gradient to 8000 V in 5 h, 8000 V for 6 h. After the ﬁrst dimension, the 
strips were equilibrated in equilibration buﬀer (100 mM Tris-HCl, 6 M urea, 
30% (v/v) glycerol, 2% (w/v) SDS, and trace of bromophenol blue, pH 8.0) 
containing 0.5% (w/v) DTT for 15 min and thereafter in equilibration buﬀer 
containing 4.5% (w/v) iodoacetamide for a further 15 min. The equilibrated 
strips were transferred onto 12% polyacrylamide gels for the second dimension 
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(Ettan Dalt six electrophoresis system, GE Healthcare). The SDS-PAGE 
electrophoresis was run using a Peltier-cooled DALT II Electrophoresis unit 
(GE Healthcare) at 30W. After the electrophoresis, the gels were scanned with 
a Typhoon 9400 variable mode imager (GE Healthcare) at 100 μm resolution, 
using appropriated individual excitation/emission wavelengths: 488/520 for 
Cy2, 532/580 for Cy3 and 633/670 for Cy5. The images were captured with 
Image Quant software and analyzed with DeCyder software (GE Healthcare). 
The most representative gel was chosen as a master gel to compare results 
obtained from other samples. 
Globally, two 2D-DIGE experiments were performed: the first to 
analyze VAT samples from 6 randomly selected obese and 3 non-obese 
females; the second to analyze 12 Ob-hA-MSCs and 6 Co-hA-MSCs. The 
Student’s t test was used to determine the fold change between the analyzed 
groups. Only protein spots with a p < 0.05 were investigated further.  
 
Protein Identiﬁcation with Liquid Chromatography−Tandem Mass 
Spectrometry (LC−MS/MS) 
 
Two preparative gels were carry out: the first gel using 250 μg of 
proteins from VAT and the second gel using 450 μg of proteins from hA-
MSCs. After 2D-electrophoresis, performed under the conditions reported for 
the analytical experiment, the gel was stained with SYPRO Ruby ready-to-use 
formula or Comassie Brillant protein stain, and the spot map so obtained was 
matched with the analytical reference gel. The spots diﬀerentially expressed in 
samples from obese and non-obese females were excised from the preparative 
gel using the Ettan Spot Picker robotic system (GE Healthcare). The excised 
spots were analyzed with LC−MS/MS (Functional and Structural Proteomics 
Facility, CEINGE−Biotecnologie Avanzate, Italy). The excised spots were 
washed in 50 mM ammonium bicarbonate pH 8.0 in 50% acetonitrile to a 
complete destaining. The gel pieces were resuspended in 50 mM ammonium 
bicarbonate pH 8.0 containing 100 ng of trypsin and incubated for 2 h at 4 °C 
and overnight at 37 °C. The supernatant containing the resulting peptide 
mixtures was removed, and the gel pieces were re-extracted with acetonitrile. 
The two fractions were then collected and freeze-dried. The peptide mixtures 
were further analyzed by LC−MS/MS using the LC−MSD Trap XCT Ultra 
apparatus (Agilent Technologies, Palo Alto, CA, USA) equipped with a 1100 
HPLC system and a chip cube (Agilent Technologies). After loading, the 
peptide mixture (8 μL in 0.5% TFA) was ﬁrst concentrated at 4 μL/min in 40 
nL enrichment column (Agilent Technologies chip), with 0.1% formic acid as 
eluent. The sample was then fractionated on a C18 reverse-phase capillary 
column (75 μm × 43 mm in the Agilent Technologies chip) at a ﬂow rate of 
300 nL/min, with a linear gradient of eluent B (0.1% formic acid in 
acetonitrile) in eluent A (0.1% formic acid) from 7 to 50% in 35 min. Elution 
was monitored on the mass spectrometer without a splitting device. Peptide 
analysis was performed using data-dependent acquisition of one MS scan (m/z 
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range from 400 to 2000 Da/e) followed by MS/MS scans of the three most 
abundant ions in each MS scan. Dynamic exclusion was used to acquire a more 
complete survey of the peptides by automatic recognition and temporary 
exclusion (2 min) of ions from which deﬁnitive mass spectral data had 
previously been acquired. A permanent exclusion list of the most frequent 
peptide contaminants (keratins and trypsin peptides) was included in the 
acquisition method, in order to focus on signiﬁcant data. Mass spectral data 
obtained from the LC−MS/ MS analysis were used to search a non-redundant 
protein database using an in-house version of the Mascot v. 2.1 (Matrix 
Science, Boston, MA, USA) software and NCBI database (221,338 human 
sequences, timestamp: March and April, 2009). Peptide mass values and 
sequence information from the LC−MS/MS experiments were used in the 
MS/MS ion search taking into account the Carbamidomethyl-Cys as ﬁxed 
modiﬁcation, Met oxidized, Pyro-Carbamidomethyl-Cys (with N-term 
Carbamidomethyl-Cys) and Pyro-Glu (with N-term E) as variable 
modiﬁcations. The maximum missed cleavage of 1, and a precursor ion and 
fragment ion mass tolerance of ±600 ppm and 0.6 Da, respectively, were used.  
 
Bioinformatics Analysis  
 
Biological targets of miRNAs diﬀerently expressed in VAT, amnios, 
and hA-MSCs from obese compared to non-obese females were predicted 
using the TargetScan Release 5.0 (http://www.targetscan.org) algorithm. This 
algorithm assigns a “total context score” for each predicted target. Target genes 
with a “total context score” < −0.30 were further analyzed using the KEGG 
database (http://www.genome.ad. jp/kegg/) to identify the pathways that 
involve the target genes of miRNAs and then using the Gene Ontology (GO) 
database (http://www.geneontology.org/ontologies) to identify the biological 
processes in which the proteins identiﬁed by DIGE participate. Gene ontology 
classiﬁcation of the diﬀerentially expressed proteins revealed by 2D-DIGE 
analysis was performed in the web-accessible DAVID (v 6.7) annotation 
system (http://david.abcc.ncifcrf.gov/home.jsp) and in STRING: functional 
protein annotation networks (v 9.1) (http://string-db.org/).  
 
Western Blot  
 
Protein evaluation by Western blot was performed with 35 μg of total 
proteins separated by SDS-PAGE (13% polyacrylamide gel) and electroblotted 
onto hydrophobic polyvinylidene diﬂuoride (PVDF) membranes (Amersham) 
for 19 h at 33 V. Blots were blocked with 5% BSA in TBS buﬀer with 0.1% 
Tween 20 for 2 h at room temperature. Immunoblotting was performed with 
the speciﬁc polyclonal antibody: rabbit anti-14-3-3γ (dilution 1:800), rabbit 
anti-RAB11A (1 μg/mL), and rabbit antiactin (dilution 1:800) (Abcam, 
Cambridge, UK) for 4 h. For the following incubation with primary antibody, 
membrane was washed in TBS buﬀer with 0.1% Tween 20 and incubated for 
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45 min IgG-HRP-conjugated secondary antibody (dilution 1:10000 for anti-14-
3-3γ and antiactin; 1:50000 for antiRAB11A). Immunoreactive bands were 
visualized with the chemiluminescence reagent kit (ECL Western blotting 
detection reagents, GE Healthcare). We used the same membrane for each 
immunoblot, washing it in TBS buﬀer with 0.1% Tween 20 for 10 min after 
each experiment. After each immunoblot, the membrane was exposed to X-ray 
ﬁlm (Amersham) for diﬀerent times. The images of three diﬀerent exposures 
were captured by Gel Doc XR (Bio-Rad) and quantitated with the Quantity 
One software (Bio-Rad). Each protein band was contained within a rectangular 
area, identical for each sample, and background values were subtracted from 
each band. The triplicate sample values were normalized to the corresponding 
triplicate actin values. Then, the mean values from the diﬀerent ratio 
calculations were calculated for each sample. The data were expressed as 
percent relative expression, the sample with the highest expression of either 
RAB11A or YWHAG having been set as 100%. The data obtained were used 
to obtain the corresponding box plots and p-values (Student’s t test) in the 
Microsoft Excel software. 
 
Oligonucleotides and Plasmids  
 
Chemically modiﬁed double-stranded RNA molecules (microRNA 
precursor molecules: pre-miR-520e and pre-miR-141) and pre-miR-negative 
control were purchased from Ambion (Austin, TX, USA). The ﬁnal 
concentration of pre-miR molecules and the corresponding pre-miR negative 
control were 100 nM each. The plasmids used were pGL3-control (Promega 
Corp., Madison, WI, USA) encoding for ﬁreﬂy luciferase and pRL-CMV 
encoding for Renilla luciferase (Promega Corp., Madison, WI, USA). The 
3′UTRs of RAB11A (1258−1264 bp 3′UTR) and of YWHAG (2489− 2495 bp 
3′UTR) genes, containing respectively the miR-520e and miR-141 binding 
sites, as well as the mutated 3′UTRs of these two genes (three bases of each 
seed region were changed by complementary bases), were obtained from 
genomic DNA by PCR with a sense and antisense primers carrying a XbaI 
restriction site and cloned downstream to Renilla luciferase gene in pRL-CMV 
vector in XbaI site.  
 
Cell Culture, Transfection, and Luciferase Assay  
 
Human embryonic kidney (HEK) 293 cells were cultured in DMEM 
(Invitrogen) supplemented with 2 mM glutamine (Invitrogen), 100 U/mL 
penicillin/streptomycin (Invitrogen), and 10% FBS (Invitrogen). The day 
before transfection, cells were plated in 24-well plates to allow adherence and 
to reach 70−90% conﬂuence at the time of transfection. Transfection of 
plasmids, carrying wild-type or mutant 3′UTRs, with pGL3control and each 
pre-miRNAs or pre-miR negative control (Ambion, Austin, TX, USA) in 
HEK293 was performed using Lipofectamine 2000, following the 
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manufacturer’s instructions. Fireﬂy and Renilla luciferase activities were 
measured 48 h after transfection, with the dual-luciferase reporter system 
(Promega) in a Sirius Luminometer (Berthold Detection Systems, Huntsville, 
AL, USA). All transfection experiments were done in triplicate.  
 
 
 
Statistical Analysis 
 
The investigated parameters were expressed as mean ± standard error of 
the mean (SEM) (parametric distribution) or as median value and interquartile 
range (nonparametric distributions). Student’s t test was used to compare group 
means, and a p level < 0.05 was considered statistically signiﬁcant. Statistical 
analyses were carried out with the PASW package for Windows (Ver.18; SPSS 
Inc. Headquarters, Chicago, Ill). 
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Table 1. Surface immunophenotypic profile investigated in hA-MSCs by flow cytometry 
 
Fluorochrome CD Antigen Other Names Molecular Weigth (kDa) Cell expression Function 
FITC CD9 Tspan-29 24-26 Platelets, pre-B, activated T 
Adhesion, migration, platelet 
activation 
APC CD10 CALLA 100 B/T precursors, stromal cells Endopeptidase 
PE CD13 APN 150 
Granulocytes, monocytes and their 
precursors, endothelial, epithelial cells, 
mesenchymal stem cells 
Metalloproteinase 
PE CD14 LPS-R 53-55 Monocytes, macrophages Receptor for LPS/LPB complex 
APC CD15 Lewis X _ Granulocyte, monocyte, epithelial cells Cell adhesion 
PE CD16 FCγRIIIa 50-65 Neutrophils, NK, macrophages 
Low affinity with FCγ receptor, 
mediates phagocytosis 
APC CD19 Bgp95 95 B, not on plasma cells Signal transduction 
FITC CD26 DPP IV 110 Mature thymocytes, T, B, NK cells Exoprotease, costimulation 
APC CD28 Tp44 44 Most T, thymocyte,NK and plasma cells Costimulation 
APC CD29 VLA β1-chain 130 
T, B, Granulocytes, monocytes, fibroblast, 
endothelial, NK , platelet 
Adhesion activation, embryogenesis 
and development 
FITC CD31 PECAM-1 130-140 
Monocytes, platelets, granulocytes and 
endothelial cells 
Cell adhesion 
APC CD33 My9 67 
Monocytes, granulocytes, masocytes and 
myeloid progenitors Cell adhesion 
APC CD34 My10 105-120 
Hematopoietic stem cells and progenitors, 
endothelial cells Cell adhesion 
APC CD36 Platelet GPIV 85 
Platelets, monocytes, macrophages, 
endothelial cells, erythroid precursors 
Adhesion and phagocytosis 
FITC CD40 Bp50 48 
Monocytes, macrophage, B, endothelial, 
fibroblast cells, keratinocytes 
Costimulation to B cells, growth, 
differentiation and isotype switching 
APC CD44 H-CAM 90 Leukocytes, erythrocytes and epithelial cells Rolling, homing and aggregation 
Per Cp CD45 LCA 180-220 
hematopoietic cells, except erythrocyte and 
platelet 
Critical for T and B cell receptor 
mediated activation 
FITC CD47 IAP I 50-55 
Hematopoietic, epithelial, endothelial, brain 
mesenchymal cells 
Adhesion 
FITC CD49d VLA-4 150 
B and T , monocytes, eosinophils, basophils, 
NK, dendritic cells 
Adhesion, migration, homing, 
activation 
APC CD54 ICAM-1 80-114 
Epithelial and endothelial cells monocyte. 
Low on resting lymphocyte, upregulate on 
activated 
T cell activation 
PE CD56 NCAM 175-220 Neural,  tumors, embryonic tissue, NK Homophilic and heterophilic adhesion 
PE CD58 LFA-3 40-70 
Leucocyte, erythrocyte, epithelial endothelial 
cells and fibroblast Costimulation 
FITC CD71 Transferrin recepor 95 Reticulocytes, erythroid precursor 
Controls iron intake during cell 
proliferation 
APC CD81 TAPA-1 26 B, T, monocytes, endothelial cells Signal transduction 
FITC CD90 Thy-1 25-35 
Hematopoietic stem cells, neurons, 
mesenchymal stem cells 
Inhibition of hematopoietic stem cells 
and neurons differentiation 
PE CD99 MIC2 32 
Leucocyte, NK, monocytes, endothelial and 
epithelial cells 
Leucocyte migration, T cell 
activation,cell adhesion 
PE CD105 Endoglin 90 
Endothelia and  mesenchymal stem cells 
erythroid precursors, monocytes 
Angiogenesis, modulates cellular 
response to TGFβ1 
PE CD117 c-kit 145 Hematopoietic stem cells and progenitors Crucial for hematopoietic stem cells 
PE CD133 Prominin-1 120 
Hematopoietic stem cell, endothelial, 
epithelial and neural precursors Unknown function, stem cells marker 
PE CD151 PETA-3 32 
Endothelial and epithelial cells, 
megakaryocye, platelets Adhesion 
PE CD166 ALCAM 100-105 
Neurons, activated T cells, epithelial cells, 
MSC Adhesion, T cells activation 
PE CD200 OX-2 33 
B , activated T, Thymocytes, neurons 
endothelium 
Down regulatory signal for myeloid 
cell functions 
FITC CD243 MDR-1 170 Stem cells, multi drug resistant tumours 
Influences the up-take, distribution, 
elimination of drugs 
APC CD271 NGFR 75 
Neurons, stromal and dendritic follicular 
cells Low affinity for NGF receptor 
APC CD324 E-cadherin 120 Epithelial, keratinocytes, platelet Adhesion, growth, differentiation 
APC CD338 ABCG-2 72 
Hematopoietic stem cells, liver, kidney, 
intestine, side population of stem cells 
Absorbition and excretion of 
xenobiotics 
FITC HLA-ABC Class I MHC 46 All nucleated cells and platelets Antigen presentation 
FITC HLA-DR Class II MHC 30 
B cells, monocytes, myeloid progenitors, 
activated T and dendritic cells 
Antigen presentation 
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4. RESULTS  
Patients 
 
 Table 2 reports the clinical and biochemical characteristics of obese and 
non-obese women. The two groups differ statistically for weight and BMI 
(p<0.0001). The cardiac frequency and glucose level were higher in obese 
compared to non-obese women (p=0.01 and p=0.03, respectively).  
 
Table 2. General characteristics of the obese (n=15) and non-obese (n=10) women 
 
 
 
 
 
 
 
 
 
 
 
Data are expressed as Mean (SEM) value and interquartile range (nonparametric distributions).  
a Statistically significant differences at Student’s t-test p<0.0001 
b Data are expressed as median value 
c p=0.01 
d p=0.03 
 
The clinical and biochemical characteristics of pregnant mothers and 
their newborns are summarized in Table 3 (A and B, respectively). Weight gain 
was significantly lower (P<0.05) and diastolic blood pressure was higher 
(P<0.05) in obese than in control pregnant women. Both the leptin 
concentration and the L/A ratio were higher (P<0.0001) in obese than in 
control pregnant women at delivery. Biometric characteristics did not differ 
significantly between newborns of obese and control women.  
 Women 
 Obese Non-obese 
Subjects (n) 15 10 
Age (years) 41.6 (4.4) 38.0 (3.5) 
Weight (kg) a 115.2 (6.3) 62.5 (2.6) 
Height (m) 1.7 (0.04) 1.6 (0.01) 
BMI (kg/m²) a 42.2 (1.6) 23.7 (1.2) 
Systolic blood pressure (mmHg) 133.6 (6.7) 115 (4.5) 
Diastolic blood pressure (mmHg)b 80.0 (80.0-90.0) 80.0 (70.0-80.0) 
Cardiac frequency c 80.0 (2.2) 67.6 (3.7) 
Glucose (mmol/L)d 4.9 (0.2) 4.3 (0.2) 
Cholesterol (mmol/L) 5.9 (0.5) 5.8 (0.6) 
Tryglicerides (mmol/L) 1.4 (0.1) 0.9 (0.1) 
AST (U/L) b 18.5 (16.0-21.0) 18.0 (13.5-19.0) 
ALT (U/L) b 17.0 (13.0-28.5) 14.0 (12.0-21.0) 
ALP (U/L) 79.3 (5.8) 89.2 (19.5) 
GGT (U/L) 28.5 (4.7) 17.3 (3.5) 
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Table 3. Clinical and biochemical characteristics of obese and normal weight control pregnant 
women at delivery and their newborns 
A   
Mother’s parameters Ob-pregnant 
women (n=16) 
Co-pregnant 
women (n=7) 
Age (years) 32.6 (0.9) 30.7 (1.5) 
Weight (kg) a 110.1 (5.4) 65.2 (3.6) 
Height (m) 163.3(1.6) 169.0 (1.7) 
BMI pre-pregnancy (kg/m2) a 40.3 (1.8) 22.4 (1.0) 
Weight gain in pregnancy b 8.4 (1.3) 14.3 (1.8) 
Systolic blood pressure (mmHg)  124.3 (2.7) 117.1 (5.1) 
Diastolic blood pressure (mmHg) b 82.5 (2.2) 74.2 (2.0) 
Frequency cardiac. 79.6 (1.7) 79.0 (3.7) 
Gestational age 38.4 (0.3) 38.7 (0.2) 
Glucose (mmol/L)  4.3 (0.1) 4.0 (0.3) 
Total cholesterol (mmol/L) 6.9 (0.4) 7.3 (0.1) 
Triglycerides (mmol/L) 2.8 (0.2) 2.3 (0.3) 
AST (U/L) 15 d  (12.2-26.5d) 14.8 (0.7) 
ALT (U/L) 13 d (9.2-17.7d) 12.1 (1.1) 
ALP (U/L) 124.2 (11.1) 115.0 (12.6) 
GGT (U/L) 11.0 (1.7) 8.8 (1.5) 
Leptin (L)(ng/ml) a 38.5 (2.2) 15.2 (3.3) 
Adiponectin (A)(g/ml) 6.0 (0.7) 7.5 (1.4) 
L/A a 7.7 (0.6) 2.6 (0.5) 
B     
Newborn’s parameters Ob-newborns 
(n=16) 
Co-newborns 
(n=7) 
Birth weight (kg) 3162 (0.1)  3401 (0.1) 
Length (cm) 49.6 (0.7)  50.8 (0.7) 
Head circumference (cm) 34.0 (0.4)  34.8 (0.3) 
Apgar 1’ 7.0 d (7.0-8.0 c) 7.8 (0.2) 
Apgar 5’ 9.0 d (8.5-9.0 c) 8.7 (0.1) 
Data are expressed as mean (SEM) (parametric distributions). 
Statistically significant difference at the Student’s t test. 
a P<0.0001.  
b P<0.05. 
c Median value and 25th-75th percentiles (nonparametric distribution). 
 
miRNAs expression signature in VAT from obese women 
 
MiRNAs expression proﬁle performed in VAT from 10/15 obese and 
4/10 non-obese females showed that a large set of the tested miRNAs was 
expressed in VAT both obese and non-obese women (243/365, 66%). A small 
set (50/365, 14%) was not expressed, whereas 72/365 (20%) miRNAs were 
expressed only in VAT from obese women. On the basis of the normalization 
criteria reported above, namely, miRNAs whose expression levels versus 
controls were up- or down-expressed (respectively, RQ > 2 or < 0.5) in at least 
6/10 obese females, we found that 61/243 (25%) miRNAs were down-
expressed, and 10/243 (4.1%) miRNAs were up-expressed (Table 4). The 
search for gene targets of these diﬀerentially expressed miRNAs was 
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performed by TargetScan 5.0 algorithm and their assembly in metabolic 
pathways by Kegg database. The main signiﬁcant (p< 0.01) pathways predicted 
to be aﬀected by miRNAs in VAT samples during obesity are considered. 
 
 
Table 4. Diﬀerentially Expressed miRNAs in VAT from Obese Vs Non-obese Women 
 
Down-expressed 
 miRNAs 
RQ value 
  
Down-expressed 
miRNAs 
 
RQ value 
Mean SEM 
 
Mean SEM 
hsa-miR-514 0,007 0,002  hsa-miR-489 0,240 0,085 
hsa-miR-520e 0,014 0,005  hsa-miR-451 0,242 0,099 
hsa-miR-520f 0,029 0,010  hsa-miR-615 0,248 0,083 
hsa-miR-184 0,030 0,010  hsa-miR-335 0,250 0,088 
hsa-miR-518d 0,057 0,021  hsa-miR-215 0,264 0,088 
hsa-miR-196a 0,059 0,019  hsa-miR-422b 0,271 0,090 
hsa-miR-337 0,065 0,025  hsa-miR-500 0,271 0,111 
hsa-miR-520d 0,066 0,022  hsa-miR-601 0,285 0,108 
hsa-miR-490 0,067 0,025  hsa-miR-203 0,298 0,122 
hsa-miR-508 0,069 0,022  hsa-miR-410 0,298 0,122 
hsa-miR-519c 0,073 0,026  hsa-miR-330 0,320 0,121 
hsa-miR-369-3p 0,075 0,025  hsa-miR-30a-5p 0,324 0,122 
hsa-miR-202 0,078 0,027  hsa-miR-486 0,327 0,133 
hsa-miR-141 0,079 0,025  hsa-miR-22 0,332 0,125 
hsa-miR-562 0,080 0,030  hsa-miR-181c 0,332 0,117 
hsa-miR-591 0,085 0,028  hsa-miR-30d 0,334 0,126 
hsa-miR-580 0,086 0,029  hsa-miR-101 0,346 0,141 
hsa-miR-380-5p 0,086 0,029  hsa-miR-376a 0,372 0,152 
hsa-miR-518a 0,092 0,035  hsa-miR-191 0,386 0,146 
hsa-miR-618 0,096 0,034  hsa-miR-99a 0,393 0,161 
hsa-miR-494 0,097 0,037  
Up-expressed miRNAs RQ 
hsa-miR-624 0,099 0,035  Mean SEM 
hsa-miR-519b 0,102 0,032  hsa-miR-7 0,396 0,162 
hsa-miR-185 0,113 0,043  hsa-miR-433 21,563 7,624 
hsa-miR-219 0,120 0,042  hsa-miR-520h 13,617 5,559 
hsa-miR-509 0,124 0,039  hsa-miR-153 12,447 4,705 
hsa-miR-548d 0,125 0,047  hsa-miR-579 12,047 4,553 
hsa-miR-206 0,126 0,042  hsa-miR-520b 9,400 3,553 
hsa-miR-200c 0,130 0,041  hsa-miR-616 3,954 1,495 
hsa-miR-196b 0,166 0,055  hsa-miR-296 3,872 1,463 
hsa-miR-653 0,168 0,068  hsa-miR-517c 3,342 1,365 
hsa-miR-493 0,178 0,059  hsa-miR-501 3,068 1,160 
hsa-miR-629 0,181 0,074  hsa-miR-594 2,714 1,108 
hsa-miR-198 0,187 0,062     
hsa-miR-450 0,199 0,070     
hsa-miR-375 0,202 0,071     
hsa-miR-518b 0,208 0,069     
hsa-miR-137 0,222 0,091     
hsa-miR-649 0,224 0,079     
hsa-miR-189 0,226 0,080     
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Protein expression signature in VAT from obese women  
The protein expression signature of VAT samples from 6/15 obese and 
3/10 non-obese subjects was carried out using 2D-DIGE analysis. Figure 5A 
shows the master gel used to match the whole set of 2-DE proﬁles obtained. 
 
Figure 5.  2D-DIGE of VAT proteins. Panel A shows scan of master gel used for the proteomic analysis. This gel is 
constituted by three overlapped images: (1) VAT proteins of a nonobese female labeled with Cy3 (green), (2) VAT 
proteins of an obese female labeled with Cy5 (red), and (3) VAT proteins from a mixture of the random selected 
samples (used for normalization) labeled with Cy2 (blue). Panel B shows scan of preparative gel of VAT proteins. 
Numbers correspond to differentially expressed protein spots. 
The analysis performed with DeCyder Software detected approximately 
2700 protein spots per gel in a 3−10 pH range, with a molecular mass of 
10−120 kDa. Approximately 1500 spots were matched throughout the gels. 
The DeCyder statistical analysis revealed 172 spots diﬀerentially expressed in 
obese vs non-obese VAT samples with an average ratio ≥ 1.50 for up-
expressed protein spots and ≤ −1.50 for down-expressed spots (p < 0.05). Some 
spots were excluded from further evaluation, i.e., those at the extreme right and 
left sides of the gel and those (30 spots) representing contaminating serum 
proteins. Furthermore, many spots were not objected to further investigation, 
because of their low abundance on the analytical gel or on the preparative gel. 
As a result, we focused on 33 spots with optimal features. Figure 4B shows the 
position of the 33 selected spots on the preparative gel. The latter was stained 
with SYPRO Ruby protein stain and used for automated spot picking. The 
isolated spots were digested with trypsin and then analyzed by LC− MS/MS, 
followed by database search. The relative expression ratios (in obese vs non-
obese VAT) for each of the 33 spots and their statistical values are listed in 
Table 5. Interestingly, most of the spots (32/33) were increased, and only 1 
spot (number 2312) was decreased. Globally, a total of 67 proteins were 
identiﬁed in these spots. Most of these proteins were predicted by 
bioinformatics (DAVID database) to be functionally annotated in two main 
clusters (Figure 6). Annotation cluster 1 (Figure 6 panel A) was constituted by 
34 
 
the following: (i) 5 members of the 14.3.3 family of proteins, namely, 
YWHAB, YWHAE, YWHAG, YWHAH, and YWHAZ; (ii) 9 proteins 
(YWHAB, YWHAE, YWHAZ, RAB11A, RAB7A, ANXA7, ARCN1, 
FLOT1, and SERPINF1) involved in the GOTERM_CC_FAT vesicle pathway, 
on the basis of their subcellular localization; and (iii) 7 regulated proteins 
involved in intracellular protein transport (YWHAB, YWHAE, YWHAH, 
YWHAG, YWHAZ, RAB11A, and ARCN1). Annotation cluster 2 (Figure 5 
panel B) was constituted by a predominance of metabolic enzymes clustered in 
the KEGG pathways: valine, leucine, and isoleucine degradation (6 members, 
ACAT2, ACADS, ALDH2, BCKDHA, ECHS1, and HADHB), butanoate 
metabolism (5 members, ACAT2, ACADS, ALDH2, ECHS1, and PDHAD1) 
and fatty acid metabolism (5 members, ACAT2, ACADS, ALDH2, ECHS1, 
and HADHB). 
 
Figure 6. Functional annotation of VAT proteins. Overexpressed proteins in obese females were predicted by 
bioinformatics (DAVID database) to be functionally annotated in two main clusters: (A) annotation cluster 1 and (B) 
annotation cluster 2. 
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Spot 
numbera 
DIGE 
(p-
value)b 
DIGE 
Obese 
/controlC 
Accession 
No.d Protein name 
MW 
(Da)e pI
f 
Nr. of Qualified 
Peptides / 
Coverage g 
Scoreh Gene symbol
 
i miRNA
l 
B1_750 0.035 1.7 gi/5031875 Lamin A/C isoform 2 65153 6.40 13/25% 743 LMNA  
   gi/20127454 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase 65089 6.27 7/16.5% 440 ATIC  
   gi/5803181 Stress induced phosphoprotein  1 63227 6.40 4/9% 228 STIP1  
C1_751 0.023 1.73 gi/55960506 Chaperonin containing TCP1, subunit 3 (gamma) 58505 6.46 17/43% 1043 CCT3  
   gi/4503377 Dihydropyrimidinase –like 2 62711 5.95 7/19% 465 DPYSL2  
   gi/11863154 Archain isoform 1 57630 5.89 9/19% 503 ARCN1* mir-206 
   gi/189926 Phosphoglucomutase 1 61674 6.35 4/9% 208 PGM1* mir-30a, -30d 
   gi/6009626 Brain carboxylesterase hBr1 47100 6.02 3/8% 189 CES1  
D1_ 976 0.004 1.67 gi/5453603 Chaperonin containing TCP1, subunit 2 57794 6.01 17/50% 1271 CCT2  
   gi/178390 Aldehyde dehydrogenase 56858 7.00 6/15% 387 ALDH2  
   gi/2183299 Aldehyde dehydrogenase 1 55427 6.30 5/12% 319 ALDH1  
   gi/5771523 3-phosphoglycerate dehydrogenase 57370 6.29 4/9% 225 PHGDH  
E1_993 0.011 1.78 gi/16306550 Selenium binding protein 1 52928 5.93 13/37% 711 SELENBP1  
F1_1021 0.008 2.01 gi/15620780 Glutamate carboxypeptidase 53161 5.71 3/7% 143 CNDP2  
G1_1092 0.039 1.88 gi/5174529 Methionine adenosyltransferase II, alpha 43975 6.05 2/7% 143 MAT2A* mir-30a,-30d,-22 
H1_1119 0.007 1.43 gi/4504169 Glutathione synthetase 52523 5.67 7/23% 458 GSS  
   gi/1049219 Gamma-aminobutyraldehyde dehydrogenase 54410 6.01 5/11% 306 E3  
   gi/21410323 Perilipin 56216 5.82 2/5% 112 PLIN  
A2_1154 0.003 1.61 gi/21361144 Proteasome 26S ATPase subunit 3 49458 5.13 15/50% 843 PSMC3  
   gi/340219 Vimentin 53738 5.03 4/9% 273 VIM  
   gi/7106299 Ataxin 10 54196 5.12 4/4% 241 ATXN10  
B2_1158 0.011 1.48 gi/4503571 Enolase 1 47481 7.01 13/46% 906 ENOI  
   gi/40068518 Phosphogluconate dehydrogenase 53619 6.8 6/17% 427 PGD  
C2_1173 0.003 1.87 gi/4503481 Eukaryotic translation elongation factor 1 gamma 50429 6.25 10/34% 576 EEF1G  
   gi/496902 Translation initiation factor 47088 6.08 5/7% 297 E2F1  
   gi/4504327 Mitochondrial trifunctional protein, beta subunit precursor 51547 9.45 4/9% 207 HADHB* mir-203 
D2_1174 0.006 2.08 gi/5031699 Flotillin 1 47554 7.08 4/12% 265 FLOT1  
E2_1182 0.002 2.01 gi/4502111 Annexin  VII isoform 1 50569 6.25 9/24% 526 ANXA7  
   gi/7546384 Chain A, Human branched- chain Alpha- Keto Acid Dehydrogenase 45770 6.32 4/11% 213 BCKDHA  
   gi/4099506 ErbB3 binding protein EBP1 38321 7.15 4/15% 211 PA2G4  
   gi/18379349 Vesicle amine transport protein 1 42122 5.88 2/8% 121 VAT1  
F2_1202 0.012 1.85 gi/39725934 Serine (or cysteine) proteinase inhibitor, clade F member 1 46454 5.97 11/38% 695 SERPINF1  
   gi/9836652 BSCv 47887 5.78 5/13% 305 C20ORF3  
   gi/285975 Human rab GDI 51088 5.94 2/5% 116 GDI  
   gi/515634 Ubiquinol-cytochrome C reductase core I protein 53270 5.94 2/4% 122 UQCRC1  
Table 5. Identification and characterization of  proteins differently expressed in visceral adipose tissue from obese vs non-obese females, by 2D-DIGE analysis followed by LC-MS/MS  
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   gi/338695 Beta–tubulin 50240 4.75 2/5% 121 TUBB  
G2_1221 0.045 2.61 gi/4503529 Eukaryotic translation initiation factor 4A isoform 1 46353 5.32 8/27% 487 EIF4A1  
H2_1268 0.013 1.6 gi/181914 DNA-binding protein 36086 9.20 2/7% 122   
A3_1271 0.002 1.54 gi/33415057 Transformation-related protein 14 43248 5.49 5/19% 309 TRG14  
B3_1272 0.010 1.99 gi/4557809 Ornithine aminotransferase precursor 48846 6.57 7/23% 435 OAT  
   gi/387011 Pyruvate dehydrogenase E1-alpha precursor 47098 8.79 4/9% 265 PDHA1* mir-203 
   gi/3641398 NADP-dependent isocitrate dehydrogenase 46944 6.34 2/7% 86 IDH1* mir-30a,-30d 
C3_1299 0.004 1.81 gi/24308406 Secernin 2 46989 5.44 4/16% 231 SCRN2  
   gi/6678271 TAR DNA binding protein 45053 5.85 2/7% 162 TARDBP* mir-137, -203 
D3_1352 0.006 1.67  Not identified 
E3_1410 0.023 1.59 gi/4557233 Acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain precursor 44611 8.13 8/30% 436 ACADS  
   gi/148539872 Acetyl-Coenzyme A acetyltransferase 2 41783 6.47 2/8% 99 ACAT2  
F3_1521 0.006 1.64 gi/7661704 Osteoglycin preprotein 34243 5.46 5/18% 307 OGN* mir-22 
   gi/25453472 Eukaryotic translation elongation factor 1delta 31217 4.90 4/17% 277 EFF1D  
G3_1560 0.033 1.69 gi/194373515 Unnamed protein product  (Corrisp. in Sprot a P68363 Tubulin alpha-1B chain) 33856 4.88 2/8% 151 DNAJB2  
   gi/157833780 Chain A, human Annexin V with Proline substitution by thioproline 36041 4.94 3/11% 153 ANXA5  
H3_1908 0.001 1.67 gi/24119203 Tropomyosin 3 isoform 2 29243 4.75 11/40% 598 TPM3  
   gi/4507651 Tropomyosin 4 28619 4.67 2/9% 104 TPM4  
   gi/13236577 Thiamine triphosphatase 25721 4.75 3/15% 165 THTPA  
A4_1948 0.001 1.68 gi/5803225 Tyrosine 3/tryptophan 5-monooxygenase activation protein, epsilon polypeptide 29326 4.63 15/65% 943 YWHAE  
B4_2005 0.001 1.91 gi/21464101 Tyrosine 3-monooxygenase /tryptophan 5-monooxygenase activation protein, gamma polypeptide 28456 4.80 5/21% 329 YWHAG* 
mir-141, -200c 
 
   gi/119598039 Tropomyosin 1 (alpha), isoform Cra_m 28730 4.78 4/17% 215 TPM1  
C4_2054 0.010 1.64 gi/4507953 Tyrosine 3 /tryptophan 5-monooxygenase activation protein, zeta polypeptide 27899 4.73 9/52% 629 YWHAZ* 
mir-206, 
-30a, -30d, -22 
D4_2065 0.001 1.72 gi/4507949 Tyrosine 3 /tryptophan 5-monooxygenase activation protein, beta polypeptide 28179 4.76 5/29% 310 YWHAB  
   gi/4507951 Tyrosine 3 /tryptophan 5-monooxygenase activation protein, eta polypeptide 28372 4.76 3/15% 225 YWHAH  
E4_2087 0.038 1.7 gi/4504517 Heat shock protein beta-1 22826 5.98 6/27% 330 HSPB1  
   gi/1922287 EnoylCoA hydratase 31807 8.34 5/23% 330 ECHS1  
F4_ 2229 0.007 1.64 gi/4758984 Ras-related protein Rab-11A 24492 6.12 2/11% 99 RAB11A* mir-520e, -520d 
G4_2245 0.039 1.51 gi/2204207 Glutathione S-transferase 23595 5.43 6/38% 372 GSTP1  
   gi/1174149 Small GTP binding protein Rab 7 23732 6.40 2/12% 101 RAB7A* mir-30a, -30d 
H4_2291 0.008 1.65 gi/14249382 Abhydrolase domain containing 14B 22446 5.94 5/32% 264 ABHD14B  
A5_2312 >0.001 -2.12 gi/5020074 Glyoxalase-I 20934 5.24 3/16% 166 GLO I  
   gi/17986273 Fast skeletal myosin alkali light chain 1 isoform 1f 21189 4.97 3/18% 215 MYL1  
B5_2417 0.024 2.27  Not identified 
a Spot numbering as shown in 2-DE gel in Figure 4. b p-value at “Student t” test. c Average abundance ratio (obeses/controls) as calculated by DeCyder Analysis. d Protein accession number from NCBI. e Theoretical 
molecular weight (Da). f Theoretical pI. g According to the Proposed Guidelines for the Analysis and Documentation of Peptide and Protein Identifications (Paris consensus) we included in this table the complete 
figures of merit regarding the MS identification as: number of identified peptides whose individual ion score (as provided by Mascot) was higher than the designated confidence level (95%)/Protein sequence coverage 
(%); h Identification score (Score) indicating a probabilistic measure of the goodness of the MS protein identification.i Gene symbol from NCBI. l Down-expressed miRNAs in at least 6/10 obese females, which 
targeted 3’UTR-mRNA regions of asterisk genes. In bold are indicated down-expressed miRNAs in VAT from 9 or 10/10 obese females and their targeted proteins.  
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miRNA/Protein target pairs in VAT from obese women 
To ﬁnd potential miRNA/protein target pairs, miRNA expression and 
proteomic data were integrated. Speciﬁcally, the list of the identiﬁed protein 
spots was combined with the miRNAs predicted to possess the ability to target 
the proteins. The last column of Table 5 shows the potential miRNA 
counterparts of the identiﬁed proteins, as revealed by bioinformatics tools 
(TargetScan). Among the potential miRNA/protein target pairs deriving from 
this analysis, were selected those including miRNAs down-expressed in almost 
all VAT samples (9/10 or 10/10): miR-206/ARCN1 (spot 751); miR-
141/YWHAG and miR-200c/YWHAG (spot 2005); miR206/YWHAZ (spot 
2054); miR-520d/RAB11A and miR-520e/ RAB11A (spot 2229) (bold 
characters in Table5). The expression levels of the above miRNAs (miR-206, 
miR141, miR-200c, miR-520e, and -520d) were further validated by qRT-
PCR. The qRT-PCR results, except slight diﬀerences due to the two diﬀerent 
methodologies, were in close agreement with those obtained by TaqMan array 
(respectively, mean RQ ± SEM): miR-206 (0.209 ± 0.066 vs 0.126 ± 0.042), 
miR-141 (0.099 ± 0.032 vs 0.079 ± 0.025), miR-200c (0.138 ± 0.044 vs 0.130 
± 0.041), miR-520e (0.554 ± 0.175 vs 0.014 ± 0.005), except for miR-520d, 
whose results did not diﬀer from controls in the qRT-PCR validation (0.944 ± 
0.299 vs 0.066 ± 0.022). Consequently the miR-520d was discarded in our 
following evaluations. All the miRNA/protein target pairs reported above 
warrant further investigation.  
Pathways deregulated in VAT 
 
Functional annotation clustering in the DAVID database revealed that 
ARCN1, YWHAG, YWHAZ, and RAB11A are present in the annotation 
cluster intracellular protein transport (Figure 5 panel A), which may be 
involved in the physiopathology of the adipose tissue. Among the miRNAs 
associated to these targets, miR-141 and miR-520e were accordingly regulated 
in the complete set of RNA samples (10/10) from obese VAT. Thus, the 
functional pairs miR-141/YWHAG and miR-520e/RAB11A were selected for 
further analysis.  
mRNA and Western blot  
Since the eﬀects of miRNA down-regulations may result in increased 
mRNA stability and/or mRNA translation, the transcript levels for RAB11A 
and YWHAG by qRT-PCR were tested. Both mRNAs were more abundantly 
expressed in VAT of obese women (RQ ± SEM: 6.1 ± 2.6 and 4.8 ± 0.7, 
respectively) compared to control VAT mRNA samples. Next, YWHAG and 
RAB11A protein expression were tested by Western blot in VAT from a subset 
of obese (8/15) and non-obese (7/10) females. These samples were also probed 
with an actin antibody for protein normalization. As shown in Figure 7, both 
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YWHAG and RAB11A proteins were signiﬁcantly more (p = 0.001 and p = 
0.00001, respectively) up-expressed in obese than in non-obese VAT tissues.  
 
Figure 7. Western blot for YWHAG and Rab11a evaluation. (A) An example of the Western blot evaluation of 
YWHAG and RAB11A proteins from VAT of randomly selected obese females (TO01, TO02, TO03, TO04) and 
controls (TC01, TC02, TC03). (B) The box plots of the data normalized to actin content, after densitometric analysis of 
YWHAG and RAB11A immunoblots. The data are expressed as percent relative expression, the sample with the 
highest expression of either RAB11A (p = 0.00001) or YWHAG (p = 0.001) having been set as 100%. The bottom and 
top of each box represent the 25th and 75th percentile, respectively; the thick band inside each box shows the 50th 
percentile (the median). The ends of the whiskers represent the minimum and maximum values of each group of data. 
 
Taken together, these data suggest that in VAT from obese females, there is a 
functional interplay between the mRNAs of two up-expressed proteins 
(YWHAG and RAB11A, as emerged from 2D-DIGE analysis, qRT-PCR, and 
Western blot validations) and two down-expressed miRNAs (miR-141 and 
miR-520e, respectively, as revealed by the transcriptomic screening and qRT-
PCR analysis).  
Luciferase Assay 
To determine whether the mRNAs of YWHAG and RAB11A are 
targets of miR-141 and miR-520e respectively, the regions encompassing the 
3′UTRs of the two mRNAs were cloned downstream the Renilla luciferase 
gene, under the transcriptional control of the cytomegalovirus promoter. The 
constructs were co-transfected with the pre-miRNAs for miR-141 or miR-520e, 
and as a transfection control, were used a pGL3-control expressing ﬁreﬂy 
luciferase. As shown in Figure 8, both pre-miR-520e (A) and pre-miR-141 (B) 
signiﬁcantly reduced the normalized Renilla luciferase activities of the 
constructs containing respectively the RAB11A (p = 0.004) and the YWHAG 
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3′UTRs (p = 0.02). No inhibition was observed in mutant 3′UTR of RAB11A 
(A) and YWHAG (B) constructs. These data are consistent with a functional 
interaction between the selected miRNAs and the 3′UTRs of their mRNA 
targets, thereby suggesting that changes in the levels of these two miRNAs 
may modulate the expression of RAB11A and YWHAG. 
 
Figure 8. Validation of interaction between selected miRNAs and proteins. To validate the interaction between 
miR-520e and miR-141 with respectively wild-type or mutant 3′UTR of RAB11A or YWHAG. HEK-293 cells were 
transfected with wild-type or mutant 3′UTR of RAB11A, pGL3-control, pre-miR-520e, or pre-miR-negative control 
(A) and with wild-type or mutant 3′UTR of YWHAG, pGL3-control, pre-miR-141, or pre-miR-negative control (B). 
Pre-miR-520e and the pre-miR-141 significantly inhibited the expression of a Renilla luciferase-expressing construct 
that contains the 3′UTR region of the RAB11A (p = 0.004) and YWHAG (p = 0.02), respectively. No inhibition was 
observed in mutant 3′UTR of RAB11A (A) and YWHAG (B) constructs. All experiments were done in triplicate. Error 
bars denote SEM. 
miRNA expression profile in amnion 
 The miRNA expression profiles were evaluated in the amnion from 10 
obese and 5 normal weight pregnant women. A large percentage (74%) of the 
analyzed miRNAs was expressed (271/365), whereas 26% was not (94/365). 
Most of the expressed miRNAs (90%, 243/271) did not differ between obese 
and control women and were not further investigated. On the contrary, 4.8% of 
miRNAs (13/271) were higher and 4.4% (12/271) were lower in obese than 
normal weight control (Figure 9). Interestingly, 7/271 miRNAs were obesity 
specific being expressed only in amnion from obese women (miR-422b, miR-
219, miR-575, miR-523, miR-579, miR-618 and miR-659). The expression 
levels of these miRNAs were further validated by quantitative real-time 
polymerase chain reaction and were in close agreement with those obtained 
with TaqMan array, except for the slight differences because of the two 
different methodologies. The mean RQ values in obese respect to control are 
the following: miR-422b=6.4; miR-23b=1.19; miR-338=1.25; miR-139=0.68; 
and miR-449b=0.9.  
Pathways deregulated in the amnion 
 
Bioinformatics showed that differently expressed miRNAs had a 
significant probability (p<0.01) of deregulating several genes and metabolic 
pathways (Figure 9 panel c and d). Among pathways regulated by differently 
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expressed miRNAs, the most represented pathway is cancer regulation 
(including 17 genes regulated by up-expressed miRNAs and 11 genes regulated 
by down-expressed miRNAs) following by focal adhesion (including 10 genes 
regulated by down-expressed miRNAs) and MAPK signaling (including 9 
genes regulated by up-expressed miRNAs). Moreover, there are many miRNA-
regulated genes involved in different pathways related to cell-cell interaction 
and cell structure maintenance.  
The obesity-specific miRNAs regulate 7 metabolic pathways, the most 
representative are MAPK and Cancer/Erb signaling (including 10 genes 
respectively) (Figure 10).  
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Figure 9. Differently expressed miRNAs in amnion from obese and control women and their predicted target genes. Panels (a) and (b) depict miRNAs up-expressed and down-expressed, respectively. miRNA 
expression levels are shown as Log RQ mean and s.e.m. (The miRNA expression values were first normalized to RNU48, after which, the relative quantification was calculated as: RQ=2-Ct, where 
Ct=(Ctobese(miRNA)-Ctobese (RNU48))-(Ctcalibrator (miRNA)-Ctcalibrator (RNU48))). Panels (c) and (d) show metabolic pathways (black squares) and genes targeted by miRNAs (P<0.01) up-expressed and down-
expressed, respectively. *Pathways significantly regulated by target genes of miR-615-3p were not reported by TargetScan. 
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Characterization of hA-MSCs 
The hA-MSCs were isolated from the mesenchymal layer of amniotic 
membranes obtained from all enrolled women at delivery. The foetal origin of 
isolated hA-MSCs was confirmed by STR typing of the mother’s DNA and of 
the hA-MSCs. All isolated hA-MSCs were collected after four population 
doublings. The mesenchymal origin of the isolated cells was confirmed 
evaluating morphology and immunophenotype. Cultured Ob- and Co-hA-
MSCs showed a similar fibroblastic-like morphology (Figure 11). The 
immunophenotype showed that isolated hA-MSCs expressed on the surface the 
following mesenchymal markers: CD9, CD10, CD13, CD26, CD29, CD44, 
CD47, CD49d, CD54, CD56, CD58, CD71, CD81, CD90, CD99, CD105, 
CD151, CD166, CD200. But they didn’t express on the surface hematopoietic 
antigens (CD14, CD15, CD16, CD19, CD28, CD33, CD34, CD45, and 
CD117), the endothelial marker PECAM-1/CD31, and non-lineage markers 
(thrombospondin receptor/CD36, Bp50/CD40, Prominin-1/CD133, MDR-
1/CD243, NGFR/CD271, ABCG-2/CD338, and HLA-DR).  
 
 
Figure 10. Pathways and genes predicted by bioinformatics to be regulated by obesity-specific miRNAs in amnion. The metabolic 
pathways and genes targeted by obesity-specific miRNAs (miR-422b, miR-219, miR-575, miR-579, miR-618 and miR-659) are reported 
in boxes . The arrows connect miRNAs to target genes in each pathway. *Conserved target genes of miR-523 were not predicted by 
TargetScan. 
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miRNA expression profile in hA-MSCs 
The miRNA expression profiles were evaluated in hA-MSCs isolated 
from amnion of 16 obese and 7 control women. A large set of the tested 
miRNAs was expressed in Ob- and Co-hA-MSCs (61.4% corresponding to 232 
miRNAs), whereas a small set (38.6%) was not expressed. Most of the 
expressed miRNAs (89.2%, 207/232 ) did not differ between Ob- and Co-hA-
MSCs and were not further investigated. Conversely, 4.8% of miRNAs 
(11/232) was higher and 6.0% (14/232) was lower in Ob- vs Co-hA-MSCs 
(Figure 12, panel A and B respectively). Interestingly, 7/232 miRNAs (miR-
365-3p, miR-155, miR-199b, miR-22, miR-542-5p, miR-597, and miR-629) 
were obesity-specific, being expressed only in hA-MSCs isolated from obese 
women (Figure 12, panel C). Among miRNAs differently expressed, miR-449b 
was down-expressed both in hA-MSCs and in amnion from obese compared 
normal weight control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Morphological characterization of isolated hA-MSC. The MSCs isolated from the amnion 
showed a similar fibroblastic-like morphology after four population doublings. 
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Pathways deregulated in hA-MSCs  
 
Bioinformatics showed that differently expressed miRNAs had a 
significant probability (p<0.001) of deregulating several genes and biological 
pathways (Table 6, Table 7, Table 8). The most represented pathway was 
composed by genes involved in metabolic pathways (including 57 genes 
regulated by up-expressed miRNA), followed by cancer regulation (including 
35 genes regulated by up-expressed miRNAs and 22 genes regulated by down-
expressed miRNAs) and MAPK signaling (including 26 genes targeted by up-
expressed and 15 genes by down-expressed miRNAs). The pathways 
potentially deregulated both up- and down-expressed miRNAs targeted 
different genes. 
The obesity-specific miRNAs in hA-MSCs regulate 2 pathways: 
endocytosis and cancer singalling.  
Up-expressed miRNAs in Ob- respect to Co-hA-MSCs were involved 
in the same pathways resulted also regulated by miRNAs in amnios from obese 
women, such as: pathways in cancer, MAPK signalling, ErbB signaling 
pathway, Neurotrophin signaling pathway, GnRH signaling pathway, focal 
adhesion, and axon guidance. 
Figure 12. Differently expressed miRNAs in Ob-hA-MSCs compared to Co-hA-MSCs. Panels A and B show up- and down- 
expressed miRNAs, respectively; panel C shows miRNA expressed only in Ob-hA-MSCs. MiRNAs expression levels are shown as 
LogRQ mean and sem.  
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APPL1 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1   
M
A
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GNG12 guanine nucleotide binding protein (G protein), gamma 12 
CAMK2A calcium/calmodulin-dependent protein kinase II alpha   RRAS related RAS viral (r-ras) oncogene homolog 
CCDC6 coiled-coil domain containing 6   RAPGEF2 Rap guanine nucleotide exchange factor (GEF) 2 
CCNE2 cyclin E2   CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit 
CREB1 cAMP responsive element binding protein 1   CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
CSF1R colony stimulating factor 1 receptor   MAP2K1 mitogen-activated protein kinase kinase 1 
DCC deleted in colorectal carcinoma   NLK nemo-like kinase 
E2F3 E2F transcription factor 3   PRKX protein kinase, X-linked 
EGFR epidermal growth factor receptor   KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
ELK1 ELK1, member of ETS oncogene family   ELK1 ELK1, member of ETS oncogene family 
EPAS1 endothelial PAS domain protein 1   CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta subunit 3 
FGF23 fibroblast growth factor 23   RPS6KA5 ribosomal protein S6 kinase, 90kDa, polypeptide 5 
GAB1 GRB2-associated binding protein 1   PDGFRA platelet-derived growth factor receptor, alpha polypeptide 
GRB2 growth factor receptor-bound protein 2   DUSP5 dual specificity phosphatase 5 
ITGAV integrin, alpha V   EGFR epidermal growth factor receptor 
KITLG KIT ligand   HSPA1B heat shock 70kDa protein 1B 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog   GRB2 growth factor receptor-bound protein 2 
LEF1 lymphoid enhancer-binding factor 1   PRKCB protein kinase C, beta 
MAP2K1 mitogen-activated protein kinase kinase 1   DUSP10 dual specificity phosphatase 10 
MAPK10 mitogen-activated protein kinase 10   RPS6KA4 ribosomal protein S6 kinase, 90kDa, polypeptide 4 
MET met proto-oncogene (hepatocyte growth factor receptor)   PPM1A protein phosphatase, Mg2+/Mn2+ dependent, 1A 
PAK6 p21 protein (Cdc42/Rac)-activated kinase 6   CACNB3 calcium channel, voltage-dependent, beta 3 subunit 
PAK7 p21 protein (Cdc42/Rac)-activated kinase 7   FGF23 fibroblast growth factor 23 
PDGFRA platelet-derived growth factor receptor, alpha polypeptide   MAP3K12 mitogen-activated protein kinase kinase kinase 12 
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma)   MAPK10 mitogen-activated protein kinase 10 
PPARG peroxisome proliferator-activated receptor gamma   CACNA1I calcium channel, voltage-dependent, T type, alpha 1I subunit 
PRKCB protein kinase C, beta   MAP2K4 mitogen-activated protein kinase kinase 4 
PTEN phosphatase and tensin homolog   
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n 
VEGFC vascular endothelial growth factor C 
RALGDS ral guanine nucleotide dissociation stimulator   SHC4 SHC (Src homology 2 domain containing) family, member 4 
RUNX1 runt-related transcription factor 1   PAK7 p21 protein (Cdc42/Rac)-activated kinase 7 
SHC4 SHC (Src homology 2 domain containing) family, member 4   MAP2K1 mitogen-activated protein kinase kinase 1 
VEGFA vascular endothelial growth factor A   ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
VEGFC vascular endothelial growth factor C   RELN reelin 
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SHC4 SHC (Src homology 2 domain containing) family, member 4   VEGFA vascular endothelial growth factor A 
PAK7 p21 protein (Cdc42/Rac)-activated kinase 7   ELK1 ELK1, member of ETS oncogene family 
MAP2K1 mitogen-activated protein kinase kinase 1   PDGFRA platelet-derived growth factor receptor, alpha polypeptide 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog   SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 
ELK1 ELK1, member of ETS oncogene family   EGFR epidermal growth factor receptor 
SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)   GRB2 growth factor receptor-bound protein 2 
EGFR epidermal growth factor receptor   PAK6 p21 protein (Cdc42/Rac)-activated kinase 6 
GRB2 growth factor receptor-bound protein 2   FYN FYN oncogene related to SRC, FGR, YES 
PAK6 p21 protein (Cdc42/Rac)-activated kinase 6   PRKCB protein kinase C, beta 
ABL2 v-abl Abelson murine leukemia viral oncogene homolog 2   PTEN phosphatase and tensin homolog 
AREG Amphiregulin   PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 
PRKCB protein kinase C, beta   COL1A2 collagen, type I, alpha 2 
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma)   ITGAV integrin, alpha V 
MAPK10 mitogen-activated protein kinase 10   MET met proto-oncogene (hepatocyte growth factor receptor) 
MAP2K4 mitogen-activated protein kinase kinase 4   MAPK10 mitogen-activated protein kinase 10 
GAB1 GRB2-associated binding protein 1  
 
  
CAMK2A calcium/calmodulin-dependent protein kinase II alpha  
 
  
Table 6. Pathways deregulated by up-expressed miRNAs 
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NDUFC2 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 
14.5kDa   
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GNG12 guanine nucleotide binding protein (G protein), gamma 12 
FUK Fucokinase   RRAS related RAS viral (r-ras) oncogene homolog 
PPCS phosphopantothenoylcysteine synthetase   WASF1 WAS protein family, member 1 
DGKZ diacylglycerol kinase, zeta   SSH1 slingshot homolog 1 (Drosophila) 
UGP2 UDP-glucose pyrophosphorylase 2   PAK7 p21 protein (Cdc42/Rac)-activated kinase 7 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2   MAP2K1 mitogen-activated protein kinase kinase 1 
SDHC succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa   ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A   KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
XYLT1 xylosyltransferase I   ENAH enabled homolog (Drosophila) 
SGMS1 sphingomyelin synthase 1   PDGFRA platelet-derived growth factor receptor, alpha polypeptide 
ADO 2-aminoethanethiol (cysteamine) dioxygenase   EGFR epidermal growth factor receptor 
SLC33A1 solute carrier family 33 (acetyl-CoA transporter), member 1   PAK6 p21 protein (Cdc42/Rac)-activated kinase 6 
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1   WASL Wiskott-Aldrich syndrome-like 
MGAT5B mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B   LIMK1 LIM domain kinase 1 
INPP1 inositol polyphosphate-1-phosphatase   CHRM5 cholinergic receptor, muscarinic 5 
PGAP1 post-GPI attachment to proteins 1   PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 
BCAT2 branched chain amino-acid transaminase 2, mitochondrial   ITGAV integrin, alpha V 
CDS1 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1   PIKFYVE phosphoinositide kinase, FYVE finger containing 
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa (NADH-coenzyme Q reductase)   FGF23 fibroblast growth factor 23 
ALDH4A1 aldehyde dehydrogenase 4 family, member A1   PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, beta 
GNS glucosamine (N-acetyl)-6-sulfatase   
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DGKZ diacylglycerol kinase, zeta 
FUT9 fucosyltransferase 9 (alpha (1,3) fucosyltransferase)   PTEN phosphatase and tensin homolog 
NMNAT2 nicotinamide nucleotide adenylyltransferase 2   PRKCB protein kinase C, beta 
MGAT4A mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A   DGKI diacylglycerol kinase, iota 
ALG13 asparagine-linked glycosylation 13 homolog (S. cerevisiae)   ITPR1 inositol 1,4,5-trisphosphate receptor, type 1 
FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase)   PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 
MAN2A1 mannosidase, alpha, class 2A, member 1   PIKFYVE phosphoinositide kinase, FYVE finger containing 
ATP6V0A2 ATPase, H+ transporting, lysosomal V0 subunit a2   DGKB diacylglycerol kinase, beta 90kDa 
ACSL4 acyl-CoA synthetase long-chain family member 4   INPP1 inositol polyphosphate-1-phosphatase 
DGKB diacylglycerol kinase, beta 90kDa   DGKE diacylglycerol kinase, epsilon 64kDa 
MMAB methylmalonic aciduria (cobalamin deficiency) cblB type   CDS1 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 
DNMT1 DNA (cytosine-5-)-methyltransferase 1   PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, beta 
CTH cystathionase (cystathionine gamma-lyase)   
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CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit 
ALG9 asparagine-linked glycosylation 9, alpha-1,2-mannosyltransferase homolog (S. cerevisiae)   CACNA1A 
calcium channel, voltage-dependent, P/Q type, alpha 1A 
subunit 
PGM1 phosphoglucomutase 1   P2RX7 purinergic receptor P2X, ligand-gated ion channel, 7 
GCNT2 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)   PRKX protein kinase, X-linked 
GALNT5 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5)   ADORA2B adenosine A2b receptor 
LDHA lactate dehydrogenase A   PDGFRA platelet-derived growth factor receptor, alpha polypeptide 
AK4 adenylate kinase 4   EGFR epidermal growth factor receptor 
ST6GALN
AC3 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 3   GRM5 glutamate receptor, metabotropic 5 
GALNT7 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T7)   PTGER3 prostaglandin E receptor 3 (subtype EP3) 
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble   ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
SPTLC2 serine palmitoyltransferase, long chain base subunit 2   PRKCB protein kinase C, beta 
PDHX pyruvate dehydrogenase complex, component X   ITPR1 inositol 1,4,5-trisphosphate receptor, type 1 
DGKE diacylglycerol kinase, epsilon 64kDa   CHRM5 cholinergic receptor, muscarinic 5 
GLCE glucuronic acid epimerase   ADRB1 adrenoceptor beta 1 
UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1   ADCY3 adenylate cyclase 3 
ATP6V1F ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F   CACNA1I calcium channel, voltage-dependent, T type, alpha 1I subunit 
DGKI diacylglycerol kinase, iota   CAMK2A calcium/calmodulin-dependent protein kinase II alpha 
GCH1 GTP cyclohydrolase 1   
N
-G
ly
ca
n 
bi
os
yn
th
es
is 
ALG9 asparagine-linked glycosylation 9, alpha-1,2-mannosyltransferase homolog (S. cerevisiae) 
ALDOA aldolase A, fructose-bisphosphate   MGAT4A mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A 
B3GALT2 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2   ALG13 asparagine-linked glycosylation 13 homolog (S. cerevisiae) 
PAFAH1B2 platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (30kDa)   FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 
GPAM glycerol-3-phosphate acyltransferase, mitochondrial   MAN2A1 mannosidase, alpha, class 2A, member 1 
B4GALT3 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3   MGAT5B mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B 
PGAM1 phosphoglycerate mutase 1 (brain)   B4GALT3 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3 
ST6GAL2 ST6 beta-galactosamide alpha-2,6-sialyltranferase 2   ST6GAL2 ST6 beta-galactosamide alpha-2,6-sialyltranferase 2 
PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, beta  
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GRB2 growth factor receptor-bound protein 2   
In
su
lin
 si
gn
al
in
g 
pa
th
w
ay
s 
GRB2 growth factor receptor-bound protein 2 
PRKCB protein kinase C, beta  PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit ITPR1 inositol 1,4,5-trisphosphate receptor, type 1  PPP1R3B protein phosphatase 1, regulatory subunit 3B MAP2K1 mitogen-activated protein kinase kinase 1  IRS1 insulin receptor substrate 1 PRKX protein kinase, X-linked  TSC1 tuberous sclerosis 1 
ADCY3 adenylate cyclase 3  SHC4 
SHC (Src homology 2 domain containing) family, member 
4 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  MAP2K1 mitogen-activated protein kinase kinase 1 ELK1 ELK1, member of ETS oncogene family  PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) MAPK10 mitogen-activated protein kinase 10  PRKX protein kinase, X-linked MAP2K4 mitogen-activated protein kinase kinase 4  KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)  ELK1 ELK1, member of ETS oncogene family CAMK2A calcium/calmodulin-dependent protein kinase II alpha  FLOT2 flotillin 2 EGFR epidermal growth factor receptor  MAPK10 mitogen-activated protein kinase 10 
G
ap
 ju
nc
tio
n 
GRB2 growth factor receptor-bound protein 2   PRKAR2A protein kinase, cAMP-dependent, regulatory, type II, alpha 
PRKCB protein kinase C, beta   
D
or
so
-v
en
tr
al
 
ax
is 
fo
rm
at
io
n GRB2 growth factor receptor-bound protein 2 
ITPR1 inositol 1,4,5-trisphosphate receptor, type 1   KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
MAP2K1 mitogen-activated protein kinase kinase 1   NOTCH1 notch 1 
ADRB1 adrenoceptor beta 1   EGFR epidermal growth factor receptor 
PRKX protein kinase, X-linked   FMN2 formin 2 
ADCY3 adenylate cyclase 3   MAP2K1 mitogen-activated protein kinase kinase 1 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog   
Ba
ct
er
ia
l i
nv
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io
n 
of
 e
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th
el
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l 
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SHC4 SHC (Src homology 2 domain containing) family, member 4 
PDGFRA platelet-derived growth factor receptor, alpha polypeptide   WASF1 WAS protein family, member 1 
SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)   WASL Wiskott-Aldrich syndrome-like 
EGFR epidermal growth factor receptor   ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
GRM5 glutamate receptor, metabotropic 5   PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 
N
eu
ro
tr
op
hi
n 
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g 
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w
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s 
GRB2 growth factor receptor-bound protein 2   MET met proto-oncogene (hepatocyte growth factor receptor) 
IRS1 insulin receptor substrate 1   GAB1 GRB2-associated binding protein 1 
SHC4 SHC (Src homology 2 domain containing) family, member 4   SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 
NGFRAP1 nerve growth factor receptor (TNFRSF16) associated protein 1   ARHGEF26 Rho guanine nucleotide exchange factor (GEF) 26 
MAP2K1 mitogen-activated protein kinase kinase 1   
En
do
cy
to
sis
 
EPN2 epsin 2 
YWHAQ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide   VPS37A vacuolar protein sorting 37 homolog A (S. cerevisiae) 
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma)   RNF41 ring finger protein 41 
RPS6KA4 ribosomal protein S6 kinase, 90kDa, polypeptide 4   VPS37B vacuolar protein sorting 37 homolog B (S. cerevisiae) 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog   ADRB1 adrenoceptor beta 1 
PSEN1 presenilin 1   MET met proto-oncogene (hepatocyte growth factor receptor) 
MAPK10 mitogen-activated protein kinase 10   FAM125B family with sequence similarity 125, member B 
RPS6KA5 ribosomal protein S6 kinase, 90kDa, polypeptide 5   PDGFRA platelet-derived growth factor receptor, alpha polypeptide 
GAB1 GRB2-associated binding protein 1   GIT2 G protein-coupled receptor kinase interacting ArfGAP 2 
CAMK2A calcium/calmodulin-dependent protein kinase II alpha   SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 
A
xo
n 
G
ui
da
nc
e 
PAK6 p21 protein (Cdc42/Rac)-activated kinase 6   PARD6B par-6 partitioning defective 6 homolog beta (C. elegans) 
SRGAP2 SLIT-ROBO Rho GTPase activating protein 2   EGFR epidermal growth factor receptor 
FYN FYN oncogene related to SRC, FGR, YES   NEDD4 neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase 
EPHB2 EPH receptor B2   HSPA1B heat shock 70kDa protein 1B 
SEMA4C sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4C   PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, beta 
SEMA4F sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4F   CSF1R colony stimulating factor 1 receptor 
PAK7 p21 protein (Cdc42/Rac)-activated kinase 7  
 
  DCC deleted in colorectal carcinoma  
 
  LIMK1 LIM domain kinase 1  
 
  RGS3 regulator of G-protein signaling 3  
 
  
SEMA7A semaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)  
 
  
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  
 
  MET met proto-oncogene (hepatocyte growth factor receptor)  
 
  
EFNB1 ephrin-B1  
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CASP3 caspase 3, apoptosis-related cysteine peptidase 
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 
COL4A6 collagen, type IV, alpha 6 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 
DVL3 transforming growth factor, beta receptor 1 
EDN1 endothelin 1 
EDNRB endothelin receptor type B 
FAS Fas (TNF receptor superfamily, member 6) 
FZD3 frizzled family receptor 3 
FZD4 frizzled family receptor 4 
FZD6 frizzled family receptor 6 
IGF1R insulin-like growth factor 1 receptor 
LAMA3 laminin, alpha 3 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 
RELA v-rel reticuloendotheliosis viral oncogene homolog A (avian) 
SMAD2 SMAD family member 2 
STK4 serine/threonine kinase 4 
TGFBR1 transforming growth factor, beta receptor 1 
TGFBR2 transforming growth factor, beta receptor II (70/80kDa) 
WNT11 wingless-type MMTV integration site family, member 11 
WNT4 wingless-type MMTV integration site family, member 4 
  
M
A
PK
 si
gn
al
lin
g 
pa
th
w
ay
s 
CASP3 caspase 3, apoptosis-related cysteine peptidase 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 
RAP1B RAP1B, member of RAS oncogene family 
TGFBR1 transforming growth factor, beta receptor 1 
MAP4K3 mitogen-activated protein kinase kinase kinase kinase 3 
NGF nerve growth factor (beta polypeptide) 
TGFBR2 transforming growth factor, beta receptor II (70/80kDa) 
FAS Fas (TNF receptor superfamily, member 6) 
MAP3K2 mitogen-activated protein kinase kinase kinase 2 
CACNB2 calcium channel, voltage-dependent, beta 2 subunit 
RELA v-rel reticuloendotheliosis viral oncogene homolog A (avian) 
PLA2G3 phospholipase A2, group III 
RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 
RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 
MAP3K1 mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase 
STK4 serine/threonine kinase 4 
Table 7. Pathways deregulated by down-expressed miRNAs l  . athways der gulated by down-expressed miRNAs 
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Protein expression signature in hA-MSCs  
The protein expression signature was performed in 12 Ob- and 6 Co-hA-
MSCs using 2D-DIGE analysis. Figure 13 shows the master gel used to match the 
whole set of 2-DE proﬁles obtained. The analysis performed with DeCyder Software 
detected approximately 7000 protein spots per gel in a 3−10 pH range. Approximately 
2384 spots were matched throughout the gels. The DeCyder statistical analysis 
revealed 166 spots deferentially expressed in Ob-hA-MSC, compared to Co-hA-MSC 
En
do
cy
to
sis
 
SMAD2 SMAD family member 2 
RAB11FIP2 RAB11 family interacting protein 2 (class I) 
STAMBP STAM binding protein 
CLTC clathrin, heavy chain (Hc) 
USP8 ubiquitin specific peptidase 8 
ARRB1 arrestin, beta 1 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 
EHD4 EH-domain containing 4 
CAV3 caveolin 3 
TGFB2 transforming growth factor, beta 2 
FAM125B family with sequence similarity 125, member B 
CBL Cbl proto-oncogene, E3 ubiquitin protein ligase 
ARF6 ADP-ribosylation factor 6 
RAB5B RAB5B, member RAS oncogene family 
ZFYVE9 zinc finger, FYVE domain containing 9 
CSF1R colony stimulating factor 1 receptor 
Pa
th
w
ay
s i
n 
ca
nc
er
 
SOS2 son of sevenless homolog 2 (Drosophila) 
SMAD2 SMAD family member 2 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 
LAMC1 laminin, gamma 1 (formerly LAMB2) 
PTEN phosphatase and tensin homolog 
FZD4 frizzled family receptor 4 
FZD3 frizzled family receptor 3 
WNT2 wingless-type MMTV integration site family member 2 
GSK3B glycogen synthase kinase 3 beta 
PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta 
CBL Cbl proto-oncogene, E3 ubiquitin protein ligase 
TGFB2 transforming growth factor, beta 2 
FZD6 frizzled family receptor 6 
CSF1R colony stimulating factor 1 receptor 
VEGFB vascular endothelial growth factor B 
Table 8. Pathways deregulated by obesity specific miRNAs 
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samples with average ratio ≥ 1.2 for up-expressed protein spots and ≤ −1.2 for down-
expressed spots (p < 0.05). Some spots were excluded from further evaluation, i.e., 
those at the extreme right and left sides of the gel. Furthermore, many spots were not 
objected to further investigation, because of their low abundance on the preparative 
gel. As a result, we focused on 40 spots with optimal features. The latter was stained 
with Comassie Brillant protein stain and used for automated spot picking. The isolated 
spots were digested with trypsin and then analyzed with mass spectrometry  followed 
by database search. The relative expression ratios (in Ob- vs Co-hA-MSC) for 
each of the identified spots and their statistical values are listed in Table 9. 
Approximately 62% (25/40) of the spots were increased, and 38% of the spots 
(15/40) were decreased. Globally, a total of 41 proteins were identiﬁed in these 
spots. The identified proteins were organized by STRING database and more 
interconnections were showed (Figure 14). Particularly, they were clustered 
into 5 Kegg pathways containing at least 3 proteins: Focal adhesion (FLNA, 
FLNB, ACTG1 and ACTN1); Processing in endoplasmic reticulum (HSP90B1, 
HSPA5, RRBP1 and VCP); Metabolic pathways (ATP5B, DLST, PKM and 
MTAP); Regulation of actin cytoskeleton (MYH9, ACTG1, and ACTN1); and 
MAPK signaling (HSPB1, FLNA and FLNB). 
 
 
 
 
Figure 13. Image of gel chosen as master gel. This gel is constituted by three overlapped images: (1) 
Ob-hA-MSC  labeled with Cy3 (green), (2) Co-hA-MSC proteins of labeled with Cy5 (red), and (3) proteins 
from a mixture of the all samples (used for normalization) labeled with Cy2 (blue).   
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Spot 
no.a 
DIGE 
Ob-/Co-
hAMSCs b 
DIGE 
(p-value)c 
Protein name Gene 
Symbol d 
MW 
(Da)e 
PIf Gene 
ID g 
Protein 
code h 
279 1.23 0.014 Pyruvate kinase PKM PKM 57937 7.96 5315 P14618 
453 1.20 0.0069 Nodal modulator 1 NOMO1  134324 5.54 23420 Q15155 
492 1.37 0.0056 Filamin-A FLNA 280739 5.70 2316 P21333 
   Filamin-B FLNB 278164 5.47 2317 O75369 
574 1.33 0.040 Ribosome-binding protein 1 RRBP1 152472 8.69 6238 Q9P2E9  
660 1.47 0.0099 Programmed cell death 6-interacting protein PDCD6IP 96023 6.13 10015 Q8WUM4  
798 -1.39 0.046 Lon protease homolog, mitochondrial LONP1 106489 6.01 9361 P36776 
829 -1.30 0.028 Endoplasmin HSP90B1 92468 4.76 7184 P14625 
918 1.27 6.4e-005 Ubiquitin-like modifier-activating enzyme 1 UBA1  117849 5.49 7317 P22314 
   Alpha-actinin-1 ACTN1 103057 5.25 87 P12814 
   Alanine-tRNA ligase, mitochondrial AARS2 107340 5.87 57505 Q5JTZ9 
1047 1.38 0.0056 Myosin-9 MYH9 226532 5.50 4627 P35579 
   Transitional endoplasmic reticulum ATPase VCP 89265 5.14 7415 P55072 
1243 -1.37 0.0038 Ran GTPase-activating protein 1 RANGAP1 63541 4.63 5905 P46060 
1385 -2.05 0.019 78 kDa glucose-regulated protein HSPA5 72332 5.07 3309 P11021 
1408 -1.28 0.00018 79 kDa glucose-regulated protein HSPA5 72332 5.07 3309 P11022 
1476 1.23 0.0029 Stress-70 protein, mitochondrial HSPA9 73680 5.87 3313 P38646 
   Annexin A6 ANXA6 75873 5.41 309 P08133 
1536 1.63 0.026 Myosin-9 MYH9 226532 5.50 4627 P35579 
   LIM domain and actin-binding protein 1 LIMA1 85225 6.41 51474 Q9UHB6 
1786 -1.22 0.0028 60 kDa heat shock protein, mitochondrial HSPD1 61054 5.70 3329 P10809 
1866 1.26 0.022 Pyruvate kinase PKM PKM 57937 7.96 5315 P14618 
1874 1.21 0.018 Pyruvate kinase PKM PKM 57937 7.96 5315 P14618 
1996 1.32 0.049 Vimentin VIM 53651 5.05 7431 P08670 
2086 -1.19 0.017 Heterogeneous nuclear ribonucleoprotein H HNRNPH1 49229 5.89 3187 P31943 
2125 -1.35 0.017 Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial 
DLST 48755 9.10 1743 P36957 
2621 -1.23 0.049 Actin, cytoplasmic 2 ACTG1 41792 5.31 71 P63261 
   COP9 signalosome complex subunit 4 COPS4 46268 5.57 51138 Q9BT78 
2710 1.77 0.031 Serpin B6 SERPINB6 42621 5.18 5269 P35237 
2730 1.47 0.049 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 38746 9.17 3178 P09651 
2748 1.77 0.031 Annexin A1  ANXA1 38714 6.57 301 P04083 
2769 1.22 0.016 Eukaryotic translation initiation factor 3, subunit 
I  
EIF3I 36501 5.38 8668 Q13347 
2770 -6.13 0.041 Annexin A1 ANXA1 38714 6.57 301 P04083 
2813 1.40 0.022 Annexin A2 ANXA2 38604 7.57 302 P07355 
   LIM and SH3 domain protein 1 LASP1 29717 6.61 3927 Q14847 
2879 1,47 0,0042 Elongation factor 1-delta EEF1D 31121 4.90 1936 P29692 
2861 1.26 0.049 Annexin A2 ANXA2 38604 7.57 302 P07355 
2925 1.37 0.053 Annexin A2 ANXA2 38604 7.57 302 P07355 
   LIM and SH3 domain protein 1 LASP1 29717 6.61 3927 Q14847 
2955 1.25 0.038 LIM and SH3 domain protein 1 LASP1 29717 6.61 3927 Q14847 
3114 1.96 0.029 Annexin A5 ANXA5 35936 4.93 308 P08758 
3162 -3.34 0.041 Chloride intracellular channel protein 1 CLIC1 26922 5.09 1192 O00299 
3248 -2.21 0.051 S-methyl-5'-thioadenosine phosphorylase MTAP 31236 6.75 4507 Q13126 
3335 1.49 0.041 Prohibitin PHB 29804 5.57 5245 P35232 
3408 1.26 0.0013 40S ribosomal protein SA RPSA 32854 4.79 3921 P08865 
3412 -1.93 0.0030 Heat shock protein beta-1 HSPB1 22782 5.98 3315 P04792 
3452 -1.70 0.00024 Heat shock protein beta-1 HSPB1 22782 5.98 3315 P04792 
3711 1.66 0.0037 Ubiquitin carboxyl-terminal hydrolase isozyme 
L1 
UCHL1 24824 5.33 7345 P09936 
3794 -1.59 0.031 Chain A, Three-Dimensional Structure Of Class 
Pi Glutathione S-Transferase From Human 
Placenta (Glutathione S-transferase P) 
GSTP1 23355 5.43 2950 P09211 
Table 9. Identification of proteins differently expressed in Ob-hA-MSCs vs Co-hA-MSCs. 
a Spot numbering to indicate the positions of spots in preparative gel. b  p-value at Student’s t test. c Average abundance ratio (Ob-
/Co-hA-MSCs) as calculated by DeCyder Analysis. d Gene symbol from NCBI. e Theoretical molecular weight (Da). f Theoretical pI. 
g Gene ID from NCBI. h  Protein code from Swiss Prot. 
52 
 
 
 
 
5. DISCUSSION 
Understanding the molecular mechanisms underlying obesity could 
open the way for new therapeutic strategies to contrast obesity-related 
metabolic disorders. MiRNAs which have been involved in the regulation of a 
variety of biological processes, including appetite regulation, adipocyte 
diﬀerentiation, and insulin secretion (Heneghan et al. 2010), are interesting 
candidate molecules to be investigated in adipose tissues as potential mediators 
of metabolic pathway alterations in obesity. Previous study performed in SAT 
have reported that miRNA expression was altered in morbidly obese patients, 
and that up-expressed miR-519d plays a role in adipocyte lipid metabolism 
(Martinelli et al. 2010). The first aim of this study was to describe the miRNA 
and proteome VAT signatures in morbidly obese females and to show several 
miRNAs and proteins diﬀerentially expressed between obese and non-obese 
Figure 14. Representation of connection among the identified proteins. The proteins identified by mass 
spectrometry were organized using STRING database (v 9.1) and more interconnections were showed. 
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females. Globally, the miRNA expression proﬁle revealed that 71 miRNAs 
were deregulated in the VAT from obese females. Interestingly, most of these 
miRNAs (61/71) were down-expressed. This latter ﬁnding coincides with a 
report of a similar global down-expression of miRNAs in VAT from obese 
individuals with nonalcoholic steatohepatitis than those with nonalcoholic fatty 
liver disease that, moreover, was correlated with enhanced expression of 
inﬂammatory adipocytokines (Estep et al. 2010). Eleven of the 61 largely 
down-expressed miRNAs in the VAT of our obese females were also found in 
the above report; in particular, 7/11 of these miRNAs were previously reported 
(miR200c, miR-519b, miR-206, miR-618, miR-30a, miR-181c, and miR-7) 
down-expressed in SAT from the same obese females (Martinelli et al. 2010). 
In a mouse model, Xie et al. reported an inverse correlation of miRNA 
expression between adipogenesis and obesity (Xie et al. 2009). In fact, they 
observed that up-expressed miRNAs during adipogenesis tended to be down-
expressed in the mouse epididymal fat pads, and vice versa, suggesting that 
these changes could be linked to the chronic local inﬂammation environment in 
the fat-mouse obese tissue. Lastly, Klöting et al. reported that miR-198, one of 
our down-expressed miRNAs, was inversely correlated with omental adipocyte 
diameter during obesity (Klöting et al. 2009).  
The 2D-DIGE analysis has showed that 172 protein spots were 
diﬀerentially expressed in VAT from obese compared to non-obese females. 
Analysis of 33 of these protein spots, those with optimal features, has led to the 
identiﬁcation of 67 proteins because most spots were related to more than one 
protein. Our data conﬁrm, and also integrate, proteomic data previously 
obtained in VAT (Pérez-Pérez et al. 2009, Cortón et al. 2008, Pérez-Pérez et al. 
2012). In particular, this study showed high levels of EIF4A1, CES1, 
SELENBP1, ALDH1, ALDH2, GSTP1, and HSPB1 proteins that were 
previously reported to be increased in the omental compared to SAT in an 
obese population. Furthermore, we have identified proteins that were 
diﬀerently expressed in VAT from obese compared to non-obese females, such 
as ACADS, LMNA, VIM, which indicates that VAT is not only a lipid storage 
site, but also a highly active metabolic tissue (Pérez-Pérez et al. 2009, Pérez-
Pérez et al. 2012). Moreover, Pérez-Pérez et al. have suggested that EIF4A1 
could be involved in the altered protein synthesis pathways preceding insulin 
resistance and/or type 2 diabetes (Pérez-Pérez et al. 2009). In agreement with 
another study, high levels of E2F1 have been detected, which could play a role 
in glucose metabolism (Fajas et al. 2010). In agreement with earlier reports, 
proteins involved in intracellular traﬃcking, i.e., ARCN1 (or COPI), PLIN, 
RAB11A, and RAB14 have also been identiﬁed (Beller et al. 2010, Stenmark. 
2009). Furthermore, resulted up-expressed proteins involved in antioxidant 
activity and in apoptosis, namely, GSS, ANXA5, ANXA7, PRDX3, and 
GSTP1, some of which were reported by Córton and collegues in a proteomic 
study of VAT from obese females with or without polycystic ovary syndrome 
(Córton et al. 2008). A novelty of the present study is that we have evaluated 
simultaneously the miRNome and the proteome of VAT in obese and non-
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obese women to identify potential biological mechanisms, based on the 
concerted action of miRNA and protein targets, associated with obesity. To this 
aim, the list of the bioinformatically predicted protein targets of the deregulated 
miRNAs were intersected with the whole set of identiﬁed proteins from the 
experimental comparison of the VAT proteomes. Thus, using this approach a 
potential miRNA-based mechanism for the up-expression of some proteins was 
identified, in particular YWHAG and RAB11A, which was associated with 
down-expression of miR-141 and miR-520e, respectively. The functional 
luciferase assay has conﬁrmed the binding of these miRNAs to the 3′UTRs of 
the YWHAG and RAB11A transcripts. We investigated YWHAG and 
RAB11A because they are involved in glucose homeostasis (Cartee et al. 2009, 
Ramm et al. 2006, Chen et al. 2011) and YWHAG also in lipid metabolism, 
and hence are potential actors in the obese phenotype (Péterfy et al. 2010, Reue 
et al. 2008). Rab proteins are a large family of small GTPases that are involved 
in vesicular traﬃcking, in cytoskeleton organization, and in the control of cell 
proliferation and diﬀerentiation (Stenmark 2009). Members of the Rab family, 
which includes about 70 proteins in humans, continuously cycle between the 
cytosol and diﬀerent membranes as inactive GDP-bound or active GTP-bound 
forms, assisted by diﬀerent Rab-associated proteins (Mitra et al. 2011). Defects 
in Rab-associated proteins lead to abnormal intracellular traﬃcking and have 
been associated with several monogenic inherited disorders and multigenic 
conditions such as type 2 diabetes (Mitra et al. 2011, Kaddai et al. 2009). 
Several Rab GTPases have been implicated in GLUT4 traﬃcking in relation to 
the cell type studied; among these, RAB10, RAB11, and RAB14 have been 
identiﬁed in adipocytes (Larance et al. 2005). An additional player in GLUT4 
traﬃcking is the GTPase-activating protein AS160. The latter, under basal 
conditions, contributes to cytosolic retention of GLUT4, whereas, upon insulin 
stimulation, it is phosphorylated at Thr642 by AKT kinase and inactivated, so 
that AS160 dissociates from GLUT4 vesicles to favor an increase in the GTP-
bound form of RAB. This event facilitates the transport of GLUT4 from 
storage vesicles toward cell surface (Cartee et al. 2009). YWHAG (also known 
as 14-3-3γ) protein belongs to a seven-member protein family in mammals. 
These proteins, by interacting with target proteins, typically at phospho-
residues, regulate a variety of functions, including subcellular redistribution 
(Ramm et al. 2006). Studies conducted in animal models and/or in cellular 
systems have shown that 14-3-3 plays a relevant role in both cellular insulin-
mediated glucose transport and lipid metabolism. In fact, in mice, insulin-
stimulated YWHAG binding to AS160 at phospho-Thr649 (equivalent to 
Thr642 in human AS160) normally regulates GLUT4 traﬃcking from storage 
vesicles to plasma membrane, thereby inﬂuencing glucose uptake (Chen et al. 
2011). AS160-Thr649Ala knock-in mice (Ala: non-phosphorylable residue) 
display impaired glucosal and insulin sensitivity (Chen et al. 2011). 
Furthermore, in 3T3-L1 adipocytes, the up-expression of 14-3-3 promotes the 
cytoplasmic localization of Lipin1, a bifunctional protein involved in lipid 
metabolism (Péterfy et al. 2011). The subcellular localization of this protein is 
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relevant to its activities; in fact, its nuclear isoform promotes the activation of 
genes involved in oxidative metabolism. In the cytosol, its insulin-mediated 
phosphorylation leads to the conversion of phosphatidate (PA) to 
diacylglycerol (DAG), a precursor of triacylglycerol (TAG) (Reue et al. 2008). 
On the basis of the above-mentioned mechanisms, we hypothesize (Figure 15) 
that in VAT from obese subjects, low expression levels of some miRNAs, 
including miR-520e and miR-141, by modulating the up-expression of 
RAB11A and YWHAG proteins, respectively, may lead to increased glucose 
uptake and to increased triglyceride synthesis. This could then contribute to 
worsen the obese phenotype by increasing the accumulation of adipose tissue. 
Obviously, the analysis of suitable cellular systems is required to provide 
mechanistic details for the proposed model and clarify the role of insulin as an 
independent, or co-operative model, linked to the observed miRNA down-
expression and protein target up-expression in obesity. Furthermore, studies on 
larger cohorts of obese and non-obese subjects are necessary to verify our 
results on the expression of miR-520e and miR-141, as well as of YWHAG 
and RAB11A proteins, in obesity risk assessment.  
 
 
Figure 15. Hypothesized model of visceral adipose tissue (VAT) accumulation based on miR-141/YWHAG and 
miR-520e/RAB11A interaction. Under basal conditions, the Akt substrate of 160 kDa (AS160) binds RAB11-bound 
guanosine diphosphate (GDP) that retains glucose transporter protein (GLUT4) vesicles in the cytosol. After insulin 
stimulation, Akt phosphorylates AS160 that binds YWHAG (14-3-3γ) and catalyzes the phosphorylation of RAB11-
GDP in RAB11-bound guanosine triphosphate (GTP). This process results in GLUT4 translocation toward the cell 
surface. In response to insulin, lipin1 is phosphorylated and interacts with YWHAG (14-3-3γ). The interaction between 
these two proteins induces increased synthesis of triglycerides in the endoplasmic reticulum.  
 
Concerning the second aim of this study, miRNA expression profiles 
were investigated in amnion and in hA-MSCs from obese pregnant women. It 
is now recognized that epigenetic modiﬁcations of the foetal genome contribute 
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to disease development in adults (Fowden et al. 2008). The present data show 
that miRNAs regulate gene expression in the amnion during obesity. In 
particular, 25 miRNAs were differently expressed in amnion from obese 
compared to control women, and seven obesity-speciﬁc miRNAs were 
identiﬁed. The differently expressed placental miRNAs include miRNAs 
previously associated with endometriosis (miR-196b, let-7d, and miR-107) 
(Hawkins et al. 2011), preeclampsia (miR-181 and let-7d) (Mayor-Lynn et al. 
2011, Yang et al. 2001), cancer (miR-422b) (Lee et al. 2009), or identiﬁed in 
sera from normal pregnancies (miR-23b, miR-372, and miR-519e) (Li et al. 
2012, Kotlabova et al. 2011). 
The predicted target genes of our miRNAs belong to pathways 
potentially important for placental development and/or functions. In fact, the 
neurotrophin pathway was regulated by three obesity-speciﬁc miRNAs (miR-
422b, miR-659, and miR-575), six miRNAs up-expressed (miR-196b, miR-96, 
miR-338-3p, miR-372, miR-492, and miR-107) and four miRNAs down-
expressed (miR-591, miR-139, miR-624, and miR-554). The brain-derived 
neurotrophic factor was recently implicated in placental development and 
foetal growth in mice and its placental expression was increased in intrauterine 
growth restriction and decreased in maternal type 1 diabetes (Mayeur et al. 
2010). Obesity-speciﬁc miRNAs (miR-422b, miR-659, and miR-219) also 
down-regulated the mammalian target of rapamycin (mTOR) and the insulin 
signaling pathways. mTOR is highly expressed in syncytiotrophoblasts of the 
human placenta and exists as two complexes with distinct regulation and 
function based on its association with accessory proteins: raptor in Complex 1 
(mTORC1) and rictor in Complex 2 (mTORC2) (Jansson et al. 2012). A 
multitude of upstream regulators of mTORC1, including insulin, cellular 
energy, and oxygen levels, could affect placental size and modulate foetal 
growth by regulating placental nutrient transporter function (Jansson et al. 
2012). Conversely, mTORC2 is involved in lipid metabolism; in fact, in C. 
elegans loss of rictor function causes developmental delay, reduced size and 
reproduction, and increased fat accumulation (Jones et al. 2009). Here, we 
highlight a new potential mechanism based on miRNA down-regulation of 
mTOR that could impact foetal growth during obesity. Mammalian mTORC2 
controls the actin cytoskeleton organization, as shown by the ﬁnding that its 
knockdown prevents actin polymerization (Jacinto et al. 2004). The 
cytoskeleton has a crucial role in basic cellular processes and in decidualization 
(Ihnatovych et al. 2009), and the down-regulation of placenta actin 
cytoskeleton signaling was observed in preeclampsia (Kang et al. 2011). In this 
study, the actin cytoskeleton pathway was predicted to be down-regulated by 
obesity-speciﬁc miR-422b, miR-659, miR-575, and miR-579, which indicates 
that the placental structural organization and function are also altered in human 
obesity. 
The miRNA expression profiles of Ob-hA-MSCs compared to Co-hA-
MSCs have showed 25 differently expressed miRNAs (11 up-expressed and 14 
down-expressed) and 7 obesity-specific miRNAs. The miRNA expression 
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profiles of hA-MSCs were different from those observed in the amnion from 
obese women, but predicted target genes of miRNAs differently expressed in 
Ob-hA-MSCs are involved in the same pathways in which are involved 
predicted target genes of miRNAs differently expressed in the amnion. For 
example, predicted target genes of differently expressed miRNAs in Ob-hA-
MSCs are involved in MAPK signalling, and in the regulation of actin 
cytoskeleton. In addition, predicted targets genes of up-expressed miRNAs in 
Ob-hA-MSCs are also involved in regulation of focal adhesion and Gap 
junction in agreement with previous reports that the signature transcriptomes of 
MSCs isolated from human tissues includes genes involved in regulation of the 
extracellular matrix and adhesion (Wang et al. 2010). 
Interestingly, some pathways were regulated by both up- and down- 
expressed miRNAs that act on different genes, such as pathways in cancer and 
MAPK signalling. 
In hA-MSCs obesity specific miRNAs regulate 2 pathways also 
regulated by up-expressed miRNAs, such as endocytosis and pathway in 
cancer. In amniotic epithelial cells it was demonstrated that the formation of 
endocytotic vesicles was an extremely active process. The activation of this 
pathway is essential for maintaining amniotic survival, because endocytosis 
plays a key role in the ability of the amnion to adapt to availability of nutrients. 
Shen and colleagues (Shen et al. 2008) suggests that the activation of 
endocytosis in amnion is also induced by nutrient limitation. Otherwise in the 
placenta from obese women this pathway may be suppressed due to the 
presence of excess nutrients and obese specific or up-expressed miRNAs could 
play a role in this regulation.  
Comparing differently expressed miRNAs in amnios and in hA-MSCs, 
we observed that only miR-449b shows the same trend. It was down-expressed 
both in amnion and in hA-MSCs from obese women. This miRNA was found 
significantly down-expressed in the bovine hatched blastocysts and by 
luciferase assay was confirmed the functional interaction with NOTCH1. 
NOTCH1 is a member of the Notch trans-membrane protein family that shares 
structural characteristics, including an extracellular domain consisting of 
multiple epidermal growth factor-like repeats, and an intracellular domain 
consisting of multiple, different domain types. The Notch signaling pathway is 
an evolutionarily conserved, but very versatile pathway, operating in many cell 
types and at various stages during development. In mouse embryos, Notch1 is 
expressed during all developmental stages from fertilized eggs until the late 
blastocyst stage. It is also expressed in trophoblast stem cells and mouse 
models carrying mutations in the Notch signaling pathway display defects in 
the development of the placenta, suggesting that this pathway is required for 
placental development (Goossens et al. 2013). These findings suggest that 
down-regulation of miR-449b could play a central role in physiological foetal 
development.  
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The proteomic approach has showed 48 differently expressed protein 
spots in Ob-hA-MSCs compared to Co-hA-MSc. Most of them (62%) were up-
expressed and the remaining (38%) was down-expressed.  
In the last years much attention has been given to the amniotic 
membrane and to mesenchymal stem cells isolated from a variety of adult 
tissues because they represent a major hope for tissue-engineered replacement 
and regenerative medicine. Roche and colleagues defined a common proteomic 
profile that distinguished multipotent MSCs from pluripotent embryonic stem 
cells. They selected Annexin A1 (ANXA1), Annexin A2 (ANXA2) and Heat 
shock protein beta-1 (HSPB1) as proteomic markers of MSCs (Roche et al. 
2009). We confirm in our hA-MSCs, the presence of these proteins between 
those characterizing the proteomic profile, both in Ob-hA-MSCs and in Co-
hA-MSc. 
Proteins identified in hA-MSCs were mainly involved in the following 
pathways: Focal adhesion; Processing in endoplasmic reticulum; Metabolic 
pathways; Regulation of actin cytoskeleton. This finding is in agreement to 
MSC proteome dataset previously described by Park and colleagues, in which 
the most abundant proteins expressed in MSC were components of cellular 
metabolic pathways, heat shock proteins, proteins associated with protein 
folding, and cellular cytoskeleton. In addition, the abundant presence of 
vimentin (VIM) and LIM and SH3 domain protein 1 (LASP1), cellular 
cytoskeleton proteins, in our Ob-hA-MSC, support data previously reported in 
other MSC studies (Wagner W et al. 2006, Sun KJ et al. 2006, Feldmann et a.l 
2005, Park et al. 2007). VIM is the most abundant intermediate filament 
protein, highly expressed in mesenchymal tissues of mesodermal origin. When 
it is phosphorylated plays a role in cell division, differentiation, and apoptosis. 
Whereas, LASP1 is a focal adhesion protein involved in cell migration and 
survival in response to growth factors and extracellular matrix (Park et al. 
2007). 
VIM was also identified in adipocytes as a lipid droplets (LD) 
associated protein, where it forms a scaffold around LD (Brasaemle et al. 
2004). Recently, it has been shown that VIM participates in lipolysis through 
hormonally regulated interaction with lipase hormone sensible (HSL). In 
vimentin null mice lipolysis is less efficient than in wild type mice (Shen et al. 
2010). Moreover, adipocytes from vimentin null mice were smaller than those 
from wild type mice, suggesting that vimentin might participate in lipid droplet 
formation and homeostasis (Shen et al. 2012). Similar results in cell size were 
described in mice with deletions of other intermediate filaments (Galarneau et 
al. 2007, Kim et al. 2006). VIM plays also a role in GLUT4 trafficking by 
binding the insulin responsive aminopeptidase (IRAP), an abundant cargo 
protein associated with GLUT4 storage vesicles. In knockdown for VIM 3T3-
L1 adipocytes, insulin-stimulated GLUT4 insertion into membrane is 
completely disrupted (Hirata et al. 2011). Overall these findings suggest that 
VIM could play a role in homeostasis of adipocyte cells and in GLUT4 
trafficking in plasmatic membrane. 
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The effect of pre-existing maternal obesity on the protein expression 
profiles was previously investigated in human placenta dissected to remove 
visible connective tissue and calcium deposits. In this study 8 proteins were 
shown to be altered. Particularly, between these proteins, the authors 
highlighted the lower expression of Annexin A5 (ANXA5), VIM and HSPB1 
in obese compared to lean subjects (Oliva et al. 2012). Our data, in confirming 
the obese associated down-regulation of HSPB1 are in contrast for the 
expression rate of ANXA5 and VIM, that we found to be up-expressed in Ob- 
compared to Co-hA-MSCs, probably due to the fact that different samples were 
analyzed. 
ANXA5, otherwise known as placenta anticoagulant protein 1, is 
abundantly expressed in humans placenta. It can form a shield around 
negatively-charged phospholipid molecules and inhibit blood coagulation. The 
anti-coagulation effects of ANXA5 includes competing with activated factor 
VIII for phosphatidylserine binding sites, inhibiting thromboplastin and 
blocking the binding of factor X to thrombin-stimulated platelets (Liu et al. 
2012). A hypercoagulable state becomes more common during pregnancy and 
it was increased during pregnancy complicated with gestational diabetes 
mellitus (GDM). ANXA5 protein was found up-expressed in placental villi 
from pregnant women complicated with GDM compared to normal placenta 
villi. In this case, the placenta may up-regulate and secrete more ANXA5 in 
order to counteract the hypercoagulation state induced by GDM. ANXA5 has 
also anti-inflammatory and anti-apoptotic properties. In placentas from obese 
women an increased inflammation was demonstrated (Oliva et al. 2012). 
Exposure of the fetus to an intrauterine inflammatory environment may have 
long term consequences, including foetal programming of obesity. The high 
expression of ANXA5 in Ob-hA-MSCs could be a signal of pregnancy 
complicated with obesity, but further investigations are needed to elucidate this 
mechanism. 
HSPB1, also know HSP27, belongs to the family of small heat shock 
proteins. Changes in expression of HSPB1 occurs in response to stress. The 
functions of HSPB1 include protein chaperone, control of apoptosis, regulation 
of cell glutathione levels, inhibition of actin polymerization as well as 
protection against heat shock, oxidative stress and mechanical stress. HSPB1 
plays a role also in oxidative stress and inflammation, both features of labor. 
The mechanisms that are involved in maintaining a human pregnancy to 
term and the changes that lead to a normal pregnancy outcome or indeed an 
adverse outcome such as miscarriage, preeclampsia, foetal growth restriction or 
preterm labor are complex but the role of the placenta is crucial to them all. 
When the production of reactive oxygen species overwhelms the intrinsic anti-
oxidant defenses oxidative stress occurs. It can induce a range of cellular 
responses depending upon how severe the insult is and the cellular 
compartment in which reactive oxidative species are generated. However, a 
recent study showed that HSPB1 mRNA and protein were reduced in placenta 
during labor. Particularly, there was less HSPB1 in the inner compared with 
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both the middle and outer area of at term placenta from pregnant women 
delivered by cesarean section.  
One reason for this may be that a fall in HSPB1 may be necessary to 
facilitate the inflammatory steps of labor which is, after all, a normal 
physiological process, not a disease (Abdulsid et al. 2013). 
The low expression of HSPB1 both in placenta and in hA-MSCs from 
obese women could suggest a defective response to oxidative stress associated 
with maternal overweight.  
Another protein involved in response to oxidative stress is glutathione 
S-transferase P (GSTP1), that was down-expressed in Ob-hA-MSCs. It is a 
glutathione S-transferase (GST) and belongs to a group of multigene and 
multifunctional detoxification enzymes, which defend cells against a wide 
variety of toxic insults from chemicals and metabolites. Low levels of placental 
GST were observed in some cases of maternal inflammatory state, such as pre-
eclampsia (Johnstone et al. 2011) and in placenta from mother living in 
radioactivity-contaminated and chemically-polluted areas (Obolenskaya et al. 
2010). In these cases the reduced GST expression or activity demonstrated 
defective anti-oxidative stress response and an imbalance in detoxification 
capacity.  
Moreover, a GSTP1 gene polymorphism was associated with diabetes 
mellitus type 2 (T2DM). Particularly, GSTP1 variant with A to G transition in 
exon 5 at codon 105 leads to Ile105Val amino acid substitution, which reduces 
the ability to conjugate reactive electrophiles with glutathione and may 
therefore sensitize cells to free radical-mediated damage. The Val105 variant 
has been associated with susceptibility to smoking-related cancer and 
cardiovascular disease. In T2DM patients were found a significant association 
between this polymorphism, inactivating GSTP1, and BMI. 
These findings suggest that in placenta from obese women could be a 
defective anti-oxidative stress response because there is reduced expression of 
glutathione S-transferase the major component of cellular protection against 
oxidative stress. 
 
6. CONCLUSIONS 
 
In conclusion, the present study provides an integrated view of both 
miRNAs and protein expression proﬁles in VAT during obesity and gives clues 
as to the metabolic pathways that may be involved in adipose tissue 
accumulation. 
In addition, we have elucidate the role of epigenetic mechanisms of gene 
regulation as risk factors in foetal programming of obesity showing that the 
miRNA expression proﬁle is altered in amnion and in hA-MSCs during 
obesity.  The research of miRNA predicted targets allow us to hypothesize that 
this deregulation could affect pathways important for placental growth and 
function, thereby contributing to an increase in the newborn’s risk of future 
metabolic diseases. 
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Finally, our data have highlighted that Ob-hA-MSCs have a different 
proteomic signature compared to Co-hA-MSCs. Even if some identified 
proteins are previously described in MSCs isolated from several adult tissues, 
in our study they are deregulated in association with obesity.  
The data concerning hA-MSC need to further considerations, particularly 
the miRNA expression levels and the proteomic data should be confirmed with 
another method.  
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Abstract
MiRNAs play a relevant role in regulating gene expression in a variety of physiological and pathological conditions including
autoimmune disorders. MiRNAs are also important in the differentiation and function of the mouse intestinal epithelium.
Our study was aimed to look for miRNA-based modulation of gene expression in celiac small intestine, and particularly for
genes involved in cell intestinal differentiation/proliferation mechanisms. A cohort of 40 children (20 with active CD, 9 on a
gluten-free diet (GFD), and 11 controls), were recruited at the Paediatrics Department (University of Naples Federico II). The
expression of 365 human miRNAs was quantified by TaqMan low-density arrays. We used bioinformatics to predict putative
target genes of miRNAs and to select biological pathways. The presence of NOTCH1, HES1, KLF4, MUC-2, Ki67 and beta-
catenin proteins in the small intestine of CD and control children was tested by immunohistochemistry. The expression of
about 20% of the miRNAs tested differed between CD and control children. We found that high miR-449a levels targeted
and reduced both NOTCH1 and KLF4 in HEK-293 cells. NOTCH1, KLF4 signals and the number of goblet cells were lower in
small intestine of children with active CD and in those on a GFD than in controls, whereas more nuclear beta-catenin
staining, as a sign of the WNT pathway activation, and more Ki67 staining, as sign of proliferation, were present in crypts
from CD patients than in controls. In conclusion we first demonstrate a miRNA mediated gene regulation in small intestine
of CD patients. We also highlighted a reduced NOTCH1 pathway in our patients, irrespective of whether the disease was
active or not. We suggest that NOTCH pathway could be constitutively altered in the celiac small intestine and could drive
the increased proliferation and the decreased differentiation of intestinal cells towards the secretory goblet cell lineage.
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Introduction
Celiac disease (CD) is an immunomediated enteropathy and
one of the most heritable complex diseases. The concordance rate
in monozygotic twins is 75% [1,2]. HLA DQ2/DQ8 haplotypes
confer the highest estimated heritability (,35%) [3] reported so
far.
Exposure to gliadin triggers an inappropriate immune response
in HLA-susceptible individuals. However, the presence of HLA-
risk alleles is a necessary but not sufficient condition for the
development of CD. In fact, about 30–40% of healthy subjects
carry HLA-risk alleles [4,5]. Attempts at identifying non-HLA
major genetic risk loci have been unsuccessful [6]. Gluten has also
been shown to affect epithelial differentiation-associated genes in
the small intestinal mucosa of celiac patients [7,8]. However, the
role of miRNA-based regulatory mechanisms in mediating gene
expression alteration in CD has not yet been investigated.
MicroRNAs (miRNAs) are small non-coding RNAs, 20–25 nt
long, that modulate gene expression through canonical base
pairing to complementary sequences in the 39UTR of target
mRNA [9]. Since their identification in 1993 [10], miRNAs have
been found to play a relevant role in regulating gene expression
in a variety of biological processes in physiological and
pathological conditions [11] including autoimmune disorders
[12]. They can be involved in the development of mature
immune cells and in the control of their function [13–15].
MiRNAs are also important in the differentiation and function of
the mouse intestinal epithelium [16].
In this study, we evaluated the miRNA expression pattern in the
small intestine of children affected by active CD, children with CD
on a gluten-free diet (GFD) and control children without CD. Our
aim was to look for miRNA-based modulation of gene expression
in celiac small intestine, and particularly for genes involved in cell
intestinal differentiation/proliferation mechanisms.
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Results
Clinical features of CD patients and controls
Clinical features of our CD patients and controls are reported in
Table 1. Villous atrophy was subtotal or total [TIIIB: n = 3 (15%)
and TIIIC: n = 17 (85%)] in all active CD patients. Only minor
histological abnormalities were present in GFD patients [T0: n = 5
(56%) and TI: n = 4 (44%)] and in control patients [T0: n = 7
(64%) and TI: n = 4 (36%)].
CD children and controls have a different miRNA
expression levels in small intestine
Figure 1 shows the miRNA expression in the small intestine of
children with active CD (panel A) and in children on a GFD (panel
B). Ninety of the 365 (25%) miRNAs tested were not expressed in
small intestine. Over 50% of miRNAs were expressed at similar
levels in the two groups of CD compared to controls. On the
contrary, the expression levels of about 20% of miRNAs (22% in
active CD and 19% in GFD) differed between CD and controls. In
particular, in active CD patients 27 and 55 miRNAs were
expressed respectively more (RQ$2.0) or less (RQ#0.5) than in
controls, whereas in GFD patients 22 and 49 miRNAs were
expressed respectively more (RQ$2.0) or less (RQ#0.5) than in
controls. The miRNAs that were differently expressed in the two
CD groups are listed in Table S1.
Two sets of miRNAs (one down-regulated and one up-
regulated compared to controls) show similar expression
levels in active and GFD CD patients, being miR-449a the
highest expressed miRNA
Among the miRNAs differently expressed between CD children
and controls, but with similar expression levels in active and in
GFD CD, 9 were up-regulated and 21 were down-regulated
(Table 2). Particularly, among the down-regulated miRNAs the set
of miR-124a, miR-189, miR-299-5p and miR-379, was previously
reported associated with autoimmune disorders [17]. Among the
up-regulated miRNAs the miR-449a was expressed at very high
levels in all active CD (55.18616.45 mean RQ6SEM) and GFD
children (15.4367.69 mean RQ6SEM). qRT-PCR confirmed the
expression levels both of miR-449a (active CD: 2.860.9 mean
RQ6SEM) and of 2 other tested miRNAs, the down-regulated
miR-124a (active CD:0.660.1 mean RQ6SEM) and the similar
to control expressed miR-564 (active CD:1.460.3 mean
RQ6SEM vs 1.260.1 at array).
Bioinformatic prediction of the target genes of miR-449a
Six of the 11 programs [Target Scan 5.1, PicTar, Miranda 1.9,
MirTarget2 (v2.0), PITA (Catalog version 3) and RNAhybrid (v2.2)],
which we used to predict putative target genes of miR-449a,
identified several proteins that are present in relevant biological
pathways. The biological pathways predicted to be deregulated by
miR-449a and sorted in functional groups are reported in Figure S1
(http://mirecords.biolead.org/interactions.php?species=Homo+sapiens
&mirna_acc=hsa-miR449a&targetgene_type=refseq_acc&targetgene_
info=&v=yes&search_int=Search (http://www.targetscan.org/cgi-bin
/targetscan/vert_50/targetscan.cgi?species=Human&gid=&mir_sc=
&mir_c=&mir_nc=&mirg=hsa-miR-449a). Among putative target
genes the programs identified NOTCH1, Krueppel-like factor 4
(KLF4), delta-like 1 (DLL1), lymphoid enhancer-binding factor 1
(LEF1) and numb homolog-like (NUMBL) proteins, which are all
involved in the Notch pathway. As this pathway plays a relevant role in
the control of intestinal cell fate in animal models we further examined
the interaction of miR-449a with Notch pathway [18].
MiR-449a binds to the 39 UTR of NOTCH1 and KLF4 and
inhibits their expression. We verified the interaction between
miR-449a and the 39 UTR of NOTCH1 and of KLF4 using the
luciferase reporter assay. In cells co-transfected with pRL-NOTCH1
vector and pre-miR-449a or with pRL-KLF4 vector, a pre-miR-
449a concentration of 100 nmol/L was sufficient to significantly
reduce (respectively, p = 0.001 and p = 0.002) Renilla luciferase
activity versus control values after 48 h (Figure S2A and S2B).This
finding confirms the interaction between miR-449a and the 39UTR
of both NOTCH1 and KLF4.
The direct interaction between miR-449a and the 39UTRs of
both NOTCH1 and KLF4 was further confirmed after mutating
the putative target sites in 39UTR of the two genes (See Materials
and Methods S1).
NOTCH1 and HES1 mRNAs are expressed in the small
intestine of CD patients
NOTCH1 and HES1 mRNA levels, tested by qRT-PCR, were
expressed in the small intestine of active CD patients (RQ6SEM:
3.461.3 and 1.460.2, respectively vs controls) and of GFD patients
(RQ6SEM: 6.564.7 and 0.760.1, respectively vs controls).
NOTCH1 and HES1 proteins are underexpressed in the
small intestine of CD patients
We next investigated the protein expression of NOTCH1 and of
HES1, which is a well known target gene of the Notch receptor
family, in small intestinal biopsies from CD patients and controls.
Figure 2 shows the results obtained for NOTCH1. NOTCH1 was
homogeneously distributed in the intestinal villi and crypts of
controls and higher expressed in crypts of controls than in crypts of
active and GFD CD patients (panel A, B).
In Figure 2 (panel C) are also the images converted for
automated analysis (white: unstained cells, yellow/orange: low/
moderately stained cells, brown: intensely stained cells). Signif-
icantly more intensely stained and less unstained cells (p = 0.02)
Table 1. General characteristics of studied celiac patients
(active CD and GFD) and control children (CTRL).
Characteristics# Subjects
Active CD
(n=20)
GFD‘
(n = 9)
CTRL
(n =11)
Sex Female (%) 55 55 45
Age (Years) 4.361.3 7.662.5 6.161.0
Clinical presentation:
Gastrointestinal symptoms (%) 80 22 82
Villous atrophy % (Marsh stage){ TIIIB 15 T0 56 T0 64
TIIIC 85 TI 44 TI 36
Positive tTG or EMA (IgA)1 19 3 0
Familiarity for:
CD (%) 20 22 0
Other autoimmune diseases (%) 5 11 0
#Data are expressed as percentage (%) or as mean 6 standard error of the
mean (SEM)
‘At gluten free diet from at least 2 years.
{According to [41].
1Only 1 active CD patient was negative for these antibodies but was positive for
both AGA IgG/IgA antibodies. Borderline tTG values in 3/9 GFD patients were
attributed to reported sporadic gluten ingestion.
doi:10.1371/journal.pone.0029094.t001
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were detected in controls than in the two groups of CD patients,
whereas no statistical significant difference was observed between
the two CD groups (Figure S3, panel A and Figure S4). These
results indicate that NOTCH1 is less expressed in the small
intestine of active and GFD CD patients than in controls.
Figure 3 shows the results obtained for HES1. HES1 was
homogeneously distributed in the intestinal villi and crypts of
controls and higher expressed in crypts of controls than in crypts
of active and GFD CD patients (panels A and B). In Figure 3
(panel C) are also the images converted for automated analysis
(white: unstained cells, yellow/orange: low/moderately stained
cells, brown: intensely stained cells). Significantly more intensely
stained cells were detected in controls than in CD patients
(p = 0.02) and significantly less unstained cells were detected in
controls than in active CD patients (p = 0.03), whereas no
statistical significant difference was observed between the two
CD groups (Figure S3, panel B and Figure S5). These results
indicate that HES1 is less expressed in the small intestine of
active and GFD CD patients with respect to controls. The above
findings confirm that NOTCH1 signaling is reduced in patients
affected by CD.
KLF4 protein is reduced and the number of goblet cells is
significantly lower in the small intestine of CD patients
versus controls
We also investigated the protein expression of KLF4, another
selected target gene of miR449a, in small intestinal villi from GFD
patients and controls, lacking the villous architecture in active CD
patients. We found that the levels of this protein (mean6SEM)
were significantly lower in villi from GFD patients vs controls,
respectively 29.065.0 vs 79.063.0 (p,0.0001) (Figure S6, panel
A). Since KLF4 negatively regulates cellular proliferation, we
examined the effect of inhibition of KLF4 on the proliferation of
intestinal crypts with the proliferation marker Ki67. The results
show that the number of Ki67 positive cells is higher in the crypts
of CD patients than in controls (Figure S6, panel B). Because
KLF4 is also involved in the differentiation and maturation of
secretory goblet cells we examined these cells by immunohisto-
chemistry and using anti-MUC-2 antibodies. We detected
statistically fewer MUC-2-stained cells (mean6SEM) in the crypts
of active CD patients (18.061.6) and GFD patients (15.063.0)
than in controls (35.067.7) (p = 0.04) (Figure 4A and B).
Moreover, there were fewer goblet cells in the villi of GFD
Figure 1. miRNA expression pattern in small intestine of CD patients. miRNA expression in the small intestine of patients with active CD
(Panel A) and of CD patients on a GFD (Panel B). Data are expressed as percentage of miRNAs tested (n = 365). White areas, miRNAs whose expression
levels were similar in the two CD groups and controls; gray areas, miRNAs not expressed; black areas, miRNAs whose expression levels differed
between CD patients and controls (up-regulated q(RQ$2.0) or down-regulated Q(RQ#0.5)).
doi:10.1371/journal.pone.0029094.g001
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patients (7.061.8) than in controls (20.064.9) (p = 0.04) (data not
shown). This finding demonstrates that the differentiation of the
secretory goblet cells is impaired in small intestine of CD patients.
Expression of beta-catenin
Because NOTCH1 and also KLF4 interact with the WNT
pathway to influence the intestinal stem cell fate, we investigated
the WNT pathway using beta-catenin antibodies. By counting the
beta-catenin positive nuclei/crypt for each patient we observed
higher even if not statistical significant mean percentage beta-
catenin positive nuclei/crypt in active CD and GFD patients than
in controls, respectively 57.0611.5 and 37.064.6 vs 27.064.6
(Figure S7). This finding suggests that cellular proliferation is
increased in the small intestine of CD patients.
Discussion
A very recent study established the importance of miRNAs in
the differentiation and function of the mouse intestinal epithelium
[16], whereas there are no data about miRNAs expression in
human CD small intestine. Our study reveals that the expression
of about 20% of miRNAs tested in the small intestine differed
among CD and control children irrespective of whether the
disease was active or not. Particularly, the miR-449a showed the
highest expression level in CD patients than in controls. The miR-
449 (a and b) cluster is embedded into an intronic sequence of the
mRNA-encoding gene CDC20B on Chr 5q11.2 [17]. MiR-449a
seems to be regulated through activation of its host gene, CDC20B,
and both were induced by the cell cycle regulator E2F1 [19]. The
mature miR-449a sequence is evolutionarily conserved across a
variety of species (monkey, horse, rodents, and dogs) and therefore
it probably exerts an important function [20]. The bioinformatics
search for putative target genes of miR-449a revealed about one
hundred proteins, among these several belonged to the Notch
pathway, i.e., NOTCH1, KLF4 (a NOTCH1 transcription factor)
[21], DLL1, LEF1 and NUMBL. Our strategy to choose
NOTCH1 gene among the other putative miRNA-target genes
was based on many studies highlighting that cellular formation of
the villi in small and large intestine is affected by signaling
pathways such as Notch, Wnt and BMP [22–25]. Notably,
deregulation of the intestinal epithelial formation has been
reported in several intestinal diseases such as Crohn, ulcerative
colitis and colon cancer [26]. Further, NOTCH1 and KLF4 genes
are both involved in the control of mouse intestinal epithelial
homeostasis [18,27]. In fact, in mouse intestine, also in
cooperation with WNT signals, NOTCH1 guides cell proliferation
and differentiation [18] and KLF4 inhibition by NOTCH1 or
KLF4 deletion was shown to reduce the differentiation and
maturation of goblet cells [21,27–29]. The Notch family is
constituted by single transmembrane receptors that, in mammals,
after interaction with ligands (DLL1,3,4 and Jagged 1–2) undergo
proteolytic cleavage and finally translocate into the nucleus where
they activate target gene transcription [30].
After confirmed the interaction between miR-449a and both
NOTCH1 and KLF4 mRNA, we measured the NOTCH1 and
KLF4 protein levels in small intestinal biopsies of CD children.
NOTCH1-positive cells were significantly fewer in biopsies from
active and GFD CD patients versus controls. Similar results were
also obtained for HES1, a target gene of NOTCH1 [31]. Globally,
these data indicate that the NOTCH1 pathway is deregulated in
intestinal epithelium of CD children, irrespective of whether the
disease is active or not, and that this alteration could be related to
the very high miR-449a expression. Accordingly, in a very recent
report miR449 by repressing the Delta/Notch pathway was
elegantly shown to control the human airway epithelium and
vertebrate multilciliogenesis [32]. In our patients we also observed
fewer KLF4-positive cells in small intestinal villi from GFD patients
than in controls, and, moreover, Ki67 signals were higher in crypts
from CD patients versus controls. These two results are in agree-
ment with data very recently reported in a mouse KLF4DELTAIS
model [27] and indicate a higher proliferation rate in our CD
patients in the presence of reduced KLF4 expression [27]. In
parallel the number of goblet cells was significantly lower in the two
CD groups than in control children. Ciacci et al [33] previously
reported fewer goblet cells/mm2 in untreated (29.1) and in treated
CD patients (42.2) than in controls (50.5), although the differences
were statistically significant only in untreated patients (p,0.02).
The WNT pathway in the small intestine of our CD patients,
evaluated based on beta-catenin expression level, did not differ
Table 2. List of miRNAs (n = 30) differently expressed in CD
patients and controls but with similar expression levels both
in active CD and GFD children.
MiRNA Active CD GFD
up-regulated miRNAs
miR-449a 55.18616.45 15.4367.69
miR-492 48.88614.56 26.8669.00
miR-644 47.8068.80 37.53618.85
miR-503 19.8462.36 20.5568.07
miR-196a 11.0662.84 8.4561.01
miR-504 5.5460.83 8.0262.86
miR-500 5.4960.70 7.8861.56
miR-330 3.8460.45 2.4860.11
miR-182 2.9560.42 2.7560.13
down-regulated miRNAs
miR-105 0.3760.03 0.2560.03
miR-409-5p 0.3560.04 0.3160.05
miR-631 0.3460.03 0.2760.04
miR-659 0.3360.03 0.3060.05
miR-379 0.3060.05 0.2360.10
miR-566 0.2960.02 0.2360.03
miR-512-3p 0.2760.03 0.2660.04
miR-614 0.2660.02 0.2160.02
miR-380-5p 0.2560.03 0.2860.04
miR-135a 0.2160.05 0.3860.05
miR-124a 0.2060.02 0.2160.05
miR-600 0.1960.02 0.2260.06
miR-618 0.1860.03 0.3260.07
miR-616 0.1760.04 0.1160.03
miR-189 0.1560.05 0.2160.06
miR-576 0.1560.04 0.4060.10
miR-412 0.1360.03 0.1860.01
miR-202 0.1260.06 0.1760.08
miR-299-5p 0.1160.01 0.1560.05
miR-323 0.1160.01 0.2360.08
miR-219 0.1060.01 0.2760.08
Data are reported as RQ# levels (mean6SEM).
#RQ=22delta deltaCT represents miRNA fold change in CD patients vs mean value
obtained in control patients.
doi:10.1371/journal.pone.0029094.t002
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from that of control children. This result is in agreement with the
western blot data reported by Ciccocioppo et al [34] and by Juuti-
Uusitalo et al [7]. However, we observed a more evident nuclear
localization of beta-catenin, albeit not statistically significant, in
the small intestinal crypts from our active and GFD CD patients
than in controls, which suggests activation of the WNT pathway.
The latter finding is in agreement with a previous study of human
CD [7] and with the increased mRNA levels of the genes in
the WNT pathway, including beta-catenin, observed in the
KLF4DELTAIS mouse [27]. Globally, our data support increased
cellular proliferation in the small intestinal epithelium in CD
patients. As it is well known, active CD is characterized by an
inversion of the differentiation/proliferation program of the
intestine with a reduction in the differentiated compartment, up
to complete villous atrophy, and an increase of the proliferative
compartment, with crypt hyperplasia [7,8]. Furthermore, although
GFD intestinal mucosa is characterized by an apparently normal
mucosal architecture, it can also be associated with increased crypt
cell proliferation (Barone M. V. et al., personal communication).
Our data are in contrast with those obtained in mouse models, in
which NOTCH1 activation resulted in a reduction of goblet cells
consequent to HES-1 dependent repression of Math1 (intestinal
secretory cell differentiation factor) [18] and in which NOTCH1
inhibited the expression of KLF4 [35]. However, our data are in
agreement with a recent report of increased proliferation, reduced
differentiation and goblet cells maturation associated with down-
regulation of the expression of components of the Notch pathway
(HES1, DLL1, JAG1) in the small intestine of the KLF4DELTAIS
mouse [27]. The authors for the latter article hypothesized that
KLF4 was involved in a feed-back loop by positively regulating
Notch signaling. Our results are suggestive that an altered
NOTCH1 and KLF4 expression could lead to the reduction of
goblet cells in the small intestine of CD patients. The maintenance
of a correct number of functional goblet cells is required for the
homeostasis of the intestinal mucosal environment, and deficien-
cies in the mucin composition renders the mucosa more
susceptible to damaging agents in the lumen [36–38]. In fact,
loss of goblet cell function leads to spontaneous colitis in mice [39].
Moreover, an altered mucous layer and increased rod-shaped
bacteria and interferon-gamma mRNA levels were found in
Figure 2. Decreased expression of NOTCH1 in small intestine of CD patients compared with controls. An example of NOTCH1
immunohistochemistry in small intestine. A. Low magnification picture of the intestinal sections (Original magnification 106). B. Intestinal crypts
(Original magnification 406). Note the homogeneous distribution of NOTCH1 in crypts and along the villi in control sample, whereas in active CD and
GFD samples the signals were prevalently detected in the crypts. Higher levels of NOTCH1 were detected in the intestinal crypts of controls than in
crypts of active and GFD CD samples. C. Images converted for automated analysis (white: unstained cells, yellow/orange: low/moderately stained
cells, brown: intensely stained cells). These results indicate that NOTCH1 is less expressed in the small intestine of active and GFD CD samples
compared with controls. (CTRL: controls; GFD: gluten free diet; CD: celiac disease).
doi:10.1371/journal.pone.0029094.g002
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intestine from CD patients [40]. Based on these experimental data,
we suggest that the mucus layer in our CD children could be
altered so deranging the protective function of the mucosal barrier
that interfaces with the environment. In our study, the observed
small intestine alterations are not related to inflammation; in fact,
they occurred in both the active CD and GFD patients. The major
criticism in our work is the gap between the results of the miRNA
array with NOTCH1 gene in a vivo system, however the lack of a
celiac animal model at moment, prevent us from this further
validation of our data. Nevertheless, our first description of
miRNA pattern in celiac disease and of the correlation of miRNA
449a over expression with NOTCH pathway could pave the way
for further research in this field. However, our choice to study
Notch pathway doesn’t exclude that other relevant biological
pathways in addition to it could be miRNA-deregulated in the
celiac intestine. Further deeper investigation are necessary to test
this hypothesis.
In conclusion we first demonstrate a miRNA mediated gene
regulation in small intestine of CD patients. We also highlighted a
reduced NOTCH1 pathway in our patients, irrespective of whether
Figure 3. Decreased expression of HES1 in small intestine of CD patients compared with controls. An example of HES1
immunohistochemistry in small intestine. A. Low magnification picture of the examined intestinal sections (Original magnification 106). B. Intestinal
crypts (Original magnification 406). Note the homogeneous distribution of HES1 in crypts and along the villi in control sample, whereas the signals
were prevalently detected in the crypts of active CD and GFD samples. Higher levels of HES1 were detected in the intestinal crypts of controls than in
crypts of active and GFD CD samples. C. Images converted for automated analysis (white: unstained cells, yellow/orange: low/moderately stained
cells, brown: intensely stained cells). These results indicate that HES1 is less expressed in the small intestine of active and GFD CD samples compared
with controls. (CTRL: controls; GFD: gluten free diet; CD: celiac disease).
doi:10.1371/journal.pone.0029094.g003
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the disease was active or not. We suggest that NOTCH pathway
could be constitutively altered in the celiac small intestine and could
drive the increased proliferation and the decreased differentiation of
intestinal cells towards the secretory goblet cell lineage.
Materials and Methods
Ethics approval
The study was conducted according to the Helsinki II
declaration and it was approved by the Ethics Committee of the
School of Medicine Federico II, Naples, Italy.
Written informed consent was obtained from the parent/guardian
of all children involved in our study before their enrollment.
Patients and controls
Forty-four children were recruited, in a two months period,
among patients attending the Department of Paediatrics of the
University of Naples Federico II where the European Laboratory
for the Investigation of Food-Induced Diseases (ELFID) is also
present. In our center about 40 biopsies are monthly performed
and about 50% of them are usually indicative of CD. Twenty/44
children were diagnosed celiacs according to the criteria
established by the European Society for Paediatric Gastroenter-
ology, Hepatology and Nutrition (ESPGHAN) [41]; the CD was
excluded based on both absence of CD antibodies and slight or no
abnormalities in the mucosal architecture in 15/44 children. In
four of these latter children (4/15) the final diagnoses were IgA
deficiency (2 cases), De George syndrome (1 case) and autoim-
mune thyroiditis (1 case), these subjects were excluded from the
study to avoid potentially confounding diseases. In the other 11/15
CD-negative children the final diagnoses were: Helicobacter pylori
infection, recurrent vomiting, food refusal or reflux esophagitis,
they were our enrolled controls. Nine out 44 children were CD
patients on gluten free diet for at least 2 years undergoing CD
Figure 4. Decreased expression of MUC2 in small intestine of CD patients compared with controls. Immunohistochemistry of goblet
cells in small intestine. A. An example of staining for MUC-2 shows fewer MUC-2 stained cells in active and in GFD CD samples than in controls.
(Original magnification 206). B. MUC2 stained cells evaluated in CD patients (6 active CD and 6 GFD patients) and in controls (n = 4). Data are
expressed as mean of the number of goblet cells/crypt measured in 10 crypts/children. Significantly fewer stained cells were detected in active and
GFD CD samples than in controls (p = 0.04). These results indicate that MUC2 is less expressed in small intestine of active and GFD CD patients
compared with controls. (CTRL: controls; GFD: gluten free diet; CD: celiac disease).
doi:10.1371/journal.pone.0029094.g004
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follow-up in the same study period of the active CD patients and
controls. There was no statistically significant difference in mean
age at diagnosis among the groups evaluated (4.361.3 years old in
active CD subjects, 7.662.5 in GFD subjects, and 6.161.0 in
controls [mean6SEM]). About 50% of each group was girls. From
all participants, we collected a fasting serum sample, a blood
sample with EDTA, and a small intestine biopsy sample.
Biochemical parameters
Anti-Endomysium IgA were detected by indirect immunofluo-
rescence on rhesus monkey esophagus substrate (Eurospital,
Trieste, Italy); tTG IgA, anti-gliadin (AGA) IgA/IgG were
analyzed by ELISA with human recombinant tTG as antigen
(DIA Medix Corp., Miami, FL, USA).
Histopathological analysis
Architectural abnormalities were classified according to the
modified Marsh classification: normal mucosa (T0), intraepithelial
lymphocytosis (TI), intraepithelial lymphocytosis and crypt hyper-
plasia (TII), intraepithelial lymphocytosis, crypt hyperplasia and
villous atrophy (partial TIIIA, subtotal TIIIB, total TIIIC) [42].
DNA and RNA extraction
Genomic DNA was extracted using the Nucleon BACC 2 kit
(Amersham Biosciences Europe, Milan, Italy). Total RNA,
including miRNAs, was extracted from small intestinal biopsy
samples using the Mirvana extraction kit (Applied Biosystems,
Foster City, CA, USA).
HLA typing
DQ2/DQ8 HLA CD-associated molecules were identified by
using primers and the PCR conditions of a commercial kit (BAG
Health care GmbH, Lich, Germany), which allows to identify the
HLA-alleles coding DQ2/DQ8 molecules.
MiRNAs evaluation
TaqMan low density arrays (TLDA), micro fluidic cards were
used to detect and quantify mature miRNAs (Applied Biosystems’
7900HT) according to manufacturer’s instructions (see Materials
and Methods S1 for details). We considered differently expressed
in CD vs controls, the miRNAs whose mean RQ levels were #0.5
(down-regulated) or $2.0 (up-regulated).
Bioinformatic approach
The prediction of putative target genes of miRNAs was
determined using miRecords (http://mirecords.biolead.org/),
which is an integration of 11 established miRNA target prediction
programs. The lists of target genes that were predicted by two or
more programs were then combined and analyzed using the Gene
Ontology Tree Machine (GOTM) (http://bioinfo.vanderbilt.edu/
gotm/) and KEGG database (http://www.genome.ad.jp/kegg/).
Finally, we identified the biological pathways that contained at
least two up- or down-regulated genes with a statistically
significant probability (p,0.01).
Quantitative real-time polymerase chain reaction (qRT-
PCR) of miRNAs and mRNAs
The levels of a group of deregulated miRNAs (up-regulated
miR-449a, down-regulated miR-124a, and similar to controls
expressed miR-564) were also evaluated with TaqMan miRNA
assays (Applied Biosystems) to validate the array results.
mRNA expression levels of neurogenic locus notch homolog
protein 1 (NOTCH1) and of hairy and enhancer of split 1 (HES1)
were measured in small intestinal tissues by qRT-PCR using single
TaqMan mRNA assays (Applied Biosystems) according to the
manufacturer’s instructions and using the housekeeping gene beta-
actin as control. Reverse transcription reactions were performed
with the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). The expression levels of miRNAs and mRNAs were
quantified using the ABI Prism 7900HT Sequence Detection
System 2.3 software.
Transfection and inhibition experiments
The oligonucleotides, plasmids (pGL3-control, pRL-NOTCH1-
encoding, pRL-KLF4-encoding and mutated pR-KLF4-encoding,
firefly luciferase and Renilla luciferase, respectively) and human
embryonic kidney cell lines (HEK293 cell line, ATCC number
CRL-1573, supplied by the Centre for Applied Microbiology and
Research, Salisbury, Wiltshire, UK) used for cell transfection
experiments are described in detail in the online Materials and
Methods S1.
Forty-eight hours after transfection, we measured firefly and
Renilla luciferase activities using a dual luciferase assay according
to the manufacturer’s instructions (Promega, Naples, Italy).
Protein evaluation by immunohistochemistry
Given the small amount of sample available for each patient (1–
2 mg of intestinal tissue/patient) we tested the expression of
selected proteins by immunohistochemistry instead of by western
blotting. The NOTCH1, HES1, MUC-2, KLF4, Ki67 and beta-
catenin proteins were identified on formalin-fixed paraffin-
embedded small intestinal tissue blocks in CD patients and in
controls. We randomly selected six active CD, six GFD and four
controls (see Materials and Methods S1 for details). We also tested
the specificity of our NOTCH1 and HES1 signals evaluating two
different human tissue samples where it is known NOTCH1 and
HES1 be present or absent respectively, that are colon cancer and
endothelial wall (Figure S8).
Scanning and automated image analysis of NOTCH1 and
HES1
To increase precision, we automated the quantification of the
immunohistochemical signals. Sections of the small intestine were
scanned with the NanoZoomer 2.0 system (Hamamatsu, Japan),
equipped with a 206, 0.7 Numerical Aperture Plan-Apochromat
lens, using a lens of 0.23 mm pixel size. The compressed jpeg files
were transferred to the Definiens Analyst LS5.0 system (Definiens
AG, Germany) that counted the NOTCH1, HES1 and beta-
catenin -positive and -negative cells and quantified the staining
signal (see materials and methods S1 for Definiens Analyst
software details). The Definiens Analyst software (Definiens AG,
Germany) is based on cognition network technology that is a
semantic network of objects and their mutual relationships. Two
rule sets, using cognition network language, were specifically
written for this evaluation to automatically detect and measure the
small intestinal area and to count positive and negative crypt cells.
The signal was classified as intensely stained, low/moderate
stained and unstained. Thus, both the percentage and intensity of
labeled cells were taken into account. The detection and exclusion
of areas not belonging to crypt were visually checked for all image
files. Ten crypts/patient were counted.
Immunohistochemical analysis of MUC-2, KLF4 and beta-
catenin
Because the MUC-2 staining of goblet cells was patchy, we
picked ten crypts from each slide and manually counted the
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number of goblet cells stained in each crypt. We also evaluated
MUC-2 staining of villi, when possible, i.e., in GFD patients and
controls. We also evaluated KLF4-positive villi (in GFD patients)
and both beta-catenin- and Ki67-positive nuclei/crypt in each
subject. Two independent observers evaluated the immunohisto-
chemical slides.
Statistics
All variables were expressed as mean6standard error of the
mean (SEM). Student t’s test and ANOVA were used to compare
group means and p values,0.05 were considered significant.
Statistically significant (p,0.01) miRNA-regulated pathways were
selected by the GOTM program.
Supporting Information
Materials and Methods S1
(DOC)
Figure S1 Bioinformatics analysis of miR-449a putative
target genes. miR-449a putative target genes with most favor-
able context score, selected by bioinformatics, were sorted into
pathways using GOTM(http://bioinfo.vanderbilt.edu/webgestalt/)
and then combined into functional groups. (http://mirecords.
biolead.org/interactions.php?species=Homo+sapiens&mirna_acc
=hsa-miR-449a&targetgene_type=refseq_acc&targetgene_info=&
v=yes&search_int=Search) (http://www.targetscan.org/cgibin/
targetscan/vert_50/targetscan.cgi?species=Human&gid=&mir_sc
=&mir_c=&mir_nc=&mirg=hsa-miR-449a). In each functional
group are reported the genes belonging to NOTCH pathway/
total gene number.
(TIF)
Figure S2 The luciferase assay confirms that miR-449a
inhibits the expression of NOTCH1 and KLF4. In
HEK293 cells co-transfected or with pRL-NOTCH1 vector
(panel A) or with pRL-KLF4 vector (panel B), a pre-miR-449a
concentration of 100 nmol/L was sufficient to significantly reduce
(respectively, p = 0.001 and p = 0.002) Renilla luciferase activity
versus control values. No inhibition of the Renilla luciferase
expression was observed in mutant 39UTR of KLF4-mRNA with
miR-449a, so confirming the miR-449a/39UTR KLF4-mRNA
direct interaction (panel B). We didn’t verify the interaction miR-
449a/39UTR NOTCH1 being this latter recently validated by
Marcet B et al [32].
(TIF)
Figure S3 Automated Counts of NOTCH1 and HES1
stained/unstained cells. A. Automated counts of NOTCH1
stained/unstained cells (reported in Figure 2) in small intestine
from CD patients (6 active CD and 6 GFD patients) and from
controls (n = 4). Data are expressed as mean percent of intensely
stained, low-moderately stained and unstained cells of the total
intraepithelial cells (IECs) counted in ten crypts. The numbers of
intensely stained and unstained cells were significantly (p = 0.02)
higher and lower, respectively, in CTRL than in active CD and
in GFD patients. B. Automated counts of HES1 stained/
unstained cells (reported in Figure 3) in small intestine from
CD patients (6 active CD and 6 GFD patients) and from controls
(n = 4). Data are expressed as mean percent of intensely stained,
low-moderately stained and unstained cells of the total intraep-
ithelial cells (IECs) counted in ten crypts. The number of
intensely stained cells was significantly higher in controls versus
CD and GFD patients (p = 0.02) and the number of unstained
cells was significantly lower in CTRL than in active CD patients
(p = 0.03). (CTRL: controls; GFD: gluten free diet; CD: celiac
disease).
(TIF)
Figure S4 Other examples of NOTCH1 immunohisto-
chemistry in CD patients. Examples of NOTCH1 immuno-
histochemistry in 4 CD patients (2 active CD: TIII Marsh stage and 2
GFD: TI and T0 Marsh stage) and 2 controls (T0 Marsh stage). The
images show that the low expression levels of NOTCH1 in intestinal
mucosa from CD patients were always present from TIII to T0 Marsh
stage. (CTRL: controls; GFD: gluten free diet; CD: celiac disease).
(TIF)
Figure S5 Other examples of HES1 immunohistochem-
istry in CD patients. Examples of HES1 immunohistochemistry
in 4 CD patients (2 active CD: TIII Marsh stage and 2 GFD: TI and
T0 Marsh stage) and 2 controls (T0 Marsh stage). The images show
that the low expression levels of HES1 in intestinal mucosa from CD
patients were always present from TIII to T0 Marsh stage. (CTRL:
controls; GFD: gluten free diet; CD: celiac disease).
(TIF)
Figure S6 Decreased KLF4 and increased Ki67 expres-
sion in small intestine from CD patients compared with
controls. A. KLF4 staining of small intestinal villi in GFD
patients and Controls (Original magnification 206). A statistically
significant reduced KLF4-positive cells/villi were counted in GFD
patients than in controls, respectively 29.065.0 vs 79.063.0
(mean6SEM) (p,0.0001). B. Increased Ki67 signal is present in
small intestinal crypts of active CD, GFD patients than in controls
(Original magnification 206). (CTRL: controls; GFD: gluten free
diet; CD: celiac disease).
(TIF)
Figure S7 Increased expression of beta-catenin in small
intestine from CD patients compared with controls.
Immunostaining with beta-catenin in small intestinal crypts from
active CD, GFD and controls. We counted the beta-catenin
labeled nuclei. Similar counts of beta-catenin labelled nuclei were
detected in the crypts of the small intestine in all groups. However,
higher even if not statistical significant mean percentage counts
(beta-catenin positive nuclei/crypt) were obtained in active CD
and GFD than in controls, respectively 57.0611.5 and 37.064.6
vs 27.064.6 (Original magnification 636). (CTRL: controls; GFD:
gluten free diet; CD: celiac disease).
(TIF)
Figure S8 Specificity of NOTCH1 and HES1 signals by
immunohistochemistry. Specificity controls of NOTCH1 and
HES1 antibodies. Positive NOTCH1 (A) and HES1 (B) immuno-
staining signals obtained in human colon cancer and negative
NOTCH1 (C) and HES1 (D) immunostaining signals obtained in
human endothelial wall.
(TIF)
Table S1 MiRNAs differently expressed in active and
GFD CD patients.
(DOC)
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ABSTRACT: Adipose tissues show selective gene expression patterns, to
whom microRNAs (miRNAs) may contribute. We evaluated in visceral
adipose tissue (VAT) from obese and nonobese females, both miRNA and
protein expression proﬁles, to identify miRNA/protein target pairs associated
with obesity (metabolic pathways miRNA-deregulated during obesity). Obese
and nonobese females [BMI 42.2 ± 1.6 and 23.7 ± 1.2 kg/m2 (mean ± SEM),
respectively] were enrolled in this study. Notably, most miRNAs were down-
expressed in obese tissues, whereas most of the proteins from the investigated
spots were up-expressed. Bioinformatics integration of miRNA expression and
proteomic data highlighted two potential miRNA/protein target pairs: miR-
141/YWHAG (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, gamma polypeptide) and miR-520e/RAB11A (Ras-related
protein RAB-11A); the functional interaction between these miRNAs and
their target sequences on the corresponding mRNAs was conﬁrmed by luciferase assays. Both RAB11A and YWHAG proteins
are involved in glucose homeostasis; YWHAG is also involved in lipid metabolism. Hence, the identiﬁed miRNA/protein target
pairs are potential players in the obese phenotype.
KEYWORDS: obesity, visceral adipose tissue, miRNAs, 2D-DIGE
■ INTRODUCTION
Obesity is an epidemic health problem worldwide that causes
morbidity and mortality associated with increased risk of
cardiovascular disease, metabolic syndrome, and cancer.1,2 In
particular, central obesity, i.e., fat accumulated in visceral
adipose tissue (VAT), is the major risk factor for obesity-related
disorders.3,4 VAT represents up to 10−20% of total fat in men
and 5−8% in females. It is anatomically present in the
mesentery and omentum, and it drains directly to the liver
through the portal vein. This characteristic allows the direct
access of the free fatty acids and of adipokines released from fat
to the liver.4 In addition, adipose tissues show selective gene
expression patterns,2,3,5,6 to whom microRNAs (miRNAs) may
contribute.7 miRNAs are small noncoding RNAs ∼21
nucleotides long that bind speciﬁc regions of mRNA targets to
mediate their cleavage or translational repression, and they regulate
about 50% of human genes.8 In mammals, miRNAs have been also
shown to modulate adipocyte diﬀerentiation.9 Previous work from
our laboratory showed that up-expression of miR-519d in
subcutaneous adipose tissue (SAT) from obese patients was
associated with down-expression of the PPARA protein.10 There
are biological diﬀerences between VAT and SAT. In fact, compared
with SAT, VAT contains more large and insulin-resistant
adipocytes and inﬂammatory cells such as macrophages that
secrete pro-inﬂammatory cytokines (TNF-α, IL-6, and CRP).4
In the present study, we evaluated miRNA and protein
signatures using transcriptomic and proteomic approaches,
respectively, in VAT from the women studied previously. Our
aim was to investigate for metabolic pathways miRNA-
regulated in VAT that could be altered during obesity. Our
results indeed show that VAT from obese females is
characterized by peculiar miRNA and protein expression
signatures. Most of the tested miRNAs are down-expressed in
VAT from obese females. Accordingly, most of proteins in VAT
from the obese group showed increased levels by proteomic
proﬁle. Finally, the functional association of the transcriptomic
and proteomic proﬁles revealed two potential miRNA/protein
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target pairs in VAT, namely, miR-141/YWHAG (tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation pro-
tein, gamma polypeptide) and miR-520e/RAB11A (Ras-related
protein RAB-11A), which may contribute to altered gene
expression in obesity.
■ EXPERIMENTAL SECTION
Subjects and Experimental Design
Fifteen obese females (age range: 19−65 years, BMI [mean ±
SEM] 42.2 ± 1.6 kg/m2) and 10 nonobese females (age range:
19−57 years, BMI [mean ± SEM] 23.7 ± 1.2 kg/m2) were
enrolled in the study. During surgery (gastric banding or
laparoscopic cholecystectomy for obese and nonobese females,
respectively), a bioptic sample of VAT was collected and frozen
in liquid nitrogen. The main anamnestic, clinical, and general
characteristics of the enrolled subjects were recorded at
admission. The day before surgery, a fasted blood sample was
collected from all subjects and tested for the main biochemical
parameters (glucose, cholesterol, triglycerides, AST, ALT, ALP,
GGT) by routine methods (Table 1). Written informed consent
was obtained from all recruited subjects, and the study was
approved by the Ethics Committee of our Faculty of Medicine.
RNA Isolation
Total RNA (including miRNAs) was isolated from the VAT of
all subjects using the mirVana miRNA isolation kit (Ambion,
Austin, TX, USA) according to the manufacturer’s instructions.
RNA concentration was evaluated using the NanoDrop ND-
1000 UV−vis spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA).
The total RNA isolated from nonobese females was pooled
to serve as control in the comparison of the miRNA expression
proﬁles of the obese females.
miRNA Expression Proﬁle
We used the commercially available TaqMan Array Human
MicroRNA Panel v1.0 (Applied Biosystems Inc., Foster City,
CA, USA) to measure miRNA expression proﬁle in 10/15
obese and 4/10 nonobese females. The panel contains 365
diﬀerent human miRNA assays in addition to two small
nucleolar RNAs (snoRNAs) that function as endogenous
controls for data normalization. We used 80 ng of total RNA
for reverse transcription. RT-PCR was performed using the
7900 HT real-time PCR system (Applied Biosystems). The
miRNA expression values were normalized to RNU48
(endogenous control), and relative expression values were obtained
using the ΔΔCT method (relative quantiﬁcation, RQ = 2−ΔΔCT)
with sequence detection system (SDS) v2.3 and RQ Manager 1.2
software (Applied Biosystems). To further normalize our miRNA
data and to minimize interindividual variability, we considered
diﬀerently expressed the miRNAs whose mean RQ levels were
<0.5 (down-expressed) or >2.0 (up-expressed) in at least 6/10
obese females.
Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR) of miRNAs and mRNAs
The expression levels of some selected miRNAs (miR-141,
miR-200c, miR-520e, and miR-520d) were also validated by
TaqMan miRNA assays (Applied Biosystems) in accordance
with the manufacturer’s instructions on the 7900 HT real-time
PCR system (Applied Biosystems). The expression of one of
these selected miRNAs, namely, miR-141, was preliminarily
tested in each nonobese control, and after ensuring that the
expression was comparable among these individuals, we pooled
their RNAs to obtain a control against which to compare
miRNA levels in obese females.
The expression levels of the selected miRNAs (miR-141,
miR-200c, miR-520e, and miR-520d) were ﬁrst normalized to
the endogenous control (RNU48), and then the relative
expression values were obtained versus the nonobese control
pool using the ΔΔCT method (relative quantiﬁcation, RQ =
2−ΔΔCT) with SDS v2.3 and RQ Manager 1.2 software (Applied
Biosystems).
Real-time RT-PCR of RAB11A and YWHAG mRNAs was
performed using gene- speciﬁc primers (RAB11a, forward:
AACATCAGCATATTATCGTGGA and reverse: GAT-
CACTCTTATTGCCCACA; YWHAG, forward: AGACC-
CAGCCCCGCGAAGAT and reverse: TCTGTCACGTTCT-
TCATGGCCGC), the Power SYBR Green PCR Master Mix
(Applied Biosystems) and the PRISM 7900HT sequence
detection system (Applied Biosystems).
Bioinformatic Analysis
Biological targets of miRNAs diﬀerently expressed in obese vs
nonobese females were predicted using the TargetScan Release
5.0 algorithm (http://www.targetscan.org). This algorithm
assigns a “total context score” for each predicted target. Target
genes with a “total context score” < −0.30 were further
analyzed using the KEGG database (http://www.genome.ad.
jp/kegg/) to identify the pathways that involve the target genes
of miRNAs and then using the Gene Ontology (GO) database
(http://www.geneontology.org/ontologies) to identify the
biological processes in which the proteins identiﬁed by DIGE
participate. Gene ontology classiﬁcation of the diﬀerentially
expressed proteins revealed by 2D-DIGE analysis was
performed in the web-accessible DAVID (v 6.7) annotation
system (http://david.abcc.ncifcrf.gov/home.jsp).11,12
Table 1. General Characteristics of the Obese (n = 15) and
Nonobese (n = 10) Females Enrolled in the Studya
females
obese nonobese
subjects (n) 15 10
age (years) 41.6 (4.4) 38.0 (3.5)
weight (kg)†b 115.2 (6.3) 62.5 (2.6)
height (m) 1.7 (0.04) 1.6 (0.01)
BMI (kg/m2)‡b 42.2 (1.6) 23.7 (1.2)
systolic blood pressure (mmHg) 133.6 (6.7) 115 (4.5)
diastolic blood pressure (mmHg)c 80.0 (80.0−90.0) 80.0 (70.0−80.0)
cardiac frequencyd 80.0 (2.2) 67.6 (3.7)
glucose (mmol/L)e 4.9 (0.2) 4.3 (0.2)
cholesterol (mmol/L) 5.9 (0.5) 5.8 (0.6)
triglycerides (mmol/L) 1.4 (0.1) 0.9 (0.1)
AST (U/L)c 18.5 (16.0−21.0) 18.0 (13.5−19.0)
ALT (U/L)c 17.0 (13.0−28.5) 14.0 (12.0−21.0)
ALP (U/L) 79.3 (5.8) 89.2 (19.3)
GGT (U/L) 28.5 (4.7) 17.3 (3.5)
aData are expressed as mean (SEM) value (unless speciﬁed otherwise)
and interquartile range (nonparametric distributions). bStatistically
signiﬁcant diﬀerences (designated by † and ‡) at Student's t test
p < 0.0001. cData are expressed as median value. dp = 0.01. ep = 0.03.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr300152z | J. Proteome Res. 2012, 11, 3358−33693359
Preparation of Protein Extracts and Two-Dimensional
Fluorescence Diﬀerence Gel Electrophoresis (2D-DIGE)
Analysis
Protein extracts from VAT samples of 6/15 obese and 3/10
nonobese females were prepared using a lysis buﬀer containing
2% SDS, 10% glycerol, 6.25 mM Tris-HCl pH 6.8, 0.5 mM
EDTA, 20 mM NaF, 1 mM Na3VO4 (Santa Cruz Biotech-
nology, Santa Cruz, CA), and the Sigma-Aldrich cocktail of
protease inhibitors. The suspensions were shaken in Tissue
Lyser II (Qiagen) for 4 min at maximum frequency. After
30 min on ice, samples were centrifuged at 15000g for 10 min
at 4 °C. The clear interface of each sample was recovered and
was transferred to a clean tube. Protein concentrations were
determined by the Bradford method using BioRad protein
reagent (Bio-Rad Laboratories, Hercules, CA). For 2D-DIGE
analysis, proteins extracted from VAT were precipitated for
16 h at −20 °C with 9 volumes of a mix composed of acetone
and methanol (9:1) and then centrifuged at 15000g for 30 min
at 4 °C; protein pellets were solubilized in a buﬀer, UTC,
containing 7 M urea, 2 M thiourea, 4% CHAPS (3-[(3-
cholamidopropyl)dimethylammonium]-1-propane sulfonate) in
30 mM Tris-HCl. Protein concentrations were redetermined
after precipitation by using BioRad protein reagent. Thirty
micrograms of each protein extract were labeled with 240 pmol
of Cy3 or Cy5 ﬂuorescent dye on ice, in the dark for 30 min.
To exclude preferential binding of a label to a set of proteins,
we dye-swapped the samples. The internal standard containing
equal amounts of proteins from each sample was labeled with
Cy2. The same internal standard was run in all gels to
normalize the experiments and to reduce gel-to-gel variations.
Labeling reactions were stopped by adding 1 mM lysine.
Sample pairs labeled with Cy3 and Cy5 and the internal
standard were combined and used to hydrate passively
individual strips as follows: each mix of labeled samples was
diluted in UTC solution containing 130 mM DTT, 2% IPG
Buﬀer pH 3−10 NL (GE Healthcare, Buckinghamshire, UK),
2.8% DeStreak reagent (GE Healthcare) in a ﬁnal volume of
400 μL. The mixtures were used to hydrate 24 cm IPG strips
pH 3−10NL required for protein separation in the ﬁrst
dimension. Isoelectric focusing (IEF) was run in an IPGphor II
apparatus (GE Healthcare) according to this voltage protocol:
300 V for 3 h, linear gradient to 600 V in 3 h, linear gradient to
1000 V in 3 h, linear gradient to 8000 V in 5 h, 8000 V for 6 h.
After the ﬁrst dimension, the strips were equilibrated in
equilibration buﬀer (100 mM Tris-HCl, 6 M urea, 30% (v/v)
glycerol, 2% (w/v) SDS, and trace of bromophenol blue,
pH 8.0) containing 0.5% (w/v) DTT for 15 min and thereafter
in equilibration buﬀer containing 4.5% (w/v) iodoacetamide for
a further 15 min. The equilibrated strips were transferred onto
12% polyacrylamide gels for the second dimension (Ettan Dalt
six electrophoresis system, GE Healthcare). The SDS-PAGE
electrophoresis was run using a Peltier-cooled DALT II
Electrophoresis unit (GE Healthcare) at 30W. After the
electrophoresis, the gels were scanned with a Typhoon 9400
variable mode imager (GE Healthcare) at 100 μm resolution,
using appropriated individual excitation/emission wavelengths:
488/520 for Cy2, 532/580 for Cy3 and 633/670 for Cy5. The
images were captured with Image Quant software and were
analyzed with DeCyder software (GE Healthcare). We chose
the most representative gel as master gel to compare results
obtained from other samples. Globally we analyzed VAT
samples from 6 randomly selected obese (mean BMI 38.7) and
3 nonobese females (mean BMI 23.5). We used the Student’s t
test to determine the fold change between obese and nonobese
females. Only protein spots with a p < 0.05 were investigated
further.
Protein Identiﬁcation with Liquid
Chromatography−Tandem Mass Spectrometry
(LC−MS/MS)
We used 250 μg of protein sample for the preparative gel. After
2D-electrophoresis, performed under the conditions reported
for the analytical experiment, the gel was stained with SYPRO
Ruby ready-to-use formula (BIORAD), and the spot map so
obtained was matched with the analytical reference gel. The
spots diﬀerentially expressed in obese and nonobese females
were excised from the preparative gel using the Ettan Spot
Picker robotic system (GE Healthcare). The excised spots were
analyzed with LC−MS/MS (Functional and Structural
Proteomics Facility, CEINGE−Biotecnologie Avanzate, Italy).
The excised spots were washed in 50 mM ammonium
bicarbonate pH 8.0 in 50% acetonitrile to a complete
destaining. The gel pieces were resuspended in 50 mM
ammonium bicarbonate pH 8.0 containing 100 ng of trypsin
and incubated for 2 h at 4 °C and overnight at 37 °C. The
supernatant containing the resulting peptide mixtures was
removed, and the gel pieces were re-extracted with acetonitrile.
The two fractions were then collected and freeze-dried. The
peptide mixtures were further analyzed by LC−MS/MS using
the LC−MSD Trap XCT Ultra apparatus (Agilent Technolo-
gies, Palo Alto, CA, USA) equipped with a 1100 HPLC system
and a chip cube (Agilent Technologies). After loading, the
peptide mixture (8 μL in 0.5% TFA) was ﬁrst concentrated at 4
μL/min in 40 nL enrichment column (Agilent Technologies
chip), with 0.1% formic acid as eluent. The sample was then
fractionated on a C18 reverse-phase capillary column (75 μm ×
43 mm in the Agilent Technologies chip) at a ﬂow rate of 300
nL/min, with a linear gradient of eluent B (0.1% formic acid in
acetonitrile) in eluent A (0.1% formic acid) from 7 to 50% in
35 min. Elution was monitored on the mass spectrometer
without a splitting device. Peptide analysis was performed using
data-dependent acquisition of one MS scan (m/z range from
400 to 2000 Da/e) followed by MS/MS scans of the three most
abundant ions in each MS scan. Dynamic exclusion was used to
acquire a more complete survey of the peptides by automatic
recognition and temporary exclusion (2 min) of ions from
which deﬁnitive mass spectral data had previously been
acquired. A permanent exclusion list of the most frequent
peptide contaminants (keratins and trypsin peptides) was
included in the acquisition method in order to focus on
signiﬁcant data. Mass spectral data obtained from the LC−MS/
MS analyses were used to search a nonredundant protein
database using an in-house version of the Mascot v. 2.1 (Matrix
Science, Boston, MA, USA) software and NCBI database
(221,338 human sequences, timestamp: March and April,
2009). Peptide mass values and sequence information from the
LC−MS/MS experiments were used in the MS/MS ion search
taking into account the Carbamidomethyl-Cys as ﬁxed
modiﬁcation, Met oxidized, Pyro-Carbamidomethyl-Cys (with
N-term Carbamidomethyl-Cys) and Pyro-Glu (with N-term E)
as variable modiﬁcations. The maximum missed cleavage of 1,
and a precursor ion and fragment ion mass tolerance of ±600
ppm and 0.6 Da, respectively, were used. In agreement with the
proposed Guidelines for the Analysis and Documentations of
Peptide and Protein Identiﬁcations (Paris Consensus), we
report the number of identiﬁed peptides whose individual ion
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score (as provided by Mascot) was higher than the designated
conﬁdence level (95%)/protein sequence coverage (%). The
sequences and charge state of the peptides used for protein
identiﬁcation of each DIGE spot obtained by LC−MS/MS are
reported in Supporting Information Table S1.
Western Blot
Protein evaluation by Western blot was performed in 8/15
obese and 7/10 nonobese females with 35 μg of total proteins
separated by SDS-PAGE (13% polyacrylamide gel) and
electroblotted onto hydrophobic polyvinylidene diﬂuoride
(PVDF) membranes (Amersham) for 19 h at 33 V. Blots
were blocked with 5% BSA in TBS buﬀer with 0.1% Tween 20
for 2 h at room temperature. Immunoblotting was performed
with the speciﬁc polyclonal antibody: rabbit anti-14-3-3γ
(dilution 1:800), rabbit anti-RAB11A (1 μg/mL), and rabbit
antiactin (dilution 1:800) (Abcam, Cambridge, UK) for 4 h.
For the following incubation with primary antibody, membrane
was washed in TBS buﬀer with 0.1% Tween 20 and incubated
for 45 min IgG-HRP-conjugated secondary antibody (dilution
1:10000 for anti-14-3-3γ and antiactin; 1:50000 for anti-
RAB11A). Immunoreactive bands were visualized with the
chemiluminescence reagent kit (ECL Western blotting
detection reagents, GE Healthcare). We used the same
membrane for each immunoblot, washing it in TBS buﬀer
with 0.1% Tween 20 for 10 min after each experiment.
After each immunoblot, the membrane was exposed to X-ray
ﬁlm (Amersham) for diﬀerent times. The images of three
diﬀerent exposures were captured by Gel Doc XR (Bio-Rad)
and quantitated with the Quantity One software (Bio-Rad).
Each protein band was contained within a rectangular area,
identical for each sample, and background values were
subtracted from each band. The triplicate sample values were
normalized to the corresponding triplicate actin values. Then,
the mean values from the diﬀerent ratio calculations were
calculated for each sample. The data were expressed as percent
relative expression, the sample with the highest expression of
either RAB11A or YWHAG having been set as 100%. The data
obtained were used to obtain the corresponding box plots and
p-values (Student’s t test) in the Microsoft Excel software.
Oligonucleotides and Plasmids
Chemically modiﬁed double-stranded RNA molecules (micro-
RNA precursor molecules: pre-miR-520e and pre-miR-141)
and pre-miR-negative control were purchased from Ambion
(Austin, TX, USA). The ﬁnal concentration of pre-miR
molecules and the corresponding pre-miR negative control
were 100 nM each. The plasmids used were pGL3-control
(Promega Corp., Madison, WI, USA) encoding for ﬁreﬂy
luciferase and pRL-CMV encoding for Renilla luciferase
(Promega Corp., Madison, WI, USA). The 3′UTRs of
RAB11A (1258−1264 bp 3′UTR) and of YWHAG (2489−
2495 bp 3′UTR) genes, containing respectively the miR-520e
and miR-141 binding sites, as well as the mutated 3′UTRs of
these two genes (three bases of each seed region were changed
by complementary bases), were obtained from genomic DNA
by PCR with a sense and antisense primers carrying a XbaI
restriction site and cloned downstream to Renilla luciferase
gene in pRL-CMV vector in XbaI site.
Cell Culture, Transfection, and Luciferase Assay
Human embryonic kidney (HEK) 293 cells were cultured in
DMEM (Invitrogen) supplemented with 2 mM glutamine
(Invitrogen), 100 U/mL penicillin/streptomycin (Invitrogen),
and 10% FBS (Invitrogen). The day before transfection, cells
were plated in 24-well plates to allow adherence and to reach
70−90% conﬂuence at the time of transfection. Transfection of
plasmids, carrying wild-type or mutant 3′UTRs, with pGL3-
control and each pre-miRNAs or pre-miR negative control
(Ambion, Austin, TX, USA) in HEK293 was performed using
Lipofectamine 2000 following the manufacturer’s instructions.
Fireﬂy and Renilla luciferase activities were measured 48 h after
transfection, with the dual-luciferase reporter system (Prom-
ega) in a Sirius Luminometer (Berthold Detection Systems,
Huntsville, AL, USA). All transfection experiments were done
in triplicate.
Statistical Analysis
The investigated parameters were expressed as mean ±
standard error of the mean (SEM) (parametric distribution)
or as median value and interquartile range (nonparametric
distributions). Student’s t test was used to compare group
means, and a p-level < 0.05 was considered statistically signiﬁcant.
Statistical analyses were carried out with the PASW package for
Windows (Ver.18; SPSS Inc. Headquarters, Chicago, Ill).
■ RESULTS
miRNA Expression Signature in Visceral Adipose Tissue
from Obese Females
Expression proﬁle showed that a large set of the tested miRNAs
was expressed in VAT from both obese and nonobese females
(243/365, 66%). A small set (50/365, 14%) was not expressed,
whereas 72/365 (20%) miRNAs were expressed only in VAT
from one or more obese females. On the basis of the
normalization criteria reported above (see the Experimental
Section), namely, miRNAs whose expression levels versus
controls were up- or down-expressed (respectively, RQ > 2 or <
0.5) in at least 6/10 obese females, we found that 61/243 (25%)
miRNAs were down-expressed, and 10/243 (4.1%) miRNAs were
up-expressed (Table 2). The search for gene targets of these
diﬀerentially expressed miRNAs was performed by TargetScan
5.0 algorithm and their assembly in metabolic pathways by
Kegg database. The main signiﬁcant (p < 0.01) pathways
predicted to be aﬀected by miRNAs in VAT samples during
obesity are reported in Supplementary Figure 1.
Protein Expression Signature in VAT from Obese Females
We studied the protein expression signature of VAT samples
from obese and nonobese subjects using 2D-DIGE analysis.
Figure 1A shows the master gel used to match the whole set of
the 2-DE proﬁles obtained. The analysis performed with
DeCyder Software detected approximately 2700 protein spots
per gel in a 3−10 pH range, with a molecular mass of 10−120
kDa. Approximately 1500 spots were matched throughout the
gels. The DeCyder statistical analysis revealed 172 spots
diﬀerentially expressed in obese vs nonobese VAT samples with
average ratio ≥ 1.50 for up-expressed protein spots and ≤
−1.50 for down-expressed spots (p < 0.05). Some spots were
excluded from further evaluation, i.e., those at the extreme right
and left sides of the gel and those (30 spots) representing
contaminating serum proteins. Furthermore, many spots were
not objected to further investigation, because of their low
abundance on the analytical gel or on the preparative gel. As a
result, we focused on 33 spots with optimal features.
Figure 1B shows the position of the 33 selected spots on the
preparative gel. The latter was stained with SYPRO Ruby
protein stain and used for automated spot picking. The isolated
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spots were digested with trypsin and then analyzed by LC−
MS/MS, followed by database search. The relative expression
ratios (in obese vs nonobese VAT) for each of the 33 spots and
their statistical values are listed in Table 3. Interestingly, most
(32/33) of the spots were increased, and only 1 spot (number
2312) was decreased.
Globally, a total of 67 proteins, after the exclusion of very
abundant proteins that we considered not informative, were
identiﬁed in these spots (http://pubs.acs.org/paragonplus/
submission/jprobs/jprobs_proteomics_guidelines.pdf) (Table
3). Most of these proteins were bioinformatically predicted
by DAVID database to be functionally annotated in two main
clusters (Figure 2). Annotation cluster 1 (Figure 2A) was con-
stituted by the following: (i) 5 members of the 14.3.3 family of
proteins, namely, YWHAB, YWHAE, YWHAG, YWHAH, and
YWHAZ; (ii) 9 proteins (YWHAB, YWHAE, YWHAZ,
RAB11A, RAB7A, ANXA7, ARCN1, FLOT1, and SERPINF1)
involved in the GOTERM_CC_FAT vesicle pathway, on the
basis of their subcellular localization; and (iii) 7 regulated
proteins involved in intracellular protein transport (YWHAB,
YWHAE, YWHAH, YWHAG, YWHAZ, RAB11A, and
ARCN1). Annotation cluster 2 (Figure 2B) was constituted
by a predominance of metabolic enzymes clustered in the
KEGG pathways: valine, leucine, and isoleucine degradation
(6 members, ACAT2, ACADS, ALDH2, BCKDHA, ECHS1, and
HADHB), butanoate metabolism (5 members, ACAT2, ACADS,
ALDH2, ECHS1, and PDHAD1) and fatty acid metabolism
(5 members, ACAT2, ACADS, ALDH2, ECHS1, and HADHB).
miRNA/Protein Target Pairs in VAT from Obese Females
To ﬁnd potential miRNA/protein target pairs, we integrated
miRNA expression and proteomic data. Speciﬁcally, we
combined the list of the identiﬁed protein spots with the
miRNAs predicted to possess the ability to target the proteins
we identiﬁed. The last column of Table 3 shows the potential
miRNA counterparts of the identiﬁed proteins, as revealed by
bioinformatics tools (TargetScan). Among the potential
miRNA/protein target pairs deriving from this analysis, we
Table 2. Diﬀerentially Expressed miRNAs in Visceral Adipose Tissue from Obese Vs Nonobese Females Identiﬁed with the
TaqMan Array Human MicroRNA Panel v1.0a
RQ value
down-expressed miRNAs mean SEM
hsa-miR-514-4373240 0.007 0.002
hsa-miR-520e-4373255 0.014 0.005
hsa-miR-520f-4373256 0.029 0.010
hsa-miR-184-4373113 0.030 0.010
hsa-miR-518d-4373248 0.057 0.021
hsa-miR-196a-4373104 0.059 0.019
hsa-miR-337-4373044 0.065 0.025
hsa-miR-520d-4373254 0.066 0.022
hsa-miR-490-4373215 0.067 0.025
hsa-miR-508-4373233 0.069 0.022
hsa-miR-519c-4373251 0.073 0.026
hsa-miR-369-3p-4373032 0.075 0.025
hsa-miR-202-4378075 0.078 0.027
hsa-miR-141-4373137 0.079 0.025
hsa-miR-562-4380939 0.080 0.030
hsa-miR-591-4380955 0.085 0.028
hsa-miR-580-4381024 0.086 0.029
hsa-miR-380-5p-4373021 0.086 0.029
hsa-miR-518a-4373186 0.092 0.035
hsa-miR-618-4380996 0.096 0.034
hsa-miR-494-4373219 0.097 0.037
hsa-miR-624-4380964 0.099 0.035
hsa-miR-519b-4373250 0.102 0.032
hsa-miR-185-4373181 0.113 0.043
hsa-miR-219-4373080 0.120 0.042
hsa-miR-509-4373234 0.124 0.039
hsa-miR-548d-4381008 0.125 0.047
hsa-miR-206-4373092 0.126 0.042
hsa-miR-200c-4373096 0.130 0.041
hsa-miR-196b-4373103 0.166 0.055
hsa-miR-653-4381012 0.168 0.068
hsa-miR-493-4373218 0.178 0.059
hsa-miR-629-4380969 0.181 0.074
hsa-miR-198-4373101 0.187 0.062
hsa-miR-450-4373208 0.199 0.070
hsa-miR-375-4373027 0.202 0.071
hsa-miR-518b-4373246 0.208 0.069
RQ value
down-expressed miRNAs mean SEM
hsa-miR-137-4373174 0.222 0.091
hsa-miR-649-4381005 0.224 0.079
hsa-miR-189-4378067 0.226 0.080
hsa-miR-489-4373214 0.240 0.085
hsa-miR-451-4373209 0.242 0.099
hsa-miR-615-4380991 0.248 0.083
hsa-miR-335-4373045 0.250 0.088
hsa-miR-215-4373084 0.264 0.088
hsa-miR-422b-4373016 0.271 0.090
hsa-miR-500-4373225 0.271 0.111
hsa-miR-601-4380965 0.285 0.108
hsa-miR-203-4373095 0.298 0.122
hsa-miR-410-4378093 0.298 0.122
hsa-miR-330-4373047 0.320 0.121
hsa-miR-30a-5p-4373061 0.324 0.122
hsa-miR-486-4378096 0.327 0.133
hsa-miR-22-4373079 0.332 0.125
hsa-miR-181c-4373115 0.332 0.117
hsa-miR-30d-4373059 0.334 0.126
hsa-miR-101-4373159 0.346 0.141
hsa-miR-376a-4373026 0.372 0.152
hsa-miR-191-4373109 0.386 0.146
hsa-miR-99a-4373008 0.393 0.161
hsa-miR-7-4373014 0.396 0.162
RQ value
up-expressed miRNAs mean SEM
hsa-miR-433-4373205 21.563 7.624
hsa-miR-520 h-4373258 13.617 5.559
hsa-miR-153-4373125 12.447 4.705
hsa-miR-579-4381023 12.047 4.553
hsa-miR-520b-4373252 9.400 3.553
hsa-miR-616-4380992 3.954 1.495
hsa-miR-296-4373066 3.872 1.463
hsa-miR-517c-4373264 3.342 1.365
hsa-miR-501-4373226 3.068 1.160
hsa-miR-594-4380958 2.714 1.108
aThe normalization criteria are detailed in the Experimental Section. Data are expressed as RQ. RQ value was calculated as 2−ΔΔCt (see the
Experimental Section for details), and it is reported as mean and SEM.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr300152z | J. Proteome Res. 2012, 11, 3358−33693362
selected those including miRNAs down-expressed in almost all
VAT samples (9/10 or 10/10): miR-206/ARCN1 (spot 751);
miR-141/YWHAG and miR-200c/YWHAG (spot 2005); miR-
206/YWHAZ (spot 2054); miR-520d/RAB11A and miR-520e/
RAB11A (spot 2229) (bold characters in Table 3).
The expression levels of the above miRNAs (miR-206, miR-
141, miR-200c, miR-520e, and -520d) were further validated by
qRT-PCR. The qRT-PCR results, except slight diﬀerences due
to the two diﬀerent methodologies, were in close agreement
with those obtained by TaqMan array (respectively, mean RQ
± SEM): miR-206 (0.209 ± 0.066 vs 0.126 ± 0.042), miR-141
(0.099 ± 0.032 vs 0.079 ± 0.025), miR-200c (0.138 ± 0.044 vs
0.130 ± 0.041), miR-520e (0.554 ± 0.175 vs 0.014 ± 0.005),
except for miR-520d, whose results did not diﬀer from controls
in the qRT-PCR validation (0.944 ± 0.299 vs 0.066 ± 0.022).
Consequently the miR-520d was discarded in our following
evaluations.
All the miRNA/protein target pairs reported above warrant
further investigation. However, functional annotation clustering
in the DAVID database revealed that ARCN1, YWHAG,
YWHAZ, and RAB11A are present in the annotation cluster
intracellular protein transport (Figure 2A), which may be
involved in the physiopathology of the adipose tissue. Among
the miRNAs associated to these targets, miR-141 and miR-520e
were accordingly regulated in the complete set of RNA samples
(10/10) from obese VAT. Thus, we selected the functional
pairs miR-141/YWHAG and miR-520e/RAB11A for further
analysis.
Since the eﬀects of miRNA down-regulations may result in
increased mRNA stability and/or mRNA translation, we tested
the transcript levels for RAB11A and YWHAG by qRT-PCR.
We indeed observed that both mRNAs were more abundantly
expressed in VAT of obese women (RQ ± SEM: 6.1 ± 2.6 and
4.8 ± 0.7, respectively) compared to control VAT mRNA
samples (data not shown). Next, we tested YWHAG and
RAB11A protein expression by Western blot in VAT from a
subset of obese (8/15) and nonobese (7/10) females whose
samples were available. These samples were also probed with an
actin antibody for protein normalization. As shown in Figure 3,
both YWHAG and RAB11A proteins were signiﬁcantly (p = 0.001
and p = 0.00001, respectively) up-expressed in obese than in
nonobese VAT tissues.
Taken together, our data suggest that in VAT from obese
females, there is a functional interplay between the mRNAs of
two up-expressed proteins (YWHAG and RAB11A, as emerged
from 2D-DIGE analysis, qRT-PCR, and Western blot
validations) and two down-expressed miRNAs (miR-141 and
miR-520e, respectively, as revealed by the transcriptomic
screening and qRT-PCR analysis). Thus, to determine whether
the mRNAs of YWHAG and RAB11A are targets of miR-141
and miR-520e, respectively, we cloned the regions encompass-
ing the 3′UTRs of the two mRNAs downstream the Renilla
luciferase gene, under the transcriptional control of the
cytomegalovirus promoter. The constructs were cotransfected
with the pre-miRNAs for miR-141 or miR-520e, and as a
transfection control, we used a pGL3-control that expresses
ﬁreﬂy luciferase. As shown in Figure 4, both pre-miR-520e (A)
and pre-miR-141 (B) signiﬁcantly reduced the normalized
Renilla luciferase activities of the constructs containing
respectively the RAB11A (p = 0.004) and the YWHAG
3′UTRs (p = 0.02). No inhibition was observed in mutant
3′UTR of RAB11A (A) and YWHAG (B) constructs. These
data are consistent with a functional interaction between the
selected miRNAs and the 3′UTRs of their mRNA targets,
thereby suggesting that changes in the levels of these two
miRNAs may modulate the expression of RAB11A and
YWHAG.
■ DISCUSSION
Understanding the molecular mechanisms underpinning
obesity could pave the way for new therapeutic strategies to
contrast obesity-related metabolic disorders. miRNAs, which
Figure 1. 2D-DIGE of visceral adipose tissue (VAT) proteins. (A) Scan of master gel used to match protein spots from the diﬀerent gels used for the
analysis. This gel is constituted by three overlapped images: (1) VAT proteins of a nonobese female labeled with Cy3 (green), (2) VAT proteins of
an obese female labeled with Cy5 (red), and (3) VAT proteins from a mixture of the random selected samples (used for normalization) labeled with
Cy2 (blue). (B) Scan of preparative gel of VAT proteins from a mixture of samples stained with SYPRO Ruby protein stain. Numbers correspond to
diﬀerentially expressed protein spots as indicated in Table 3.
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Table 3. Identiﬁcation and Characterization of Proteins Diﬀerently Expressed in Visceral Adipose Tissue from Obese Vs
Nonobese Females by 2D-DIGE Analysis Followed by LC−MS/MS
spot no.a
DIGE
(p-value)b
DIGE
obese/
controlc accession no.d protein name
MW
(Da)e pIf
no. of qualified
peptides/
coverage (%)g scoreh gene symboli miRNAj
B1_750 0.035 1.7 gi/5031875 Lamin A/C isoform 2 65153 6.40 13/25 743 LMNA
gi/20127454 5-aminoimidazole-4-carboxamide
ribonucleotide formyltransferase/IMP
cyclohydrolase
65089 6.27 7/16.5 440 ATIC
gi/5803181 Stress induced phosphoprotein 1 63227 6.40 4/9 228 STIP1
C1_751 0.023 1.73 gi/55960506 Chaperonin containing TCP1, subunit 3
(gamma)
58505 6.46 17/43 1043 CCT3
gi/4503377 Dihydropyrimidinase −like 2 62711 5.95 7/19 465 DPYSL2
gi/11863154 Archain isoform 1 57630 5.89 9/19 503 ARCN1* mir-206
gi/189926 Phosphoglucomutase 1 61674 6.35 4/9 208 PGM1* mir-30a,
-30d
gi/6009626 Brain carboxylesterase hBr1 47100 6.02 3/8 189 CES1
D1_ 976 0.004 1.67 gi/5453603 Chaperonin containing TCP1, subunit 2 57794 6.01 17/50 1271 CCT2
gi/178390 Aldehyde dehydrogenase 56858 7.00 6/15 387 ALDH2
gi/2183299 Aldehyde dehydrogenase 1 55427 6.30 5/12 319 ALDH1
gi/5771523 3-phosphoglycerate dehydrogenase 57370 6.29 4/9 225 PHGDH
E1_993 0.011 1.78 gi/16306550 Selenium binding protein 1 52928 5.93 13/37 711 SELENBP1
F1_1021 0.008 2.01 gi/15620780 Glutamate carboxypeptidase 53161 5.71 3/7 143 CNDP2
G1_1092 0.039 1.88 gi/5174529 Methionine adenosyltransferase II, alpha 43975 6.05 2/7 143 MAT2A* mir-30a,
-30d,-22
H1_1119 0.007 1.43 gi/4504169 Glutathione synthetase 52523 5.67 7/23 458 GSS
gi/1049219 Gamma-aminobutyraldehyde
dehydrogenase
54410 6.01 5/11 306 E3
gi/21410323 Perilipin 56216 5.82 2/5 112 PLIN
A2_1154 0.003 1.61 gi/21361144 Proteasome 26S ATPase subunit 3 49458 5.13 15/50 843 PSMC3
gi/340219 Vimentin 53738 5.03 4/9 273 VIM
gi/7106299 Ataxin 10 54196 5.12 4/4 241 ATXN10
B2_1158 0.011 1.48 gi/4503571 Enolase 1 47481 7.01 13/46 906 ENOI
gi/40068518 Phosphogluconate dehydrogenase 53619 6.8 6/17 427 PGD
C2_1173 0.003 1.87 gi/4503481 Eukaryotic translation elongation factor 1
gamma
50429 6.25 10/34 576 EEF1G
gi/496902 Translation initiation factor 47088 6.08 5/7 297 E2F1
gi/4504327 Mitochondrial trifunctional protein, beta
subunit precursor
51547 9.45 4/9 207 HADHB* mir-203
D2_1174 0.006 2.08 gi/5031699 Flotillin 1 47554 7.08 4/12 265 FLOT1
E2_1182 0.002 2.01 gi/4502111 Annexin VII isoform 1 50569 6.25 9/24 526 ANXA7
gi/7546384 Chain A, Human branched- chain Alpha-
Keto Acid Dehydrogenase
45770 6.32 4/11 213 BCKDHA
gi/4099506 ErbB3 binding protein EBP1 38321 7.15 4/15 211 PA2G4
gi/18379349 Vesicle amine transport protein 1 42122 5.88 2/8 121 VAT1
F2_1202 0.012 1.85 gi/39725934 Serine (or cysteine) proteinase inhibitor,
clade F member 1
46454 5.97 11/38 695 SERPINF1
gi/9836652 BSCv 47887 5.78 5/13 305 C20ORF3
gi/285975 Human rab GDI 51088 5.94 2/5 116 GDI
gi/515634 Ubiquinol-cytochrome C reductase core I
protein
53270 5.94 2/4 122 UQCRC1
gi/338695 Beta-tubulin 50240 4.75 2/5 121 TUBB
G2_1221 0.045 2.61 gi/4503529 Eukaryotic translation initiation factor 4A
isoform 1
46353 5.32 8/27 487 EIF4A1
H2_1268 0.013 1.6 gi/181914 DNA-binding protein 36086 9.20 2/7 122
A3_1271 0.002 1.54 gi/33415057 Transformation-related protein 14 43248 5.49 5/19 309 TRG14
B3_1272 0.010 1.99 gi/4557809 Ornithine aminotransferase precursor 48846 6.57 7/23 435 OAT
gi/387011 Pyruvate dehydrogenase E1-alpha
precursor
47098 8.79 4/9 265 PDHA1* mir-203
gi/3641398 NADP-dependent isocitrate dehydrogenase 46944 6.34 2/7 86 IDH1* mir-30a,
-30d
C3_1299 0.004 1.81 gi/24308406 Secernin 2 46989 5.44 4/16 231 SCRN2
gi/6678271 TAR DNA binding protein 45053 5.85 2/7 162 TARDBP* mir-137,
-203
D3_1352 0.006 1.67 not identified
E3_1410 0.023 1.59 gi/4557233 Acyl-Coenzyme A dehydrogenase, C-2 to
C-3 short chain precursor
44611 8.13 8/30 436 ACADS
gi/148539872 Acetyl-Coenzyme A acetyltransferase 2 41783 6.47 2/8 99 ACAT2
F3_1521 0.006 1.64 gi/7661704 Osteoglycin preprotein 34243 5.46 5/18 307 OGN* mir-22
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have been involved in the regulation of a variety of biological
processes, including appetite regulation, adipocyte diﬀer-
entiation, and insulin secretion,13 are interesting candidate
molecules to be investigated in adipose tissues as potential
mediators of metabolic pathway alterations in obesity. We
previously reported that miRNA expression was altered in SAT
from morbidly obese patients, and that up-expressed miR-519d
plays a role in adipocyte lipid metabolism.10 We now describe
the miRNA and proteome VAT signatures in morbidly obese
females and show several miRNAs and proteins diﬀerentially
expressed between obese and nonobese females.
Globally, our miRNA expression proﬁle revealed that 71
miRNAs were deregulated in the VAT from obese females.
Interestingly, most of these miRNAs (61/71) were down-
expressed. This latter ﬁnding coincides with a report of a similar
global down-expression of miRNAs in VAT from obese
individuals with nonalcoholic steatohepatitis than those with
nonalcoholic fatty liver disease that, moreover, was correlated
with enhanced expression of inﬂammatory adipocytokines.14
Eleven of the 61 largely down-expressed miRNAs in the VAT
of our obese females were also found in the above report;14 in
particular, we previously reported 7/11 of these miRNAs (miR-
200c, miR-519b, miR-206, miR-618, miR-30a, miR-181c, and
miR-7) down-expressed in SAT from the same obese females.10
In a mouse model, Xie et al.15 reported an inverse correlation
of miRNA expression between adipogenesis and obesity.15 In
fact, they observed that up-expressed miRNAs during adipo-
genesis tended to be down-expressed in the mouse epididymal
fat pads, and vice versa, and suggested that these changes could
be linked to the chronic local inﬂammation environment in the
fat mouse obese tissue. Lastly, Kloting et al.7 reported that miR-198,
one of our down-expressed miRNAs, was inversely correlated with
omental adipocyte diameter during obesity.7
Our 2D-DIGE analysis showed that 172 protein spots were
diﬀerentially expressed in VAT from obese vs nonobese
females. Analysis of 33 of these protein spots, those with
optimal features, led to the identiﬁcation of 67 proteins because
most spots were related to more than one protein. Our data
conﬁrm, and also integrate, proteomic data previously obtained
in VAT.3,16,17 In particular, we detected high levels of EIF4A1,
CES1, SELENBP1, ALDH1, ALDH2, GSTP1, HSPB1 proteins
that were previously reported to be increased in the omental vs
Table 3. continued
spot no.a
DIGE
(p-value)b
DIGE
obese/
controlc accession no.d protein name
MW
(Da)e pIf
no. of qualified
peptides/
coverage (%)g scoreh gene symboli miRNAj
gi/25453472 Eukaryotic translation elongation factor
1delta
31217 4.90 4/17 277 EFF1D
G3_1560 0.033 1.69 gi/194373515 Unnamed protein product (Corrisp. in
Sprot a P68363 Tubulin alpha-1B chain)
33856 4.88 2/8 151 DNAJB2
gi/157833780 Chain A, human Annexin V with Proline
substitution by thioproline
36041 4.94 3/11 153 ANXA5
H3_1908 0.001 1.67 gi/24119203 Tropomyosin 3 isoform 2 29243 4.75 11/40 598 TPM3
gi/4507651 Tropomyosin 4 28619 4.67 2/9 104 TPM4
gi/13236577 Thiamine triphosphatase 25721 4.75 3/15 165 THTPA
A4_1948 0.001 1.68 gi/5803225 Tyrosine 3/tryptophan 5-monooxygenase
activation protein, epsilon polypeptide
29326 4.63 15/65 943 YWHAE
B4_2005 0.001 1.91 gi/21464101 Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein,
gamma polypeptide
28456 4.80 5/21 329 YWHAG* mir-141,
-200c,
gi/119598039 Tropomyosin 1 (alpha), isoform Cra_m 28730 4.78 4/17 215 TPM1
C4_2054 0.010 1.64 gi/4507953 Tyrosine 3/tryptophan 5-
monooxygenase activation protein, zeta
polypeptide
27899 4.73 9/52 629 YWHAZ* mir-206,
-30a,
-30d, -22
D4_2065 0.001 1.72 gi/4507949 Tyrosine 3/tryptophan 5-monooxygenase
activation protein, beta polypeptide
28179 4.76 5/29 310 YWHAB
gi/4507951 Tyrosine 3/tryptophan 5-monooxygenase
activation protein, eta polypeptide
28372 4.76 3/15 225 YWHAH
E4_2087 0.038 1.7 gi/4504517 Heat shock protein beta-1 22826 5.98 6/27 330 HSPB1
gi/1922287 EnoylCoA hydratase 31807 8.34 5/23 330 ECHS1
F4_ 2229 0.007 1.64 gi/4758984 Ras-related protein Rab-11A 24492 6.12 2/11 99 RAB11A* mir-520e,
-520d,
G4_2245 0.039 1.51 gi/2204207 Glutathione S-transferase 23595 5.43 6/38 372 GSTP1
gi/1174149 Small GTP binding protein Rab 7 23732 6.40 2/12 101 RAB7A* mir-30a,
-30d
H4_2291 0.008 1.65 gi/14249382 Abhydrolase domain containing 14B 22446 5.94 5/32 264 ABHD14B
A5_2312 >0.001 −2.12 gi/5020074 Glyoxalase-I 20934 5.24 3/16 166 GLO I
gi/17986273 Fast skeletal myosin alkali light chain 1
isoform 1f
21189 4.97 3/18 215 MYL1
B5_2417 0.024 2.27 not identified
aSpot numbering as shown in 2-DE gel in Figure 1. bp-value at Student's t test. cAverage abundance ratio (obeses/controls) as calculated by
DeCyder Analysis. dProtein accession number from NCBI. eTheoretical molecular weight (Da). fTheoretical pI. gAccording to the Proposed
Guidelines for the Analysis and Documentation of Peptide and Protein Identiﬁcations (Paris consensus), we included in this table the complete
ﬁgures of merit regarding the MS identiﬁcation as the number of identiﬁed peptides whose individual ion score (as provided by Mascot) was higher
than the designated conﬁdence level (95%)/protein sequence coverage (%). hIdentiﬁcation score indicating a probabilistic measure of the goodness
of the MS protein identiﬁcation. iGene symbol from NCBI. jDown-expressed miRNAs in at least 6/10 obese females, which targeted 3′UTR-mRNA
regions of asterisk genes. In bold are indicated down-expressed miRNAs in VAT from 9 or 10/10 obese females and their targeted proteins.
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SAT in an obese population, or proteins that were diﬀerently
expressed in VAT from obese vs nonobese females, such as
ACADS, LMNA, VIM,17 which indicates that VAT is not only a
lipid storage site, but also a highly active metabolic tissue.3
Furthermore, Peŕez-Peŕez et al.3 suggested that EIF4A1 could
be involved in the altered protein synthesis pathways preceding
insulin resistance and/or type 2 diabetes.3 In agreement with
another study,18 we detected high levels of E2F1, which could
play a role in glucose metabolism.18 We also identiﬁed proteins
involved in intracellular traﬃcking, i.e., ARCN1 (or COPI),
PLIN, RAB11A, and RAB14, in agreement with earlier
reports.19,20 Furthermore, we observed an up-expression of
proteins involved in antioxidant activity and in apoptosis,
namely, GSS, ANXA5, ANXA7, PRDX3, and GSTP1, some of
which were reported by Coŕton et al.16 in a proteomic study of
VAT from obese females with or without polycystic ovary
syndrome.16
A novelty of our study is that we evaluated simultaneously
the miRNome and the proteome of VAT in obese and
nonobese women to identify potential biological mechanisms,
based on the concerted action of miRNA and protein targets,
associated with obesity. To this aim, we intersected the list of
the bioinformatically predicted protein targets of the
deregulated miRNAs with the whole set of identiﬁed proteins
from the experimental comparison of the VAT proteomes. This
screening enabled us to identify in the obese VAT samples a
potential miRNA-based mechanism for the up-expression of
some proteins, in particular YWHAG and RAB11A, which was
associated with down-expression of miR-141 and miR-520e,
respectively. The functional luciferase assay conﬁrmed the
binding of these miRNAs to the 3′UTRs of the YWHAG and
RAB11A transcripts. We investigated YWHAG and RAB11A
because they are involved in glucose homeostasis,21−23 and
YWHAG also in lipid metabolism,24,25 and hence are potential
actors in the obese phenotype.
Rab proteins are a large family of small GTPases that are
involved in vesicular traﬃcking, in cytoskeleton organization,
and in the control of cell proliferation and diﬀerentiation.20
Members of the Rab family, which includes about 70 proteins
in humans, continuously cycle between the cytosol and
diﬀerent membranes as inactive GDP-bound or active GTP-
bound forms, assisted by diﬀerent Rab-associated proteins.26
Defects in Rab-associated proteins lead to abnormal intra-
cellular traﬃcking and have been associated with several
monogenic inherited disorders and multigenic conditions such
as type 2 diabetes.26,27 Several Rab GTPases have been
implicated in GLUT4 traﬃcking in relation to the cell type
studied; among these, RAB10, RAB11, and RAB14 have been
identiﬁed in adipocytes.28 An additional player in GLUT4
traﬃcking is the GTPase-activating protein AS160. The latter,
under basal conditions contributes to cytosolic retention of
GLUT4, whereas, upon insulin stimulation, it is phosphorylated
at Thr642 by AKT kinase and inactivated, so that AS160
dissociates from GLUT4 vesicles to favor an increase in the
GTP-bound form of RAB. This event facilitates the transport of
GLUT4 from storage vesicles toward cell surface.21
YWHAG (14-3-3γ) protein belongs to a seven-member
protein family in mammals. These proteins, by interacting with
target proteins, typically at phospho-residues, regulate a variety
of functions, including subcellular redistribution.22 Studies
conducted in animal models and/or in cellular systems have
shown that 14-3-3 plays a relevant role in both cellular insulin-
mediated glucose transport and lipid metabolism. In fact, in
mice, insulin-stimulated YWHAG binding to AS160 at
phospho-Thr649 (equivalent to Thr642 in human AS160)
normally regulates GLUT4 traﬃcking from storage vesicles to
plasma membrane, thereby inﬂuencing glucose uptake.23
AS160-Thr649Ala knock-in mice (Ala: nonphosphorylable
residue) display impaired glucosal and insulin sensitivity.23
Furthermore, in 3T3-L1 adipocytes, the up-expression of
14-3-3 promotes the cytoplasmic localization of Lipin1, a
bifunctional protein involved in lipid metabolism.24 The
subcellular localization of this protein is relevant to its
activities; in fact, its nuclear isoform promotes the activation
Figure 2. VAT proteins, overexpressed in obese females and identiﬁed by LC−MS/MS, were bioinformatically predicted by DAVID database to be
functionally annotated in two main clusters: (A) annotation cluster 1 and (B) annotation cluster 2.
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of genes involved in oxidative metabolism. In the cytosol, its
insulin-mediated phosphorylation leads to the conversion of
phosphatidate (PA) to diacylglycerol (DAG), a precursor of
triacylglycerol (TAG).25
Figure 4. Validation of interaction between miR-520e and miR-141 with respectively wild-type or mutant 3′UTR of RAB11A or YWHAG. HEK-293
cells were transfected with wild-type or mutant 3′UTR of RAB11A, pGL3-control, pre-miR-520e, or pre-miR-negative control (A) and with wild-type
or mutant 3′UTR of YWHAG, pGL3-control, pre-miR-141, or pre-miR-negative control (B). Pre-miR-520e and the pre-miR-141 signiﬁcantly
inhibited the expression of a Renilla luciferase-expressing construct that contains the 3′UTR region of the RAB11A (p = 0.004) and YWHAG
(p = 0.02), respectively. No inhibition was observed in mutant 3′UTR of RAB11A (A) and YWHAG (B) constructs. All experiments were done in
triplicate. Error bars denote SEM.
Figure 3. (A) An example of the Western blot evaluation of YWHAG and RAB11A proteins from VAT of randomly selected obese females (TO01, TO02,
TO03, TO04) and controls (TC01, TC02, TC03). (B) The box plots of the data normalized to actin content, after densitometric analysis of YWHAG and
RAB11A immunoblots. The data are expressed as percent relative expression, the sample with the highest expression of either RAB11A (p = 0.00001) or
YWHAG (p = 0.001) having been set as 100%. The bottom and top of each box represent the 25th and 75th percentile, respectively; the thick band inside
each box shows the 50th percentile (the median). The ends of the whiskers represent the minimum and maximum values of each group of data.
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On the basis of above-mentioned mechanisms, we
hypothesize (Figure 5) that in VAT from obese subjects, low
expression levels of some miRNAs, including miR-520e and
miR-141, by modulating the up-expression of RAB11A and
YWHAG proteins, respectively, may lead to increased glucose
uptake and to increased triglyceride synthesis. This could then
contribute to worsening the obese phenotype by increasing the
accumulation of adipose tissue. Obviously, the analysis of suitable
cellular systems is required to provide mechanistic details for the
proposed model and clarify the role of insulin as an independent,
or co-operative model, linked to the observed miRNA down-
expression and protein target up-expression in obesity.
Furthermore, studies on larger cohorts of obese and
nonobese subjects are necessary to verify our results on the
expression of miR-520e and miR-141, as well as of YWHAG
and RAB11A proteins, in obesity risk assessment.
Lastly, we did not study the 72/365 miRNAs that were
expressed only in VAT from obese females. Further investigations
are necessary to test if these miRNAs may play a role in obesity
insurgence and/or in the metabolic-associated alterations.
In conclusion, our study provides an integrated view of both
miRNAs and protein expression proﬁles in VAT during obesity
and gives clues as to the metabolic pathways that may be
involved in adipose tissue accumulation.
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Abstract
Type 2 Maturity Onset Diabetes of the Young (MODY2) is a monogenic autosomal disease characterized by a primary defect
in insulin secretion and hyperglycemia. It results from GCK gene mutations that impair enzyme activity. Between 2006 and
2010, we investigated GCK mutations in 66 diabetic children from southern Italy with suspected MODY2. Denaturing High
Performance Liquid Chromatography (DHPLC) and sequence analysis revealed 19 GCK mutations in 28 children, six of which
were novel: p.Glu40Asp, p.Val154Leu, p.Arg447Glyfs, p.Lys458_Cys461del, p.Glu395_Arg397del and c.580-2A.T. We
evaluated the effect of these 19 mutations using bioinformatic tools such as Polymorphism Phenotyping (Polyphen), Sorting
Intolerant From Tolerant (SIFT) and in silico modelling. We also conducted a functional study to evaluate the pathogenic
significance of seven mutations that are among the most severe mutations found in our population, and have never been
characterized: p.Glu70Asp, p.His137Asp, p.Phe150Tyr, p.Val154Leu, p.Gly162Asp, p.Arg303Trp and p.Arg392Ser. These seven
mutations, by altering one or more kinetic parameters, reduced enzyme catalytic activity by .40%. All mutations except
p.Glu70Asp displayed thermal-instability, indeed .50% of enzyme activity was lost at 50uC/30 min. Thus, these seven
mutations play a pathogenic role in MODY2 insurgence. In conclusion, this report revealed six novel GCK mutations and
sheds some light on the structure-function relationship of human GCK mutations and MODY2.
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Introduction
Maturity Onset Diabetes of the Young (MODY), a monogenic
diabetes inherited in an autosomal dominant mode, accounts for
1–2% of all diabetes forms in Europe [1,2]. It is a clinically
heterogeneous group of diseases caused by at least eight gene
defects in the pancreatic b-cell that impair insulin secretion [3].
MODY is characterized by onset before 25 years of age; patients
usually lack auto-antibodies, and clinical manifestations go from
slight non-ketotic hyperglycemia to severe complicated hypergly-
cemia [4]. Heterozygous mutations in the glucokinase (GCK) gene
produce two distinct diseases, MODY type 2 (MODY2)
(MIM:125851) and persistent hyperinsulinemia of infancy
(MIM:601820) [5,6]. Persistent hyperinsulinemia of infancy is
associated with hyperactive GCK variants, while MODY2 is
associated with GCK mutations that impair its activity [7]. GCK
(hexokinase IV) catalyzes the ATP-dependent phosphorylation of
glucose in the first, rate-limiting step of glycolysis in pancreatic b-
cells [1]. The crystal structure determination of the enzyme by
Kamata et al. [8] revealed that the enzyme exists in at least two
distinct forms, the super-open ligand-free form and the closed
active form that is bound to glucose and ATP. The molecule
consists of two domains, namely a small and large domain
separated by the glucose site. In detail, amino acid residues 1–64
and 206–439 belong to the large domain, amino acid residues 72–
201 and 445–465 to the small domain, and amino acid residues
65–71, 202–205 and 440–444 to the three loops connecting the
domains [8]. The GCK protein switches from an inactive
conformation to a close active conformation upon ligand binding.
A huge conformational transition occurs through a large rotation
of the small domain [8].
The heterozygous loss-of-function GCK mutations causative of
MODY2 diabetes include missense, nonsense, splicing, small
deletions/insertions/duplications variants, and result in stable
fasting hyperglycemia from birth (.5.5 mol/L) and rare micro-
vascular complications [1]. Over 644 GCK mutations have been
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38906
described, and a study of the mutational mechanisms for a number
of these has shed light on GCK regulation [9].
The molecular diagnosis of MODY2 is important: to classify the
type of diabetes correctly, to predict prognosis, and to initiate
screening of family members [1]. It is particularly important to
identify MODY2 in diabetic pregnant patients in order to start
‘‘ad hoc’’ treatment [10]. However, the identification of GCK
mutations by molecular analysis will not always reveal whether a
variant is really pathogenic or how serious the diabetic phenotype
could be. Therefore, in this five-year study, we applied an
integrated approach to investigate the effect of GCK mutations in
the diabetic phenotype in children from southern Italy. First, we
used DHPLC and mutation sequencing to identify variants, then a
computational approach to predict the effect of the variants
identified, and finally a functional study to determine the effect of
seven candidate variants on enzyme activity and on enzyme
thermo-stability.
Results
Among the 66 enrolled patients with suspected MODY2, 28/66
were diagnosed as MODY2 based on mutations in the GCK gene
(MODY2+) and 38/66 were MODY2-negative (MODY22). All
mutated patients were unrelated, except two pairs of siblings
(patient identification: MD19/20: two sisters and MD69/70:
brother/sister). The mean age at diagnosis (6 Standard Deviation:
SD) was lower, albeit not significantly, in MODY2+ than in
MODY22 patients (105645 months vs 113645 months). Mean
triglyceride levels did not differ between the two groups (0.660.2
and 0.760.3 mmol/L, respectively). Mean Fasting Plasma Glu-
cose (FPG) and glycosylated hemoglobin (HbA1c) concentrations
were significantly higher (p,0.003 and p,0.001, respectively) in
MODY2+ than in MODY22 patients (6.760.8 mmol/L and
6.260.3% vs 6.160.7 mmol/L and 5.560.5%, respectively). The
Body Mass Index zeta-score (BMIz-score) of enrolled children at
first admission was always in the reference range for the children’s
age (reference range: 21.5/+1.5), except in one patient (BMIz-
score: 2.5). Two/28 MODY2+ patients were positive for only one
type-1 diabetes auto antibody (glutamate decarboxylase: 8 and
18 U/mL). The patients were untreated until diagnosis.
Identification of GCK Mutations
We identified 19 different GCK mutations in 28/66 patients
(Table 1). Six of them were novel: two missense mutations
(p.Val154Leu and p.Glu40Asp), one splice site variant (c.580-
2A.T) and three deletions (p.Lys458_Cys461del, p.Arg447Glyfs,
and p.Glu395_Arg397del). We also found 13 previously reported
mutations: 11 missense mutations (p.Arg303Trp, p.Gly261Arg,
p.Phe150Tyr, p.Ala259Thr, p.Glu70Asp, p.Lys420Glu,
p.Ala188Thr, p.Tyr289Cys, p.Asp278Glu, p.Gly223Ser, and
p.Ala449Thr) and two splice site variants (c.864-1G.A and
c.1019+5G.A). All the detected mutations were always present in
the children’s mother or father and were absent from 200
chromosomes of our euglycemic controls. Seven mutations were
each present in two unrelated families: p.Arg303Trp, p.Lys458_-
Cys461del, p.Arg447Glyfs, p.Gly261Arg, p.Phe150Tyr, p.Lys420-
Glu and p.Ala259Thr, the latter was also identified in two siblings.
The splice variant c.580-2A.T was present in two siblings.
Table 1 shows, for each mutation (except the three splice variants
c.864-1G.A, c.580-2A.T and c.1019+5G.A, the frameshift
mutation p.Arg447Glyfs and the p.Lys458_Cys461del), the
nucleotide position, the amino acid change (if present), the effect
on the protein predicted by bioinformatics.
Bioinformatics Study of the GCK Variants
All substitutions, except p.Val154Leu and p.Glu40Asp, were
predicted to be deleterious mutations by online prediction tools
(Table 1, column 4). Overall, the theoretical structural models of
the mutants we obtained in silico (Table 1, column 5), preserve the
overall protein fold. In detail, however, all mutations produced
local conformational alterations 2 in some cases, such as
p.Gly162Asp, dramatic perturbations – that well account for the
functional alterations we found (Table 2). p.Arg303Trp-Arg303
is a highly conserved residue located in the a8 helix within the
large domain. Mutation p.Arg303Trp disrupts two salt-bridges
between the side chain of Arg303 and the side chain of Glu300,
located in the same helix. These salt-bridges may be essential for
the stability of the helix and their loss could destabilize the helix
structure. p.Val154Leu-The p.Val154Leu mutation (Figure 1)
does not cause any significant change in the local structure.
Indeed, Val154 is located in the b-sheet that encompasses the
small domain hydrophobic core. Its substitution with a leucine
residue does not affect the hydrophobic interactions. Nevertheless,
Val154 is involved in the large conformational variation from the
super-open to close form upon glucose binding (Figure 1A).
p.Gly261Arg-Gly261 is located in the loop connecting the b-
sheet and the a6 helix in the large domain. p.Gly261Arg is a
dramatic mutation because the small, flexible hydrophobic Gly
residue is replaced by a very large Arg residue that bears a positive
net charge. This substitution causes a local re-arrangement that
involves the nearby residues such as Leu266 and Leu270. This
process results in destabilization of the local structure.
p.Phe150Tyr-Phe150 is a highly conserved residue located in
the b-sheet that encompasses the small domain hydrophobic core.
The p.Phe150Tyr mutation (Figure 1B, C) introduces a polar
residue inside the hydrophobic core in a region rich in
phenylalanine. This replacement can influence the stability of
the b-sheet thereby altering the structure of the domain.
p.Ala259Thr-Ala259 residue is located in the large domain near
the glucose-binding cleft. Introduction of a larger and polar side
chain of threonine in the p.Ala259Thr mutant could influence the
hydrogen bond network in that area. In fact, Thr259 can compete
with other residues in the formation of hydrogen bonds with two
water molecules. See our previous study for a description of the
p.Glu70Asp variant [11]. p.Lys420Glu-Mutation p.Lys420Glu
involves an inversion from a positively charged lysine to a
negatively charged glutamic acid. The substitution affects the
interaction of Lys420 with surrounding residues. Indeed, Lys420 is
located in the a12 helix (Figure S1) in the large domain and forms
a salt bridge with Glu440 located in a connecting loop between the
two domains. The loss of this bond, caused by the mutation, could
destabilize the region. p.Ala188Thr-The p.Ala188Thr mutation
alters a highly conserved amino acid. Ala188 is located in the a4
helix within the small domain. The mutation leads to the
substitution of a hydrophobic residue, alanine, with a polar
residue, tyrosine, on the hydrophobic side of an amphipathic helix.
Thr188 can form hydrogen bonds through the hydroxyl group
with the side chains of the Ser127 and Asp124 residues on the a3
helix that is on the surface of the enzyme. The introduction of the
threonine can cause a different arrangement of such side chain.
p.Tyr289Cys-Tyr289 is located in the a7 helix in the large
domain. The substitution of the bulk tyrosine in position 289 with
the smaller cysteine side chain leads to the formation of a cavity.
The mutant disrupts a favorable interaction between Tyr289 and
Met381 of the a11 helix that may be important to keep helices
together. It is noteworthy that, in our model, Cys289 is not bound
to the nearby Cys230 because the distance (4.1 A˚) between the two
sulfur atoms too long for a disulfide bond formation. p.As-
Characterization of GCK Mutations
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p278Glu-The p.Asp278Glu mutation affects a highly conserved
amino acid. Asp278 is located on the polar side of the a6 helix in
the large domain. The replacement of Asp with a Glu residue in
the mutant does not seem to cause significant changes in the
enzyme structure. p.Gly223Ser-Gly223 is a highly conserved
residue located in the b-sheet of the large domain hydrophobic
core. The substitution with a serine involves the serine side-chain
hydrogen bonding to Cys 233, close to Gly223 in the structure of
GCK and could perturb the b-strand. p.Glu40Asp-The
pGlu40Asp mutation substitutes a conserved glutamate residue
with aspartate. Glu40 is located on the polar side of the a2 helix in
the large domain. These amino acids are acidic residues but the
side chain of the aspartate is shorter than the side chain of the
glutamate. Nevertheless, the mutation does not seem to cause
significant changes in the structure of the enzyme. p.Ala449Thr-
Ala449 is a highly conserved residue located on the C-terminal
a13 helix. This helix is part of the small domain in the closed form,
but it lies between the two domains in the super-open form. In the
closed form, the small domain has a three-layer architecture and
the a13 helix is in the inner layer. At the domain interface, the a13
helix makes favorable interactions with the a5 helix of the large
domain. Because the conformational features of this region are
essential for the super-open (inactive form)/closed (active form)
conversion, the introduction of a larger and polar side chain of the
threonine in the p.Ala449Thr mutant could influence the
enzymatic activity and/or stability. p.Glu395_Arg397del–The
p.Glu395_Arg397 deletion causes the elimination of the last
residue, Glu395, of the a11 helix in the large domain and two
residues of the following loop, Ser396 and Arg397. In the wild-
type enzyme, Glu395 is involved, through the backbone N atom,
in the formation of a hydrogen bond of the a11 helix. Its deletion
in the mutant causes the lack of this bond and could destabilize the
C-terminal region of the helix. Moreover, also the backbone N
atom of Arg397 interacts with an oxygen atom of Arg394 thereby
Table 1. GCK mutations detected in MODY2 children from South Italy.
Patient
code
GCK
Exona
cDNA
mutationb
Polyphen/SIFT
predictionc
Aminoacid changed/Domain
localization/Secondary structure Effect on protein 3D-structure Reference
MD01/92 8 c.907C.T 1/deleterious p.Arg303Trp/Large domain/a8 helix Disruption of two salt-bridges [25]
MD05/71 10 c.1373_1385del p.Lys458_Cys461del/Small domain/
a13 helix
NOVEL
MD10 4 c.460G.T 2/tolerated p.Val154Leu/Small domain/b-strand 6 Severe perturbation during the
transition from the super-open to
closed form. Mild local structural
alteration
NOVEL
MD12/89 10 c.1339delC p.Arg447Glyfs/Small domain/a13 helix NOVEL
MD16/75 7 c.781G.T 1/deleterious p.Gly261Arg/Large domain/loop Replacement of a small and flexible
hydrophobic residue with a large
positive residue
[26]
MD18/94 4 c.449T.A 1/deleterious p.Phe150Tyr/Small domain/b-strand 5 Introduction of a polar residue in the
hydrophobic core. Perturbation of
the b-sheet
[27]
MD19e/20e/79 7 c.775G.A 3/deleterious p.Ala259Thr/Large domain/loop Influence on the hydrogen bond
network near the glucose-binding
cleft
[28]
MD25 2 c.210A.C 1/deleterious p.Glu70Asp/Connection/Loop
spatially near a13 helix
Weakness of salt bridge interaction
with K458 (a13 helix)
[11]
MD26/65 10 c.1258A.G 2/deleterious p.Lys420Glu/Large domain/a12 helix Loss of a salt bridge between K420
and E440
[29]
MD38 Intron 7 c.864-1G.A IVS7-1G.A [9]
MD57 5 c.562G.A 1/deleterious p.Ala188Thr/Small domain/a4 helix Substitution of a hydrophobic
residue with a polar residue
[30]
MD59 8 c.866A.G 1/deleterious p.Tyr289Cys/Large domain/a7 helix Disruption of a favorable interaction
between Y289 and M381
[9]
MD68 7 c.834G.A 1/deleterious p.Asp278Glu/Large domain/a6 helix Mild structural alteration [9]
MD69e/70 e Intron 5 c.580-2A.T IVS5-2A.T NOVEL
MD80 6 c.667G.A 3/deleterious p.Gly223Ser/Large domain/b-strand 9 Perturbation of the b-strand [31]
MD86 Intron 8 c.1019+5G.A IVS8+5G.A [27]
MD90 2 c.120G.C 2/tolerated p.Glu40Asp/Large domain/a2 helix Mild structural alteration NOVEL
MD91 10 c.1345G.C 3/deleterious p.Ala449Thr/Small domain in the
closed form/a13 helix
Introduction of a larger and polar
side chain
[9]
MD95 9 c.1182_1191del p.Glu395_Arg397del/Large domain/
last residue of a11 helix and following
loop
Destabilization of the C-terminal
region of the helix and shortening
of loop
NOVEL
aGenBank: accession number (AH005826). bThe reference cDNA sequence was obtained from GenBank (NM_000162) and +1 corresponds to the A of the ATG translation
initiation codon. cPolyphen prediction: probably damaging (1), benign (2), possibly damaging (3). SIFT score: ,0.05 deleterious variant, $0.05 tolerated variant.
dSwissprot accession number: P35557. eSibling pairs (MD19/20: two sisters; MD69/70: brother/sister).
doi:10.1371/journal.pone.0038906.t001
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stabilizing the helix. In the mutant, the loop becomes shorter and
the side chain of Arg394, which in the wild-type enzyme is
directed towards the loop, changes the orientation because of
steric interactions. This change disrupts interactions between the
side chain of Arg394 and some residues of the loop. Although the
interaction between the side chains of Arg394 and Ser433 in the
loop following the a12 helix is conserved, the binding appears to
be weakened compared with the wild-type enzyme.
Kinetic Analysis and Thermo-stability of Recombinant
GCK Mutants
To select representative mutations for a functional study to
evaluate their pathogenic significance, we considered all the
mutations found in our population in the last decade (11 and
present work) in terms of severity and location. All the selected
mutations were mapped in the whole GCK structure: p.Hi-
s137Asp, pPhe150Tyr, p.Val154Leu, p.Gly162Asp, in the small
domain, Arg303Trp and p.Arg392Ser, in the large domain and
p.Glu70Asp in a loop connecting the two domains. Three among
these mutations, (p.Gly162Asp, p.His137Asp and p.Arg392Ser)
were the most severe and none have been produced or
characterized. Figure 2 shows the position of selected mutated
residues in the structure model of the GCK enzyme. All variants
displayed reduced enzyme activity versus the wild-type GST-
GCK, as shown by the Ia index. The kinetic characteristics of
GST-GCK-wt and GST-GCK-mutants, determined in vitro
enzymatic assays, are shown in Table 2. Mutations p.Gly162Asp,
p.Phe150Tyr and p.Val154Leu, localized in the core of the
molecule, not far from the substrate binding site, produced the
strongest effect. The p.Gly162Asp change is very deleterious since
no enzymatic activity was detected in the mutant protein, and
mutations p.Phe150Tyr and p.Val154Leu reduced enzyme
activity to below 10% of the wild-type enzyme. In contrast,
mutations p.Glu70Asp, p.His137Asp, p.Arg303Trp and p.Arg392-
Ser, localized in more peripheral positions, retained at least 25%
of wild-type activity. We also evaluated the protein stability of
wild-type and of mutant GST-GCK and the time-course of
thermal inactivation at different temperatures (Figure 3A and B
respectively). Wild-type GCK activity remained practically con-
stant under temperatures up to 50uC, but fell abruptly at 55uC. In
contrast, the enzyme activity of all mutants, except GST-GCK
(p.Glu70Asp), rapidly decreased by more than 50% at 50uC
(Figure 3A). The time-course analysis of GCK thermal inactiva-
tion indicated that the mutants rendered the enzyme thermo-
unstable (more than 50% of GCK activity was lost within 30 min
at 50uC), whereas 50% of wild-type GCK activity was present
after 30 min of incubation at the critical temperature (Figure 3B).
Discussion
A correct diagnostic approach to the MODY2 patient is
important to avoid useless, expensive analyses and misclassification
of the diabetes. In this study, we characterized the GCK gene by
DHPLC followed by sequence analysis in 66 patients with
suspected MODY2 enrolled between 2006 and 2010. We
identified 19 GCK mutations in 28 children accounting for
42.4% of suspected MODY2 children. Our data are similar to
those we obtained between 2001 and 2005 [11] and are also in
agreement with the high prevalence of MODY2 (up to 61% of
MODY forms) found in Italy and in southern Europe [12,13].
Among the 19 GCK variants described herein, six are new
(p.Lys458_Cys461del, p.Val154Leu, p.Arg447Glyfs, IVS5-2A.T,
p.Glu40Asp and p.Glu395_Arg397del) and 13 previously report-
ed. Glucokinase missense mutations are the most frequent causes
of MODY2 [9]. In our study, the missense mutations (13/19: two
new and 11 known), and deletions (n = 3) were distributed
throughout the protein: six/16 (38%) in the small domain, nine/
16 (56%) in the large domain and one/16 (6%) in the connecting
region of the protein. These findings are in agreement with a study
in which no hot spot mutations were reported [9].
In the attempt to understand how the detected mutations could
contribute to MODY2 insurgence, we searched for structure/
function correlations of the disease-causing mutated proteins. First,
we evaluated the impact of each mutation (except splice variants
and deletions) on the enzyme 3D-structure and then, for seven
selected mutations, we carried out functional studies. All the
mutations considered here are buried in the enzyme, except for
p.Glu70Asp that is located on the surface of the protein, and all
mutations are far from the active and ATP binding sites (Table 1).
Apart from p.Val154Leu and p.Phe150Tyr that undergo large
movements during the conformational transition from the super-
open to the closed active form, all the mutant structures exhibit
local structural alterations (Table 1) that well correlate to kinetic
parameters and thermal inactivation data (Table 2, Figure 3). In
all cases, the amino-acid replacement either provokes the loss of
stabilizing interactions or generates unfavorable interactions that
may destabilize the enzyme.
Table 2. Kinetic constants of human recombinant wild type-GCK and mutant b-cell GST-GCK fusion proteins.
Preparation
Protein yield
(mg/L of culture) Kcat (s21)
S0.5 for glucose
(mmol/L) nH
Km for ATP
(mmol/L) Ia
Wild-type GST-GCK 3.1260.91 44.1067.50 7.2060.40 1.4060.08 0.4060.00 1.060.07
GST-GCK(Glu70Asp] 2.3560.55 27.4064.80* 20.1063.20{ 1.2060.07 0.2560.05 0.2560.06**
GST-GCK(His137Asp] 2.8260.47 17.2061.20** 18.1063.10* 1.1060.03** 0.2360.03* 0.2660.09**
GST-GCK(Phe150Tyr] 3.0760.55 9.9262.38* 101.4066.20** 1.0660.05* 3.1160.48* 0.01460.003*
GST-GCK(Val154Leu] 2.7760.48 46.6064.40 26.0063.40* 1.5460.01 1.6260.16* 0.09960.036**
GST-GCK(Gly162Asp] 2.7860.58 Undetectable activity
GST-GCK(Arg303Trp] 1.5860.26 14.6061.38** 4.6260.10** 1.5260.02 0.2960.01* 0.5960.09*
GST-GCK(Arg392Ser] 2.4460.74 41.30611.30 11.9061.70* 1.3060.03 0.6360.03* 0.6060.25
Data represent means 6 SEM of 3 separate enzyme expressions each tested in duplicate. Note that the Hill coefficient (nH) and the relative activity index (Ia) are unit
less. Kcat: GCK catalytic constant; S0.5: affinity constant for glucose; nH: Hill coefficient; Km for ATP: affinity constant for ATP; Ia: GCK activity index. (*)p,0.05, t test;
(**)p,0.005, t test.
doi:10.1371/journal.pone.0038906.t002
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We evaluated the effects on GCK kinetics and thermo-stability
of seven GCK variants distributed in different functional
domains of the enzyme: three variants described in the present
study (p.Phe150Tyr, p.Val154Leu, p.Arg303Trp) and four
(p.Glu70Asp, p.His137Asp, p.Gly162Asp and p.Arg392Ser)
previously reported [11]. The GST-GCK (p.Glu70Asp) mutant
showed a GCK activity index significantly lower than the wild
type (mean Ia = 0.25). This effect is due to discrete defects in the
kinetic constants, in particular, glucose affinity was significantly
reduced (S0.5 for glucose: 20.163.2 vs 7.260.4 mM). Variant
p.Glu70Lys displayed a similarly decreased activity index (mean
Ia = 0.31) without significant thermo-instability [14,15]. The
substitution of histidine with aspartic acid (p.His137Asp) affected
GCK function (mean Ia = 0.26). As shown by molecular
modelling, this mutation introduces a negative charge in the
region that may affect the charge distribution of the protein [11].
The previously reported mutation p.His137Arg, in which His is
replaced by the positively charged arginine, did not affect
enzyme activity (mean Ia = 0.92) [15]. This finding shows that a
negatively charged amino acid is not tolerated at this site.
p.Phe150Tyr and the novel p.Val154Leu mutations dramatically
reduced GCK activity (mean Ia = 0.014 and 0.099, respectively)
Figure 1. View of the mutations p.Phe150Tyr and p.Val154Leu in the whole structures and in their local environment. A: The
structures of GCK in the super-open inactive form (PDB code code: 1v4t) and in the closed active form (PDB code code: 1v4s) are shown on the left
and on the right, respectively. In the closed form (right) the sugar is shown as a yellow stick. In both panels, the large domain is in the same
orientation and is circled. It is clear that the small domain undergoes a large conformational variation from the super-open to the closed form.
Specifically the region embodying the residues Phe150 (blue sphere) and Val154 (red sphere) dramatically changes its orientation. B: Close-up view of
the wild-type closed structure showing the hydrophobic core rich in aromatic/hydrophobic amino acids. Leu79, Phe123, Phe148, Phe150, Val154,
Leu164, Trp167 and Phe171 form an intricate network of stabilizing hydrophobic interactions. C: Structure of GCK closed structure containing the
both the Tyr150 and Leu154 mutated residues. Introduction of the oxydryl group (red) of Tyr150 within the hydrophobic core disrupts the
interactions present in the wt-enzyme. The replacement of Val154 by leucine produces only small changes in the closed form.
doi:10.1371/journal.pone.0038906.g001
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and thermo-stability (,40% at 50uC/30 min than in wild-type).
Both mutations displayed high S0.5 and ATP Km values, which
indicate a greatly reduced affinity for glucose and ATP. In
particular, the cooperativity of p.Phe150Tyr was significantly
reduced (nH = 1.06 vs 1.40, t test, p = 0.038). It is noteworthy
that Val154 is one of residues that undergo large movements
during the transition from the super-open to the closed form.
Even though the replacement of Val by Leu provokes only small
local perturbations, the latter may be relevant during the
conformational transition induced by ATP and glucose binding.
The substitution of glycine 162 by aspartic acid (p.Gly162Asp)
affected the hydrophobic core of the enzyme and, as predicted
by molecular modelling [11], markedly alters the structure and
dynamics of the domain. This is one of the most dramatic
mutations we identified as it introduces a net negative charge
into a hydrophobic environment [11]. In fact, the enzyme
activity of this mutant was undetectable. Although any reduction
in the Ia below 30% of the wild type would have little further
effect on the fasting plasma glucose [15], it is noteworthy that
fasting glycemia was higher in the child with this mutation
(10.0 mmol/L) [11] than in other MODY2 children (mean
6.760.8 mmol/L). Arg 303 is located in the a8 helix and
molecular modelling indicates that the Arg-to-Trp change at this
position would destabilize the helix structure. Mutation
p.Arg303Trp caused a reduction of the activity index (mean Ia
= 0.59), mainly due to a decrease in the catalytic constant, being
Figure 2. Distribution of the selected GCK mutations. The structure of GCK in the active closed form is shown (PDB code: 1v4s); the small and
large domains are drawn in cyan and red, respectively; glucose appears as a yellow stick. Mutation sites are shown as green or blue spheres.
doi:10.1371/journal.pone.0038906.g002
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both glucose and ATP affinities modified. Our results concord
with the finding that other mutations in the same helix
(p.Leu309Pro and p.Arg308Trp) increased thermal inactivation
and/or modified glucose affinity [16,17]. Taken together, these
results suggest that the a8 helix plays a role in the regulation of
substrate affinity and protein stability. Mutation p.Arg392Ser is
located in the protein periphery and, like the neighboring
mutation p.Arg397Leu [17], it only slightly affected GCK
activity. Thus, our mutants reduced the enzyme’s catalytic
activity by altering one or more kinetic parameters. Moreover, all
mutants, except GCK-Glu70Asp, displayed thermal-instability,
which has been implicated in hyperglycemia in MODY2 patients
[17,18]. Nevertheless, additional defects caused by these muta-
tions on other mechanisms of GCK control, such as post-
translational regulation, interaction with other protein partners
or organelles, cannot be excluded. Globally our evaluation of
enzyme activity indicates that all seven mutants play a
pathogenic role in MODY2 insurgence. In addition although
altered glucose and ATP binding, and thermal stability appear to
be the major causes of the disease, in a few cases mutations
affected cooperativity and molecular motions, and hence
impaired enzyme activity.
Although the in vitro functional evaluation of a GCK-mutant is
a useful method with which to predict the effect exerted by a DNA
change on enzyme activity, it is not a practical approach to the
diagnosis of MODY. In our experience, taking into account all the
experimental data concerning the seven mutants expressed, we
found that the mutations induced structural alterations predicted
by modeling that were in good agreement with kinetics/
thermostability analyses. Therefore, this approach could be a
reliable surrogate to predict the pathogenic role of a GCK variant.
In conclusion, in this five-year update of GCK mutations in
MODY2 children from southern Italy, we have identified six new
GCK variants thereby expanding the MODY2 mutation panel.
Furthermore, our study, carried out by integrating DHPLC,
sequencing, bioinformatics and functional analysis, provides new
information about the structure-function relationship of human
glucokinase mutations and MODY2.
Figure 3. Effect of temperature on the stability of GST-GCK mutants. Stock enzyme solutions were diluted to 250 mg/ml in storage buffer
containing 30% glycerol, 50 mM glucose, 10 mM glutathione, 5 mM DTT, 200 mM KCl and 50 mMTris/HCl, pH 8.0. Panel A: The enzyme solutions
were incubated for 30 min at temperatures ranging from 30 to 55uC and then assayed at 30uC as described in the Methods section. Panel B: The
enzyme solutions were incubated for periods of time from 5 to 60 min at 50uC. Results are means and SEM of three independent enzyme
preparations for each mutant except for GST-GCK (Phe150Tyr) which corresponds to two independent enzyme preparations. (*) p#0.03, ({) p,0.008.
doi:10.1371/journal.pone.0038906.g003
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Materials and Methods
Ethics Approval
The study was conducted according to the Helsinki II
declaration and it was approved by the Ethics Committee of the
School of Medicine Federico II, Naples, Italy.
Written informed consent to the study was obtained from each
adult subject and from both parents of children.
Subjects
Between 2006 and 2010, 720 hyperglycemic children were
monitored at the Departments of Pediatrics of the University of
Naples ‘‘Federico II’’ and of the Second University of Naples,
Italy. Sixty-six patients (mean age 109 months, 53% girls) who had
fasting hyperglycemia (.5.5 mmol/L), HbA1c ,7.0% and a
family history of diabetes for at least two consecutive generations
were enrolled in the study as suspected MODY2 individuals. The
autoimmune markers of type-1 diabetes (glutamate decarboxylase,
protein tyrosine phosphatase-like protein and insulin antibodies)
were evaluated; the presence of more than one antibody was
considered an exclusion criterion. One hundred unrelated
euglycemic controls (mean age 363 months, 69% girls) were
recruited at CEINGE (Advanced Biotechnologies, s.c.a.r.l. Naples)
also between 2006–2010.
Patients, their mother and father, and controls provided 2 blood
samples for biochemical testing and for DNA extraction. BMIz-
score (Center for Disease Control normative, http://www.cdc.
gov), family history of diabetes and/or other diseases, birth weight
and age at admission were recorded for each patient. FPG,
triglycerides (evaluated with routine methods) and HbA1c
measure with HPLC (HLC-723 G7 TOSOH Bioscience Tokyo,
Japan) were evaluated in each suspected MODY2 child. Genomic
DNA from patients, their mother and father, and controls was
extracted with the Nucleon BACC 2 kit (Amersham Biosciences
Europe, Milan, Italy).
GCK Gene Analysis
The 10 exons, including their flanking intronic regions, of the
GCK gene were amplified using primers and PCR conditions
described elsewhere [11]. The amplified fragments were dena-
tured at 95uC for 10 min and then renatured for 10 min to
generate heteroduplices. Each fragment was run on the DHPLC
WAVE DNA fragment analysis system (Transgenomic, Inc.
Omaha, NE) using DHPLC conditions reported in Table S1.
Any additional or abnormal peak shape observed in the
chromatogram was further sequenced (ABI PRISM 3730;
Biosystems Foster City, CA, USA). All sequences were analysed
in comparison with the wild-type reference sequence
(NM_000162, http://www.ncbi.nlm.nih.gov/nuccore/
NM_000162) by the ABI Seqscape software v.2.5 (Applied
Biosystems). The mutations and variants were then numbered
according to the Human Genome Variation Society (http://www.
hgvs.org/).
Analysis of GCK Mutations
We first evaluated each detected GCK mutation by bioinfor-
matics (Polyphen and SIFT algorithms and Modeller programs).
We also examined the enzyme function of seven mutations among
the most severe found in our population in the last decade and
never characterized. The mutations for the latter study mapped in
the whole enzyme structure (small, large and loops connecting
domains).
Bioinformatic Analysis
Two free online prediction programs, Polyphen (http://
genetics.bwh.harvard.edu/pph/) and SIFT (http://sift.jcvi.org/
www/SIFT_seq_submit2.html), [1] were used to predict the effect
of GCK mutations on the protein. The Polyphen program [19] is
a tool for the prediction of the impact of an amino acid
substitution on the structure of a human protein using straight
forward physical and comparative considerations. The SIFT
program [20] tests a query sequence and uses multiple alignment
information to predict tolerated and deleterious substitutions for
every position of the query sequence. SIFT is a multistep
procedure that searches for similar sequences, chooses closely
related sequences that may share a function similar to that of the
query sequence, obtains the alignment of these chosen sequences,
and calculates normalized probabilities for all possible substitu-
tions from the alignment. Models of all mutants of GCK were
generated in silico with the Modeller 9v8 program using the active
form of the GCK crystal structure as template [2.3 A˚, Brookhaven
Protein Database code (PDB code) 1v4s]. The inactive super-open
form (3.4 A˚, PDB code 1v4t) was also considered for comparison.
After alignment with using BODIL [21], the query and
template sequences were used as input in the Modeller program
[22] and 20 models were generated. The most abundant
conformers of the replaced residue were selected and a simulated
annealing procedure was carried out to optimize side chain
conformations. The model that presented the best Modeller
Discrete Optimized Protein Energy (DOPE) score was selected to
be used in subsequent analyses. The initial models of selected
mutants were energy minimized with the GROningen MAchine
for Chemical Simulations (GROMACS) package using the
GROningen MOlecular Simulation (GROMOS) 43a1 force field,
to regularize the protein structure geometry. The molecules were
solvated in boxes containing simple point charge water molecules.
The energy minimization was obtained by 1000 steps of the
steepest descent method and subsequently by 1000 steps of the
conjugate gradient method. The notation used for secondary
structure was taken from Kamata et al. [8].
Production of Recombinant Wild-type and Mutant
Glutathionyl-S-transferase-glucokinase (GST-GCK)
Recombinant human wild-type beta cell GCK fused to GST
(GST-GCK) was prepared as described previously [23]. Mutations
were introduced into the GST-GCK construct by PCR using the
QuikChangeH II Site Directed Mutagenesis Kit (Stratagene, La
Jolla, CA, USA); the oligonucleotides are reported in Table S2.
Mutant constructs were checked by sequencing and digestion with
specific restriction enzymes (Table S2). Fusion proteins from E. coli
were expressed and purified as described previously [24]. Fusion
proteins were stored at a concentration of about 1 mg/ml at –
80uC in 30% glycerol, 50 mM glucose, 10 mM glutathione, 5 mM
DTT, 200 mM KCl and 50 mM Tris/HCl, pH = 8.0. Protein
concentrations were determined with the Bio-Rad Protein Assay
(Bio-Rad Laboratories, GmbH Mu¨nchen Germany), and bovine
serum albumin as standard. GST-GCK purification was verified
by Coomassie-stained SDS-PAGE as a single band of 75 kDa.
Enzymatic Assay
GCK activity was measured spectrophotometrically on a
UVIKONxl spectrophotometer (Secoman, France), using a
NADP+-coupled assay with glucose-6-phosphate dehydrogenase.
Determination of kinetic parameters and thermal inactivation
were performed as previously described [23]. The Km for ATP
was measured at a glucose concentration near the relative S0.5
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values (7, 15, 8.5, 100, 20, 5 and 11 mM respectively for wild type,
p.Glu70Asp, p.His137Asp, p.Phe150Tyr, p.Val154Leu,
p.Gly162Asp, p.Arg303Trp and p.Arg392Ser). Thermal inactiva-
tion experiments were assayed at a glucose concentration of
100 mM. Results are reported as means 6 standard error of the
mean (SEM) of three independent enzyme preparations assayed at
least in duplicate.
Statistical Analysis
Variables are reported as mean6SD (continuous variables) or
mean 6SEM (categorical variables). We used the Student t test to
compare variables; significance was set at p,0.05. The SPSS
statistical software was used.
Supporting Information
Figure S1 Close-up view of the p.Lys420Glu mutation at
the inter-domain interface. The small and large domains are
drawn in cyan and red, respectively. Helix 13 is shown in orange.
Lys420 (red stick) forms a salt-bridge with Glu440 (yellow stick)
which is located in a loop connecting the two domains.
(DOCX)
Table S1 DHPLC conditions to detect GCK variants.
(DOCX)
Table S2 Primers used for site-directed mutagenesis in
GCK cDNA.
(DOCX)
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Mitochondrial DNA (mtDNA) haplogroups have been associated with the expression of mitochondrial-related diseases and with
metabolic alterations, but their role has not yet been investigated in morbid obese Caucasian subjects. Therefore, we investigated
the association between mitochondrial haplogroups and morbid obesity in patients from southern Italy. The mtDNA D-loop of
morbid obese patients (𝑛 = 500; BMI > 40 kg/m2) and controls (𝑛 = 216; BMI < 25 kg/m2) was sequenced to determine themtDNA
haplogroups. The T and J haplogroup frequencies were higher and lower, respectively, in obese subjects than in controls. Women
bearing haplogroup T or J had twice or half the risk of obesity. Binomial logistic regression analysis showed that haplogroup T and
systolic blood pressure are risk factors for a high degree of morbid obesity, namely, BMI > 45 kg/m2 and in fact together account for
8% of the BMI. In conclusion, our finding that haplogroup T increases the risk of obesity by about two-fold, suggests that, besides
nuclear genome variations and environmental factors, the T haplogroup plays a role in morbid obesity in our study population
from southern Italy.
1. Introduction
Obesity is a multifactorial disorder caused by a combination
of environmental, behavioural, and genetic factors; however,
themolecularmechanisms by which these factors provoke fat
mass accumulation and maintenance are not yet completely
elucidated [1]. Moreover, mitochondrial dysfunctions that
result in lipid accumulation and insulin resistance have
been implicated in the pathogenesis of obesity [2]. Several
mitochondrial DNA (mtDNA) variants have been investi-
gated in diverse populations with obesity-related and lipid
metabolism alterations [3, 4], and it was suggested that
particular mtDNA haplogroups could be associated with
inefficient energy expenditure [5]. A mitochondrial hap-
logroup (mt-haplogroup) is a collection of single nucleotide
polymorphisms [6] accumulated throughout human history
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in specific populations that could be attributed to genetic drift
and/or climate selection [7–9]. Mitochondrial haplogroups
have been associated with the expression of mitochondrial-
related diseases (metabolic syndrome, type 2 diabetes, neu-
rological disorders, infertility, and Parkinson’s disease) and
with various individual characteristics (aging and endurance
training capacity) [3, 10–14], but, to our knowledge, their
role has not yet been investigated in morbid obese Caucasian
subjects. We previously reported that several DNA variants
and epigenetic alterations are associated with the obese phe-
notype and/or with obese-related diseases [15–19]. Here, we
have characterized mt-haplogroups in a large population of
morbid obese adults and nonobese individuals from southern
Italy to look for associations among specific mt-haplogroups
and the obese phenotype.
2. Methods
2.1. Study Population. Five hundred unrelated morbid obese
patients (64% females, age range 17–70 years, median; 2.5th–
97.5th percentiles BMI = 45.1; 38.2–65.4 kg/m2), and 216 non
obese controls (66% females, age range 26–76 years, BMI
= 22.9; 18.2–25.6 kg/m2) were recruited from the Obesity
Outpatient Clinic of the Dipartimento di Medicina Clinica
e Chirurgia and from the Dipartimento di Medicina Moleco-
lare e BiotecnologieMediche, Federico IIUniversityHospital,
Naples (Italy), respectively. All participants were Caucasians
and had lived in southern Italy for at least 3 generations.
Written informed consent for participation in the study was
obtained from all subjects. The research was approved by the
Ethics Committee of the School of Medicine, University of
Naples Federico II, and was in accordance with the principles
of the Helsinki II Declaration.
2.2. Laboratory Investigations. Two blood samples (one for
biochemical analysis and one for DNA extraction) were
obtained after an overnight fast from each enrolled subject.
Biochemical parameters were measured enzymatically with
routine methods on an automated analyzer (Hitachi 747;
Boehringer Mannheim, Germany). Insulin resistance was
estimated in obese subjects with the homeostasis model
assessment (HOMA) and the formula: fasting insulin (mU/L)
X fasting glucose (mmol/L)/22.5.
The clinical and anamnestic data of each obese subject
were collected, and the main metabolic parameters were
evaluated. Fat mass (FM) and fat-free mass (FFM) were
measured by bioimpedentiometry (Sta/BIA Akern, Florence,
Italy) and respiratory quotient (RQ) and basal metabolic
rate (BMR) by indirect calorimetry (Sensor Medics Vmax29,
Anaheim, CA, USA). The BMI was calculated as weight
(kg)/square height (m2). Systolic and diastolic blood pres-
sure, and cardiac frequency (beats/min) were collected by
standard procedures. Metabolic syndrome (MS), which is a
cluster of metabolic risk factors, namely, abdominal obesity,
dyslipidemia (hypertriglyceridemia or low HDL-cholesterol
concentrations), elevated blood pressure, and hyperglycemia,
as defined by the American Heart Association criteria, was
diagnosed if 3 out of the 5 risk factors were present [20].
2.3. Mitochondrial DNA Amplification and Sequencing.
Genomic DNA was extracted from whole blood (Illustra
BACC-2; GE Healthcare, UK). The D-loop region (about
1100 bp) was amplified with primers (HVI-forward:
GTAAACCGGAGATGAAAACCT; HVII-reverse
ACTGCATACCGCCAAAAGATA) chosen by the PRIMER
3 program (http://frodo.wi.mit.edu/) in a final volume of
25 𝜇L containing a PCR mixture (10 𝜇M each primer, 10x
PCR buffer, 200𝜇M each deoxynucleotide triphosphate,
and 0.5U of Taq DNA polymerase) and 50 ng of genomic
DNA. PCR consisted of an initial denaturation at 95∘C for
5min, followed by 35 cycles of 95∘C for 30 s, 60∘C for 1min,
and 72∘C for 1min, followed by a final extension at 72∘C
for 5min. The PCR fragment was run on a 1.5% agarose
gel, purified, and sequenced in both directions (BigDye
Terminator v3.1 cycle sequencing method on an ABI-Prism
3730 DNA Analyzer; Applied Biosystems). Sequences were
assembled with the SeqScape program v.2.5. The mtDNA
nucleotide sequences were numbered according to the rCRS
reference sequence (NC 012920). Haplogroups were defined
by nucleotides at specific known polymorphic sites in the
mtDNA [6].
2.4. Statistical Analysis. Haplogroup frequencies in patients
and control subjects were compared using the 𝜒2 test. A
𝑃 < 0.05 was considered the level of statistical significance.
The odds ratio (OR) and 95% confidence intervals (CI)
values for each haplogroupwere calculated for the statistically
significant haplogroup. ANOVA was performed to compare
metabolic parameters in the different haplogroups. Multiple
comparisons were corrected with the Bonferroni test. The
Student’s t-test, followed by a binomial logistic regression
analysis, was used to investigate the association between
the biochemical and clinical characteristics and the pres-
ence/absence of a specific haplogroup. Sample estimates were
verified by bootstrapping. Statistical analyses were carried
out with the PASW package for Windows (Ver.18; SPSS Inc.
Headquarters, Chicago, Il, USA).
3. Results
The clinical and biochemical characteristics of the obese sub-
jects are reported in Table 1. Metabolic syndrome was present
in 41.3% of our obese subjects and was significantly more
frequent inmen than in women (47.9% versus 37.5%; OR/95%
CI = 1.17/1.01–1.35, 𝑃 = 0.031). Concurrent MS factors in
our obese patients were hypertriglyceridemia (OR/95% CI:
16.7/10.8–26.0), hyperglycemia (OR/95% CI: 8.5/5.6–12.8),
hypertension (OR/95% CI: 7.1/4.7–10.7), low serum levels
of HDL cholesterol (OR/95% CI: 5.1/3.6–7.4). Haplogroup
frequencies in obese and nonobese subjects are reported in
Table 2. All nine common European haplogroups (H, I, J,
K, T, U, V, W, and X) [21] were identified in most of our
subjects (94.4%), whereas the R, L, N, B, and F haplogroups
(collectively indicated as “others” in Table 2) were rare (5.6%).
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European haplogroup frequencies were very similar in our
obese and nonobese subjects, and the H haplogroup was the
most frequent (about 40% of subjects).The T (𝑃 = 0.004) and
J (𝑃 = 0.02) haplogroup frequencies were higher and lower,
respectively, in obese subjects than in controls (haplogroup T:
13.2% versus 6%; haplogroup J: 5% versus 9.7%). At the𝜒2 test,
subjects with the T haplogroup had an increased risk of about
two-fold for obesity (OR/95%CI = 1.94/1.16–3.22;𝑃 = 0.004),
whereas subjects with the J haplogroup were less exposed to
obesity (OR/95%CI= 0.63/0.45–0.89;𝑃 = 0.02) than subjects
with the other haplogroups. These findings were confirmed
by the results of bootstrap analysis based on 100 bootstrap
samples.
Whenwe divided our populations intomales and females, the
prevalence of the T and J haplogroups remained significantly
higher and lower, respectively, in the obese females (12.4%
versus 4.9%, OR/95% CI = 2.18/1.01–4.39; 𝑃 = 0.012 for
haplogroup T; 4.7% versus 11.9%, OR/95% CI = 0.55/0.38–
0.78; 𝑃 = 0.009 for haplogroup J). In addition, the T hap-
logroup was correlated to the degree of obesity. In fact,
this haplogroup was significantly more frequent in obese
subjects with a BMI higher than in those with a BMI lower
than the median BMI (45 kg/m2) (16% versus 10%, resp.;
𝑃 = 0.04). Binomial logistic regression analysis (dependent
variable: median BMI and independent variables: clinical
and biochemical investigated parameters) showed that hap-
logroup T and systolic blood pressure are risk factors for
a high degree of morbid obesity, namely, BMI > 45 kg/m2
(OR/95% CI: 2.3/1.3–4.3 and OR/95% CI: 1.1/1.02–1.4, resp.);
in fact together they account for 8% of the BMI. We did
not find an association between mtDNA haplogroups and
the clinical/biochemical tested variables, or in haplogroup
frequencies according to MS presence/absence.
4. Discussion
Mitochondrial DNA haplogroups have been associated with
metabolic disorders in various populations [3, 22, 23],
although not yet in morbid obese Caucasians from southern
Italy. The prevalence of MS in our obese patients (41%) was
similar to that previously reported in a multicenter Italian
study (43.6%) [24]. We found that haplogroup H was the
most common haplogroup in both obese and control subjects
(46.6% and 40.7%, resp.) from southern Italy, which is in
agreement with the H frequency reported in other European
populations (haplogroupH frequency: 13.3%–41.7%) [21].We
also show that haplogroups T and J conferred an increased
and decreased risk for obesity, respectively. The J haplogroup
was reported to protect against the onset of diseases related
to oxidative stress and/or low inflammation grade, such as
ischemic cardiomyopathy [25]. In fact, subjects bearing this
haplogroup showed lower oxygen consumption (because the
lower efficiency of the electron respiratory chain resulted in
reduced production of radical oxygen species) than those
with the H haplogroup [25].
On the other hand, subjects with haplogroup T could be
intrinsically prone to develop defects in the mitochondrial
oxidative phosphorylation system, which, in turn, negatively
Table 1: General and biochemical characteristics of the morbid
obese patients studied (𝑛 = 500).
Median Percentiles
2.5th 97.5th
Age (years) 32.59 17.50 57.00
Height (m) 1.66 1.51 1.85
Weight (kg) 125.54 98.00 178.40
BMI (kg/m2) 45.10 38.20 65.40
Waist circumference (cm) 131.00 106.00 170.00
Hips circumference (cm) 134.00 114.90 158.10
W/H ratio 0.99 0.82 1.19
RQ 0.87 0.74 1.01
BMR (kcal) 2237.50 1581.38 3278.63
FFM (%) 51.40 40.28 64.11
FM (%) 48.55 35.89 59.73
SBP (mmHg) 124.45 100.00 160.00
DBP (mmHg) 80.00 60.00 100.00
Heart rate (beats/min) 80.00 60.00 100.00
Glucose (mmol/L) 5.05 3.89 7.53
Total cholesterol (mmol/L) 4.75 3.11 7.12
HDL cholesterol (mmol/L) 1.21 0.73 1.82
Triglycerides (mmol/L) 1.42 0.56 3.16
AST (U/L) 23.00 13.55 64.45
ALT (U/L) 31.00 12.00 84.45
GGT (U/L) 26.00 10.00 87.50
CHE (U/mL) 10066.37 5828.90 15084.55
Total bilirubin (𝜇mol/L) 9.41 4.28 20.94
Uric acid (mmol/L) 0.35 0.21 0.57
Albumin (g/dL) 4.30 3.60 4.90
Total Protein (g/dL) 7.56 6.76 8.30
Creatinine (𝜇mol/L) 70.72 44.20 106.08
Urea (mmol/L) 5.33 3.33 8.16
ALP (U/L) 76.00 42.75 247.75
C-peptide (ng/mL) 3.90 1.80 7.35
Insulin (mU/L) 19.00 6.90 53.03
HOMA 4.26 1.43 14.66
ALP: alkaline phosphatase; ALT: alanine transaminase; AST: aspartate
transaminase; BMI: Body Mass Index; BMR: basal metabolic rate; CHE:
cholinesterase; DBP: diastolic blood pressure; FFM: fat-free mass; FM: fat
mass; GGT: 𝛾-glutamyl transferase; HOMA: homeostatic model assessment;
RQ: respiratory quotient; SBP: systolic blood pressure; W/H: waist/hip.
affects the performance of mitochondrial ATP production
[11]. In fact, haplogroup T was reported to be more fre-
quent in white men with fertility problems (a condition
strongly dependent on ATP production) [13] and among
Spanish patients affected by left ventricular hypertrophy
[26]. Indeed, haplogroup T was less frequent among elite
endurance athletes (possibly related to a negative effect on
cardiac adaptation to endurance training) [11]. Amo et al.
[27] reported that mitochondrial bioenergetic capacities and
coupling efficiencies in cultured carcinoma cells did not differ
between transmitochondrial cybrids harbouring mitochon-
dria with haplogroup H and those harbouring mitochondria
with haplogroup T [27]. However, the authors suggest that
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Table 2: Haplogroup frequencies in morbid obese patients (𝑛 =
500) and controls (𝑛 = 216).
Haplogroup Obesepatients 𝑛 (%)
Control
subjects 𝑛 (%) 𝑃 OR/95% CI
H 233 (46.6) 88 (40.7)
I 7 (1.4) 6 (2.8)
J 25 (5.0) 21 (9.7) 0.02 0.63/0.45–0.89
K 29 (5.8) 18 (8.3)
T 66 (13.2) 13 (6.0) 0.004 1.94/1.16–3.22
JT 0 (0) 1 (0.5)
U 85 (17.0) 39 (18.1)
V 13 (2.6) 4 (1.9)
W 8 (1.6) 2 (0.9)
X 10 (2.0) 8 (3.7)
Others 24 (4.8) 16 (7.4)
this result could be partially inconclusive because the effect of
mitochondrial haplogroupsmight be too small to be detected
by the procedures used [27], or they might need particular
nuclear genes in order to be expressed, or they might
need additional signals (nutrients and/or oxidative stress
molecules) to influence oxidative phosphorylation functions,
as previously described for the Uk haplogroup [28]. The
foregoing studies suggest that, in our obese patients, the T
haplogroup could contribute to affect the mechanisms of
energy balance regulation so leading to increased fat depots.
In conclusion, our finding that haplogroup T increases
the risk of obesity by about two-fold suggests that, besides
nuclear genome variations and environmental factors, the
T haplogroup contributes to morbid obesity in our study
population from southern Italy.
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SHORT COMMUNICATION
Characterization and predicted role of the microRNA expression
proﬁle in amnion from obese pregnant women
C Nardelli1,2,6, L Iaffaldano1,2,6, M Ferrigno2, G Labruna3, GM Maruotti4, F Quaglia4, V Capobianco1,2, R Di Noto1,2, L Del Vecchio1,2,
P Martinelli4, L Pastore1,2 and L Sacchetti5
Maternal obesity and nutrient excess in utero increase the risk of future metabolic diseases. The mechanisms underlying this
process are poorly understood, but probably include genetic, epigenetic alterations and changes in fetal nutrient supply.
We have studied the microRNA (miRNA) expression proﬁle in amnion from obese and control women at delivery to investigate
if a speciﬁc miRNA signature is associated with obesity. The expression proﬁle of 365 human miRNAs was evaluated with the
TaqMan Array in amnion from 10 obese and 5 control (prepregnancy body mass index (BMI) 430 and o25 kgm 2,
respectively) women at delivery. Target genes and miRNA-regulated pathways were predicted by bioinformatics.
Anthropometric and biochemical parameters were also measured in mothers and newborns. Seven miRNAs were expressed
only in obese women (miR-422b, miR-219, miR-575, miR-523, miR-579, miR-618 and miR-659), whereas 13 miRNAs were
expressed at a higher level and 12 miRNAs at a lower level in obese women than in controls. MicroRNAs signiﬁcantly
downregulated the neurotrophin, cancer/ErbB, mammalian target of rapamycin, insulin, adipocytokine, actin cytoskeleton and
mitogen-activated protein kinase signaling pathways. In conclusion, we show that the miRNA proﬁle is altered in amnion during
obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to
an increase in the newborn’s risk of future metabolic diseases.
International Journal of Obesity advance online publication, 30 July 2013; doi:10.1038/ijo.2013.121
Keywords: pregnancy; miRNA; pathway
INTRODUCTION
Maternal obesity and nutrient excess in utero increase the risk
of future metabolic diseases.1 The mechanisms underlying this
process are poorly understood, but probably include genetic,
epigenetic alterations and changes in fetal nutrient supply.1
Placenta, and particularly amnion, is the in utero environment
that could modify fetal growth and adiposity by exerting
stimulatory or inhibitory effects on fetal genome expression.1
Examples of epigenetic mechanisms are DNA methylation,
histone modiﬁcations and microRNAs (miRNAs),1 the latter
being a class of endogenous non-coding RNA molecules
(18–25 nucleotides long) that exert tissue-speciﬁc regulation
in a variety of biological and pathological processes.2
The expression of placental miRNAs is altered during
pregnancy in such pathological conditions as preeclampsia,
small-for-gestational-age newborns3 and fetal congenital heart
defects,4 but their role in obesity has not yet been investigated.
We previously reported that miRNAs were implicated in the
deregulation of metabolic pathways in subcutaneous and
visceral adipose tissues in obese adults.5,6 The aim of this
study was to analyze the miRNA expression proﬁle in
amnion from obese and control women at delivery to
determine if a speciﬁc miRNA signature could be associated
with obesity.
MATERIALS AND METHODS
Patients and samples collection
Fifteen Caucasian pregnant women (5 controls and 10 obese subjects of a
similar age (mean/s.e.m.: 29/1.3 and 31.1/1.0 years, P¼NS, respectively)
and prepregnancy body mass index (BMI) (mean/s.e.m.: 22.8/1.4 and 38.7/
1.4 kgm 2, respectively)) were consecutively enrolled at the Dipartimento
Neuroscienze/Scienze Riproduttive/Odontostomatologiche (University of
Naples Federico II). The exclusion criteria were neoplasia, viral infection,
diabetes and drug assumption. One maternal blood sample and one cord
blood sample were collected at delivery. Sera and cord plasma were
obtained and stored at  80 1C until required for the measurement of
biochemical parameters and leptin/adiponectin concentrations by routine
methods and immunoassay (Bio-Rad, Hemel Hempstead, Herts, UK),
respectively.
The term placentas, collected at delivery by cesarean section, were
processed immediately. The maternal decidua was removed,
the amnion was ﬁrst manually separated from the chorion, washed in
phosphate-buffered saline (Sigma-Aldrich, St Louis, MO, USA),
mechanically minced into small pieces and immediately cryopreserved
in liquid nitrogen. The newborn’s weight, length, head circumference
and Appearance-Pulse-Grimace-Activity-Respiration score (Apgar 1 and
5min) were recorded at birth. All patients and controls gave their
informed consent to the study and both parents gave consent for
their newborns. The study was performed according to the Helsinki II
Declaration and was approved by the Ethics Committee of our
Faculty.
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RNA isolation
Total RNA (including miRNAs) was puriﬁed from amnion (mirVana miRNA
Isolation Kit; Ambion, Austin, TX, USA) and quantiﬁed by NanoDrop
ND-1000 UV–Vis spectrophotometer (Thermo Fisher Scientiﬁc, Wilmington,
DE, USA).
MiRNAs detection
We studied the miRNA proﬁles by the TaqMan low-density arrays human
MicroRNA Panel v.1.0 (Applied Biosystems, Foster City, CA, USA) that
contains 365 preloaded miRNAs and two endogenous controls (RNU48 and
RNU44). We used 640 ng of total RNA for reverse transcription. Reverse
transcription–polymerase chain reaction was performed using the 7900 HT
Real-Time PCR System (Applied Biosystems). The miRNA expression values
were normalized to RNU48 and to RNA isolated from controls as calibrator;
relative expression values were obtained using the DDCt method (relative
quantiﬁcation, RQ¼ 2DDCt) by sequence detection system v.2.3 and RQ
Manager 1.2 software (Applied Biosystems). To normalize our miRNA data
further and to minimize interindividual variability, we considered the
miRNAs whose mean RQ levels were o0.5 (downexpressed) or 42.0
(upexpressed) in 70% of the obese vs control women to be expressed
differently. The expression levels of selected miRNAs (miR-422b, miR-23b,
miR-338, miR-449b and miR-139) were also validated by single TaqMan
miRNA assay (Applied Biosystems) in accordance with the manufacturer’s
instructions on the 7900 HT Real-Time PCR System.
Bioinformatic analysis
TargetScan Release 6.2 algorithm (http://www.targetscan.org) and the KEGG
database (http://www.genome.ad.jp/kegg/) were used to predict biological
targets of miRNAs and to select biological pathways, respectively.
Statistical analysis
All variables were expressed as mean and s.e.m. Student’s t-test was used
to compare groups and P-values o0.05 were considered statistically
signiﬁcant. Statistical analyses were carried out with the PASW Statistics
(v. 18; SPSS Headquarters, Chicago, IL, USA).
RESULTS
Obese and control women differed in weight gain (mean/s.e.m.:
7.6/1.0 and 15.0/2.6 kg) and total cholesterol levels (mean/s.e.m.:
5.8/0.4 and 7.3/0.2mmol l 1), which were signiﬁcantly lower
(P¼ 0.008 and 0.016) in obese women than in controls.
In addition, levels of triglycerides (mean/s.e.m.: 3.1/0.2 and
2.4/0.3mmol l 1, P¼ 0.048) and leptin (mean/s.e.m.: 47.7/10.4
and 12.4/3.9 ngml 1, P¼ 0.010) were signiﬁcantly higher in obese
women than in controls.
Newborns of obese and control women showed similar birth
weight (mean/s.e.m.: 3.268/0.374 and 3.340/0.190 kg), length
(mean/s.e.m.: 50.4/1.1 and 50.4/0.7 cm), head circumference
(mean/s.e.m.: 33.9/0.7 and 34.5/0.7 cm) and Apgar scores
(mean/s.e.m. (1–5min): 7.3/0.4–8.5/0.2 and 8.0/0.3–8.8/0.2),
respectively. Cord plasma adiponectin levels were signiﬁcantly
lower in newborns of obese women than in newborns of controls
(mean/s.e.m.: 47.0/7.7 and 107.9/18.9 mgml 1, respectively,
P¼ 0.004), whereas cord plasma leptin levels did not differ
between the two groups.
A large percentage of the tested miRNAs, about 74% (271/365),
was expressed in amnion, whereas 26% (94/365) was not. Most of
the expressed miRNAs (90%, 243/271) did not differ between
obese women and controls and were not further investigated.
Conversely, 4.8% of miRNAs (13/271) were higher (Figure 1a) and
4.4% (12/271) were lower (Figure 1b) in obese women than in
controls. Interestingly, 7/271 miRNAs (miR-422b, miR-219, miR-575,
miR-523, miR-579, miR-618 and miR-659) were obesity-speciﬁc,
being expressed only in amnion from obese women.
Bioinformatics showed that miRNAs had a signiﬁcant probability
(Po0.01) of deregulating several genes and metabolic pathways
(Figures 1c, d and 2).
The expression levels of several miRNAs were further validated
by quantitative real-time polymerase chain reaction and, except
for slight differences because of the two different methodologies,
Figure 1. Differently expressed miRNAs in amnion from obese and control women. Panels (a) and (b) depict miRNAs upexpressed
(13/271) and downexpressed (12/271), respectively. miRNA expression levels are shown as Log RQ mean and s.e.m. (The miRNA expression
values were first normalized to RNU48, after which, the relative quantification was calculated as: RQ¼ 2DDCt, where DDCt¼ (Ctobese
(miRNA)Ctobese (RNU48)) (Ctcalibrator (miRNA)Ctcalibrator (RNU48))). Panels (c) and (d) show metabolic pathways (black squares) and
genes targeted by miRNAs (Po0.01) upexpressed and downexpressed, respectively. *Pathways significantly regulated by target genes
of miR-615-3p were not reported by TargetScan.
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they were in close agreement with those obtained with TaqMan
array (mean RQ values in obese vs control: miR-422b¼ 6.4;
miR-23b¼ 1.19; miR-338¼ 1.25; miR-139¼ 0.68; miR-449b¼ 0.9).
DISCUSSION
It is now recognized that epigenetic modiﬁcations of the fetal
genome contribute to disease development in adults.7 Here, we
show that miRNAs regulate gene expression in the amnion during
obesity. In particular, we found that 25 miRNAs are differently
expressed in obese with respect to control women, and have
identiﬁed seven obesity-speciﬁc miRNAs.
Our differently expressed placental miRNAs include miRNAs
previously associated with endometriosis (miR-196b, let-7d
and miR-107),8 preeclampsia (miR-181 and let-7d),9,10 cancer
(miR-422b)11 or identiﬁed in sera from normal pregnancies (miR-23b,
miR-372 and miR-519e).12,13 The predicted target genes of our
miRNAs belong to pathways potentially important for placental
development and/or functions. In fact, the neurotrophin pathway
was regulated by three obesity-speciﬁc miRNAs (miR-422b,
miR-659 and miR-575), six miRNAs upexpressed (miR-196b, miR-96,
miR-338-3p, miR-372, miR-492 and miR-107) and four miRNAs
downexpressed (miR-591, miR-139, miR-624 and miR-554).
The brain-derived neurotrophic factor was recently implicated in
placental development and fetal growth in mice14 and its
placental expression was increased in intrauterine growth
restriction and decreased in maternal type 1 diabetes.14
Obesity-speciﬁc miRNAs (miR-422b, miR-659 and miR-219) also
downregulated the mammalian target of rapamycin (mTOR) and
the insulin signaling pathways. mTOR is highly expressed in
syncytiotrophoblasts of the human placenta and exists as two
complexes with distinct regulation and function based on its
association with accessory proteins: raptor in Complex 1 (mTORC1)
and rictor in Complex 2 (mTORC2).15 A multitude of upstream
regulators of mTORC1, including insulin, cellular energy and
oxygen levels, could affect placental size and modulate fetal
growth by regulating placental nutrient transporter function.15
Conversely, mTORC2 is involved in lipid metabolism; in fact,
in C. elegans loss of rictor function causes developmental
delay, reduced size and reproduction, and increased fat
accumulation.16 Here, we highlight a new potential mechanism
based on miRNA downregulation of mTOR that could impact on
fetal growth during obesity. Mammalian mTORC2 controls the
actin cytoskeleton organization, as shown by the ﬁnding that its
knockdown prevents actin polymerization.17 The cytoskeleton has
a crucial role in basic cellular processes and in decidualization,18
and the downregulation of placenta actin cytoskeleton signaling
was observed in preeclampsia.19 In our study, the actin
cytoskeleton pathway was predicted to be downregulated by
obesity-speciﬁc miR-422b, miR-659, miR-575 and miR-579, which
indicates that the placental structural organization and function
are also altered in human obesity.
We also found that adiponectin levels were higher in umbilical
cord plasma than in the mother’s serum, and lower in obese
than in control samples, in agreement with a previous report.20
Hypoadiponectinemia might have a role in placental development
and in pregnancy-related complications,20 and also through p38
mitogen-activated protein kinase signaling activation. In this
study, both the adipocytokine and mitogen-activated protein
kinase signaling pathways were downregulated by obesity-
speciﬁc miR-422b, miR-659, miR-579, miR-575 and miR-219,
which supports the concept that epigenetic regulation
of placental adiponectin and of its signaling could be involved
in the pathophysiology of obesity during pregnancy.
In conclusion, we show that the miRNA proﬁle is altered in amnion
during obesity and hypothesize that this could affect pathways
important for placental growth and function, thereby contributing to
an increase in the newborn’s risk of future metabolic diseases.
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Figure 2. Pathways and genes predicted by bioinformatics to be regulated by obesity-specific miRNAs in the amnion. In boxes are
reported the metabolic pathways and genes targeted by obesity-specific miRNAs (miR-422b, miR-219, miR-575, miR-579, miR-618 and
miR-659) (Po0.01). The arrows connect miRNAs to target genes in each pathway. *Conserved target genes of miR-523 were not
predicted by TargetScan.
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High Aminopeptidase N/CD13 Levels Characterize
Human Amniotic Mesenchymal Stem Cells and Drive
Their Increased Adipogenic Potential in Obese Women
Laura Iaffaldano,1,2,* Carmela Nardelli,1,2,* Maddalena Raia,1 Elisabetta Mariotti,1 Maddalena Ferrigno,1
Filomena Quaglia,3 Giuseppe Labruna,4 Valentina Capobianco,1,2 Angela Capone,3
Giuseppe Maria Maruotti,3 Lucio Pastore,1,2 Rosa Di Noto,1,2 Pasquale Martinelli,3
Lucia Sacchetti,1,2 and Luigi Del Vecchio1,2
Maternal obesity is associated to increased fetal risk of obesity and other metabolic diseases. Human amniotic
mesenchymal stem cells (hA-MSCs) have not been characterized in obese women. The aim of this study was to
isolate and compare hA-MSC immunophenotypes from obese (Ob-) and normal weight control (Co-) women, to
identify alterations possibly predisposing the fetus to obesity. We enrolled 16 Ob- and 7 Co-women at delivery
(mean/SEM prepregnancy body mass index: 40.3/1.8 and 22.4/1.0 kg/m2, respectively), and 32 not pregnant
women. hA-MSCs were phenotyped by flow cytometry; several maternal and newborn clinical and biochemical
parameters were also measured. The expression of membrane antigen CD13 was higher on Ob-hA-MSCs than
on Co-hA-MSCs (P < 0.005). Also, serum levels of CD13 at delivery were higher in Ob- versus Co-pregnant
women and correlated with CD13 antigen expression on Ob-hA-MSCs (r2 = 0.84, P < 0.0001). Adipogenesis in-
duction experiments revealed that Ob-hA-MSCs had a higher adipogenic potential than Co-hA-MSCs as wit-
nessed by higher peroxisome proliferator-activated receptor gamma and aP2 mRNA levels (P < 0.05 and P < 0.05,
respectively), at postinduction day 14 associated with increased CD13 mRNA levels from baseline to day 4
postinduction (P < 0.05). Adipogenesis was similar in the two sets of hA-MSCs after CD13 silencing, whereas it
was increased in Co-hA-MSCs after CD13 overexpression. CD13 expression was high also in Ob-h-MSCs from
umbilical cords or visceral adipose tissue of not pregnant women. In conclusion, antigen CD13, by influencing
the adipogenic potential of hA-MSCs, could be an in utero risk factor for obesity. Our data strengthen the
hypothesis that high levels of serum and MSC CD13 are obesity markers.
Introduction
The increase in the incidence of obesity in pregnantwomen in the last two decades has paralleled that ob-
served in the general population [1–3]. Although maternal fat
stores increase in all pregnant women, irrespective of pre-
pregnancy weight [4], the storage capacity of subcutaneous
adipose tissue is impaired, and fat predominantly accumu-
lates in the visceral adipose tissue (VAT) in obeses [5]. VAT is
an important risk factor for metabolic imbalance in human
subjects, also during pregnancy [6–8]. In fact, maternal
obesity is related to offspring obesity [9], and there is an
increased risk of adverse outcomes for bothmother and child
[10–13]. Moreover, the risk of childhood obesity was qua-
drupled if the mother was obese before pregnancy [14],
which suggests that the in utero environment is obesogenic.
In mammals, the placenta is the main interface between the
fetus and the mother; it regulates intrauterine development
and modulates adaptive responses to suboptimal in utero
conditions [15,16].
Placenta is also an important source of stem/progenitor
cells [17–19]. In particular, human amniotic mesenchymal
stem cells (hA-MSCs) have been shown to differentiate into
cell types of mesenchymal origin such as chondrocytes,
adipocytes, and osteocytes [20–22]. The phenotype of hA-
MSCs from normal pregnant women has been characterized
and found to differ in terms of cytokine expression from
that of pregnant women affected by pre-eclampsia [23].
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Thus far, little is known about hA-MSCs from obese
women.
The aim of this study was to characterize hA-MSCs from
term placenta of obese (Ob-) women and to test their adi-
pogenic potential with respect to that of normal weight
control (Co-) women. We also measured several maternal
and newborn clinical and biochemical parameters, and
looked for correlations between these parameters with the
hA-MSC immunophenotype. We found that the Ob-hA-MSC
immunophenotype was characterized by increased expres-
sion levels of the CD13 surface antigen that correlated with
maternal CD13 serum levels. Adipogenesis was higher in
Ob-hA-MSCs than in Co-hA-MSCs, and returned to the
control value after CD13 silencing. On the other hand, CD13
overexpression increased the adipogenic potential of Co-hA-
MSCs. Our findings suggest that CD13 could contribute to
obesity programming in the fetus and indicate that maternal
serum CD13 is an obesity risk marker.
Materials and Methods
Patients and controls
Sixteen Ob- (age range: 26–39 years) and seven Co-pregnant
women, (age range: 26–38 years), prepregnancy body mass
index (BMI) (mean/SEM) 40.3/1.8 and 22.4/1.0 kg/m2, re-
spectively, and thirty-two not pregnant women (16 obese and
16 normal weight, BMI>30kg/m2 and <25kg/m2, respec-
tively), were recruited at the Dipartimento di Neuroscienze e
Scienze Riproduttive ed Odontostomatologiche, University of
Naples ‘‘Federico II.’’ The clinical, personal, and family history
of the 23 women was recorded during a medical interview
conducted by an expert upon hospitalization. Data relative to
each pregnancy follow-up and delivery were also recorded.
The general characteristics of the newborn and clinical data
(birth weight, length, head circumference, Apgar score) were
recorded at birth.
Sample collection
Two fasting peripheral blood samples were collected in
the morning from not pregnant women and from Ob- and
Co-pregnant women, immediately before delivery. One
sample was used for DNA extraction, whereas the other was
centrifuged at 2,500 rpm for 15min and serum was stored at
- 80C until further processing. At delivery, placentas were
collected by the C-section from each enrolled woman and
immediately processed. Bioptic samples of VAT were also
collected from not pregnant obese and control women dur-
ing obstetric surgery (ovarian cysts). All patients and con-
trols gave their informed consent to the study and both
parents gave consent for their newborns. The study was
performed according to the Helsinki II Declaration and was
approved by the Ethics Committee of our Faculty.
Biochemical evaluations
The main serum biochemical parameters were evaluated
by routine assays. Leptin and adiponectin were measured in
maternal serum with Luminex xMAP Technology on a
BioRad Multiplex Suspension Array System (Bio-Rad), ac-
cording to the manufacturer’s instructions. The ratio leptin/
adiponectin (L/A) was also calculated.
Aminopeptidase N/CD13 ELISA assay
Aminopeptidase N (APN)/CD13 serum levels were
measured by ELISA (Life Science). Briefly, the microtiter
plate was precoated with a specific anti-CD13 antibody.
Standards or samples were then added to the appropriate
microtiter plate wells with a biotin-conjugated polyclonal
antibody preparation specific for CD13. Next, avidin conju-
gated to horseradish peroxidase was added to each micro-
plate well and incubated for 15min at room temperature. A
TMB substrate solution (3,3¢,5,5¢-tetramethylbenzidine) was
then added to each well. The enzyme-substrate reaction was
terminated by the addition of a sulfuric acid solution and the
color change was measured spectrophotometrically at a
wavelength of 450 nm. The amount of CD13 in each sample
was determined by comparing the absorbance of the sample
to a standard curve.
Cell isolation from placenta tissue
Placentas were collected and immediately processed, ac-
cording to Parolini et al. [24]. After removal of the maternal
decidua, the amnion was manually separated from the cho-
rion and extensively washed 5 times in 40mL of phosphate-
buffered saline (PBS) containing 100U/mL penicillin,
100 mg/mL streptomycin, and 250 mg/mL amphotericin B (all
from Sigma-Aldrich), after which, it was mechanically
minced into small pieces [24]. Amnion fragments were di-
gested overnight at 4C in the ACCUMAX reagent (In-
novative Cell Technology), a combination of DNase,
protease, and collagenolytic enzymes [25], containing 100U/
mL penicillin, 100 mg/mL streptomycin, and 250 mg/mL
amphotericin B. The next day, digestion enzymes were in-
activated with a complete culture medium constituted by the
low-glucose DMEM (Sigma-Aldrich) supplemented with
10% of heat-inactivated bovine serum (FBS), 1% of nones-
sential amino acids, and 2% of ultraglutamine (all from
Lonza). After centrifugation at 300 g for 10min, cell pellets
and digested tissue fragments were seeded in a cell culture
dish (BD Falcon) in the complete culture medium and incu-
bated at 37C in 5% CO2. One week later, digested tissue
pieces were removed from the dish and discarded, and iso-
lated cells formed distinct fibroblast colony-forming units.
When the colonies reached 70% confluence, they were wa-
shed with PBS and detached with trypsin/EDTA (Sigma-
Aldrich), counted, and reseeded in the complete medium for
expansion at a concentration of about 5,000/cm2 [24].
Cell preparation
hA-MSCs were expanded for several passages. The ab-
sence of mycoplasma contamination was assessed as de-
scribed previously [26]. The population doubling level was
calculated for each subcultivation with the following equa-
tion: population doubling = [log10 (NH) – log10 (NI)]/log10 (2),
where NI is the cell inoculum number and NH is the cell
harvest number [27]. The increase in population doubling
was added to the population doubling levels of the previous
passages to yield the cumulative population doubling level.
When 70%–80% confluent cultures reached about 4 popula-
tion doublings, they were detached with trypsin/EDTA, re-
suspended in PBS with 10% FBS, and processed for flow
cytometry, DNA, and RNA extraction. Cellular viability was
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Table 1. Surface Immunophenotypic Profile Investigated in Human Amniotic
Mesenchymal Stem Cells by Flow Cytometry
Fluorochrome
CD
antigen
Other
names
Molecular
weight (kDa)
Cell
expression Function
FITC CD9 Tspan-29 24–26 Platelets, pre-B cells, activated
T cells
Adhesion, migration,
platelet activation
APC CD10 CALLA 100 B/T precursors, stromal cells Endopeptidase
PE CD13 APN 150 Granulocytes, monocytes and
their precursors, endothelial
cells, epithelial cells,
mesenchymal stem cells
Metalloproteinase
PE CD14 LPS-R 53–55 Monocytes, macrophages Receptor for LPS/LPB
complex
APC CD15 Lewis X _ Granulocyte, monocyte,
epithelial cells
Cell adhesion
PE CD16 FCgRIIIa 50–65 Neutrophils, NK,
macrophages
Low affinity with FCg
receptor, mediates
phagocytosis
APC CD19 Bgp95 95 B cells, not on plasma cells Signal transduction
FITC CD26 DPP IV 110 Mature thymocytes, T, B,
NK cells
Exoprotease, costimulation
APC CD28 Tp44 44 Most T cells, thymocytes,
NK and plasma cells
Costimulation
APC CD29 VLA b1-chain 130 T, B, granulocytes, monocytes,
fibroblasts, endothelial cells,
NKs, platelet
Adhesion activation,
embryogenesis,
and development
FITC CD31 ECAM-1 130–140 Monocytes, platelets,
granulocytes, and
endothelial cells
Cell adhesion
APC CD33 My9 67 Monocytes, granulocytes,
mastocytes, and myeloid
progenitors
Cell adhesion
APC CD34 My10 105–120 Hematopoietic stem cells
and progenitors,
endothelial cells
Cell adhesion
APC CD36 Platelet GPIV 85 Platelets, monocytes,
macrophages, endothelial
cells, erythroid precursors
Adhesion and
phagocytosis
FITC CD40 Bp50 48 Monocytes, macrophages,
B cells, endothelial cells,
fibroblasts, keratinocytes
Costimulation to B cells,
growth, differentiation,
and isotype switching
APC CD44 H-CAM 90 Leukocytes, erythrocytes,
and epithelial cells
Rolling, homing,
and aggregation
Per Cp CD45 LCA 180–220 Hematopoietic cells, except
erythrocytes and platelets
Critical for T and B cell
receptor-mediated
activation
FITC CD47 IAP I 50–55 Hematopoietic, epithelial,
endothelial, and brain
mesenchymal cells
Adhesion
FITC CD49d VLA-4 150 B cells, T cells, monocytes,
eosinophils, basophils,
NKs, dendritic cells
Adhesion, migration,
homing, activation
APC CD54 ICAM-1 80–114 Epithelial and endothelial
cells monocytes. Low
on resting lymphocytes,
upregulate on activated
T cell activation
PE CD56 NCAM 175–220 Neural, tumors, embryonic
tissue, NK
Homophilic and
heterophilic adhesion
PE CD58 LFA-3 40–70 Leucocytes, erythrocytes,
epithelial endothelial
cells, and fibroblasts
Costimulation
FITC CD71 Transferrin
recepor
95 Reticulocytes, erythroid
precursor
Controls iron intake
during cell proliferation
APC CD81 TAPA-1 26 B and T cells, monocytes,
endothelial cells
Signal transduction
(continued)
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assessed by both Trypan blue dye exclusion and the analysis
of light scatter proprieties in flow cytometry, and it was
never lower than 90%.
Using the above cell isolation and preparation procedures,
h-MSCs were also isolated from the umbilical cord (hUC-
MSCs) of one obese and one control pregnant woman.
Isolation of hVAT-MSCs
Briefly, VAT bioptic samples were washed with PBS
containing 100U/mL penicillin, 100mg/mL streptomycin,
and 250mg/mL amphotericin B (all from Sigma-Aldrich),
minced into small pieces, and digested with 1.5mg/mL
collagenase type I (GIBCO) at 37C. The digestion enzymes
were inactivated with FBS. After centrifugation at 1500 g for
5min, cell pellets and digested tissue fragments were wa-
shed and seeded in a cell culture dish (BD Falcon) in the
complete culture medium and incubated at 37C in 5% CO2.
When the colonies reached 60%–70% confluence, they were
washed with PBS and detached with trypsin/EDTA (Sigma-
Aldrich), counted, and reseeded in the complete medium for
expansion at a concentration of about 5,000/cm2 [28].
DNA typing
The fetal origin of both amnion and hA-MSCs was verified
by DNA typing. Genomic DNA was extracted from the
mother’s peripheral blood, from amnion samples, and from
hA-MSCs using the Nucleon BACC2 extraction kit (Illustra
DNA Extraction Kit BACC2; GE Healthcare). The DNA
concentration was evaluated using the NanoDrop ND-1000
UV-Vis spectrophotometer (NanoDrop Technologies).
Genomic DNA (1 ng) was amplified in a final volume of
25 mL using the AmpFlSTR Identifiler PCR Amplification
Kit (Applied Biosystems). The AmpFlSTR Identifiler PCR
Amplification Kit is a short tandem repeat (STR) multiplex
assay that amplifies 15 repeat loci and the Amelogenin
gender determining marker in a single polymerase chain
reaction (PCR) amplification using a primer set labeled with
four fluorescent molecules. The amplification was performed
with the GeneAmp PCR System 9700 (Applied Biosystems)
instrument. PCR products were then analyzed by capillary
electrophoresis on the ABI Prism 3130 Genetic Analyzer
(Applied Biosystems) together with an allelic ladder, which
contained all the most common alleles for the analyzed loci
Table 1. (Continued)
Fluorochrome
CD
antigen
Other
names
Molecular
weight (kDa)
Cell
expression Function
FITC CD90 Thy-1 25–35 Hematopoietic stem cells,
neurons, mesenchymal
stem cells
Inhibition of hematopoietic
stem cells and neuron
differentiation
PE CD99 MIC2 32 Leucocyte, NK, monocytes,
endothelial and
epithelial cells
Leucocyte migration, T cell
activation, cell adhesion
PE CD105 Endoglin 90 Endothelial and mesenchymal
stem cells, erythroid
precursors, monocytes
Angiogenesis, modulates
cellular response
to TGFb1
PE CD117 c-kit 145 Hematopoietic stem cells
and progenitors
Crucial for hematopoietic
stem cells
PE CD133 Prominin-1 120 Hematopoietic stem cell,
endothelial, epithelial,
and neural precursors
Unknown function, stem
cell marker
PE CD151 PETA-3 32 Endothelial and epithelial
cells, megakaryocytes,
platelets
Adhesion
PE CD166 ALCAM 100–105 Neurons, activated
T cells, epithelial cells,
mesenchymal stem cells
Adhesion, T cell activation
PE CD200 OX-2 33 B cells, activated T cells,
thymocytes, neurons,
endothelium
Downregulatory signal for
myeloid cell functions
FITC CD243 MDR-1 170 Stem cells, multidrug-
resistant tumors
Influences the uptake,
distribution, elimination
of drugs
APC CD271 NGFR 75 Neurons, stromal and
dendritic follicular cells
Low affinity for
NGF receptor
APC CD324 E-cadherin 120 Epithelial, keratinocytes,
platelet
Adhesion, growth,
differentiation
APC CD338 ABCG-2 72 Hematopoietic stem cells,
liver, kidney, intestine, side
population of stem cells
Absorption and
excretion of xenobiotics
FITC HLA-ABC Class I MHC 46 All nucleated cells and platelets Antigen presentation
FITC HLA-DR Class II MHC 30 B cells, monocytes, myeloid
progenitors, activated
T and dendritic cells
Antigen presentation
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that were present in Caucasian populations and both a
negative- and a positive-quality control sample. Typically,
1mL of each sample was diluted in 18.7mL of deionized
formamide; each sample was supplemented with 0.3 mL of an
internal size standard (LIZ 500 Applied Biosystems) labeled
with an additional fluorophore. The samples were denatured
at 95C for 4min, and then placed in the auto sampler tray
(maximum of 96 samples) on the ABI Prism 3130 for auto-
matic injection in the capillaries. The data were analyzed by
Gene Mapper Software (Applied Biosystems).
Immunophenotyping of h-MSCs by flow cytometry
We analyzed the expression of 38 hematopoietic, mesen-
chymal, endothelial, epithelial, and no-lineage membrane
antigens on the surface of hA-MSCs, hUC-MSCs, and hVAT-
MSCs by four-color flow cytometry (Table 1). The antibody
cocktails contained in each tube are detailed in Supplementary
Table S1 (Supplementary Data are available online at www
.liebertpub.com/scd). All monoclonal antibodies (MoAbs)
were from Becton Dickinson (San Jose) except anti-CD338-
APC, which was from R&D (Minneapolis), anti-CD-133-PE
and anti-CD271-APCMoAbs, which were fromMilenyi Biotec
(Bergisch Gladbach). For all antibody staining experiments, at
least 1· 105 hA-MSCs isolated from each placenta samplewere
incubated at 4C for 20min with the appropriate amount of
MoAbs, washed twice with PBS, and finally analyzed with an
unmodified Becton-Dickinson FACSCanto II flow cytometer
(Becton-Dickinson), that was set up according to published
guidelines [29]. For each sample, the respective control was
prepared to determine the level of background cellular auto-
fluorescence without antibody staining.
CaliBRITE beads (Becton-Dickinson, catalog no. 340486)
were used as quality controls across the study as described
elsewhere [30,31], according to themanufacturer’s instructions.
Daily control of CaliBRITE intensity showed no change in in-
strument sensitivity throughout the study. The relative voltage
range for each detector was assessed una tantum using the
eight-peak technology (Rainbow Calibration Particles, Becton-
Dickinson, catalog no. 559123) at the beginning of the study.
Compensation was set in the FACS-DiVa (Becton-Dickinson)
software, and compensated samples were analyzed. Samples
were acquired immediately after staining using the FACSCanto
II instrument, and at least 10,000 events were recorded for each
monoclonal combination. Levels of CD antigen expressionwere
displayed as median fluorescence intensity (MFI). The FACS-
DiVa software (Becton-Dickinson) was used for cytometric
analysis.
Differentiation potential toward the adipogenic
lineage
hA-MSCs and hVAT-MSCs were cultured in the low-
glucose DMEM (Sigma-Aldrich) supplemented with 10% of
FBS, 2% of ultraglutamine, and 1% of nonessential amino acids
at 37C in 5% CO2 (all from Lonza). The cells were passaged
twice before the addition of the differentiation medium com-
posed of the DMEM with the addition of 10% FBS, 1mM
dexamethasone, 0.5mM 3-isobutyl-1-methylxhantine, 200mM
indomethacin, and 10mg/mL insulin. Media were changed
every 2 days and cells were either stained or collected for RNA
extraction.
CD13 RNA interference and overexpression
hA-MSCs plated at a density of 5,000 cells/cm2 were
transfected using 20 mL Lipofectamine 2000 according to the
manufacturer’s instructions (Invitrogen) with 8mg short
hairpin RNAs (shRNAs) expressing plasmids (Open Bio-
system) or with an 8mg pCMV-Sport 6 Vector (Invitrogen), to
silence or to overexpress CD13 mRNA, respectively. Trans-
fected cells were induced to differentiate toward the adipo-
genic lineage up to 4 days.
Effect of interferon-c on the expression
of CD13 on the surface of h-MSCs
The expression of CD13 on the surface of Co- and of Ob-h-
MSCs isolated from the amnion, umbilical cord, and VAT was
measured after exposure of cells to 0.8 and 12.5 ng/mL in-
terferon (IFN)-g at 37C for 24h, using untreated Co- and Ob-
h-MSCs as controls. At the end of incubation, the cells were
Table 2. Clinical and Biochemical Characteristics
of Obese and Normal Weight Control
Pregnant Women at Delivery and Their Newborns
A
Mother’s parameters
Ob-pregnant
women (n= 16)
Co-pregnant
women (n= 7)
Age (years) 32.6 (0.9) 30.7 (1.5)
Weight (kg)a 110.1 (5.4) 65.2 (3.6)
Height (m) 163.3 (1.6) 169.0 (1.7)
BMI prepregnancy (kg/m2)a 40.3 (1.8) 22.4 (1.0)
Weight gain in pregnancyb 8.4 (1.3) 14.3 (1.8)
Systolic blood pressure
(mmHg)
124.3 (2.7) 117.1 (5.1)
Diastolic blood pressure
(mmHg)c
82.5 (2.2) 74.2 (2.0)
Frequency cardiac 79.6 (1.7) 79.0 (3.7)
Gestational age 38.4 (0.3) 38.7 (0.2)
Glucose (mmol/L) 4.3 (0.1) 4.0 (0.3)
Total cholesterol (mmol/L) 6.9 (0.4) 7.3 (0.1)
Triglycerides (mmol/L) 2.8 (0.2) 2.3 (0.3)
AST (U/L) 15d (12.2–26.5d) 14.8 (0.7)
ALT (U/L) 13d (9.2–17.7d) 12.1 (1.1)
ALP (U/L) 124.2 (11.1) 115.0 (12.6)
GGT (U/L) 11.0 (1.7) 8.8 (1.5)
Leptin (L) (ng/mL)a 38.5 (2.2) 15.2 (3.3)
Adiponectin (A) (mg/mL) 6.0 (0.7) 7.5 (1.4)
L/Aa 7.7 (0.6) 2.6 (0.5)
B
Newborn features
Ob-newborns
(n= 16)
Co-newborns
(n = 7)
Birth weight (kg) 3162 (0.1) 3401 (0.1)
Length (cm) 49.6 (0.7) 50.8 (0.7)
Head circumference (cm) 34.0 (0.4) 34.8 (0.3)
Apgar 1¢ 7.0d (7.0–8.0d) 7.8 (0.2)
Apgar 5¢ 9.0d (8.5–9.0d) 8.7 (0.1)
Data are expressed as mean (SEM) (parametric distributions).
Statistically significant difference at the Student t test.
aP< 0.0001.
bP < 0.05.
cP< 0.05.
dMedian value and 25th–75th percentiles (nonparametric distri-
butions).
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harvested by trypsin, washed in PBS, counted, and adjusted to
the same concentrations of 1· 105 h-MSCs. Subsequently, their
immunophenotype was examined by flow cytometry.
Adipocyte staining
After 14 days of differentiation, the adipocyte cultures were
stained for lipid droplets, which are an index of differentia-
tion. The cells were washed in PBS and fixed in 10% formalin
for 1 h. Then, they were washed in PBS and the lipids were
stained for 15min with Oil Red O prepared by mixing vig-
orously three parts of a stock solution (0.5% Oil Red O in 98%
isopropanol) with two parts of water, and then eliminating
undissolved particles with a 0.4-mm filter. Cells were then
washed with water and the number of adipocytes was eval-
uated with a microscope. Relative lipid levels were assessed
Table 3. Immunophenotyping of Human Amniotic Mesenchymal Stem Cells
Isolated from Obese and Control Pregnant Women
Ob-hA-MSCs Co-hA-MSCs
Fluorochrome Antigen MFI 25th-75th Percentiles MFI 25th-75th Percentiles P value
Not expressed antigens
FITC CD31 364.0 278.3–511.3 306.5 286.8–368.0 0.3254
CD40 444.0 336.5–568.3 388.0 357.0–457.8 0.4824
CD243 363.0 292.3–528.3 307.5 274.0–378.3 0.2061
HLA-DR 355.0 283.8–530.0 297.0 272.5–374.8 0.2415
NC 325.0 250.0–516.3 279.0 218.8–418.8 0.4260
PE CD14 166.5 125.5–197.8 134.5 124.5–157.8 0.2815
CD16 36.0 11.5–71.7 65.5 50.5–72.0 0.2407
CD117 142.5 109.5–189.3 121.0 116.0–176.8 0.6065
CD133 95.5 80.5–112.8 87.5 76.50–110.5 0.5423
NC 115.5 91.75–181.5 102.5 93.25–135.0 0.5427
APC CD15 122.0 91.0–283.5 122.5 80.0–162.5 0.6065
CD36 241.5 194.0–388.5 200.5 145.5–267.3 0.2417
CD271 208.0 127.0–296.5 170.0 127.5–233.3 0.6065
CD338 200.5 106.5–373.0 107.5 101.8–146.8 0.1223
CD19 192.0 154.0–241.3 144.0 120.3–182.2 0.1012
CD28 91.0 5.2–228.5 85.5 0–122.0 0.1722
CD33 147.5 10.0–189.5 105.5 90.0–132.3 0.6734
CD34 186.5 105.0–241.5 133.0 17.5–206.0 0.4250
NC 169.0 99.5–244.8 92.0 64.0–204.0 0.2061
Per Cp CD45 215.5 133.8–251.3 167.0 146.0–208.0 0.6734
NC 305.0 252.0–483.3 288.5 261.3–348.8 0.7431
Expressed antigens
FITC CD9 3,538.0 2,172.0–6,871.0 2,156.0 1,743.0–3,495.0 0.2417
CD26 1,287.0 651.8–3,235.0 1,308.0 742.3–1,920.0 0.9626
CD47 1,339.0 980.3–2,312.0 1,287.0 1,106.0–1,344.0 0.4824
CD49d 1,185.0 946.8–1,393.0 941.0 708.3–1,140.0 0.2061
CD71 1,271.0 796.5–2,147.0 1,093.0 897.0–1,538.0 0.7431
CD90 37,140.0 22,740.0–52,690.0 36,210.0 21,640.0–50,260.0 0.8149
CD324 517.0 463.0–551.0 436.0 375.0–545.0 0.3027
HLA-ABC 9,363.0 4,033.0–14,180.0 5,424.0 3,987.0–6,539.0 0.1223
NC 325.0 250.0–516.3 279.0 218.8–418.8 0.4260
PE CD13 9,802.0 6,786.0–17,130.0 3,950.0 3,634.0–4,961.0 0.0043a
CD56 496.0 293.8–711.0 528.0 151.0–1,048.0 0.9626
CD58 2,432.0 1,723.0–2,792.0 2,009.0 1,798.0–2,459.0 0.5427
CD99 405.0 296.5–586.3 467.5 360.5–651.0 0.3736
CD105 652.0 507.0–1,329.0 790.0 746.0–847.8 0.6734
CD151 16,010.0 10,970.0–21,430.0 19,410.0 11,090.0–23,690.0 0.4260
CD166 5,215.0 3,551.0–7,382.0 4,634.0 3,962.0–5,608.0 0.6734
CD200 722.5 205.8–1,699.0 1,137.0 631.5–1,444.0 0.3736
NC 115.5 91.7–181.5 102.5 93.2–135.0 0.5427
APC CD10 1,247.0 999.3–2,319.0 1,890.0 1,122.0–3,031.0 0.3736
CD29 45,150.0 25,130.0–54,610.0 24,240.0 17,660.0–40,000.0 0.0832
CD44 11,440.0 8,186.0–16,290.0 7,259.0 6,613.0–9,753.0 0.0678
CD54 9,910.0 5,404.0–14,260.0 10,660.0 9,486.0–24,670.0 0.3736
CD81 31,240.0 19,110.0–55,050.0 38,890.0 24,500.0–44,640.0 0.8149
NC 169.0 99.5–244.8 92.0 64.0–204.0 0.2061
aSignificant P value at the Mann–Whitney test.
hA-MSC, human amniotic mesenchymal stem cells; MFI, median fluorescence intensity.
2292 IAFFALDANO ET AL.
by redissolving the Oil Red O present in stained cells in 98%
isopropanol, and then determining absorbance at 550nm.
RNA isolation
Total RNA was purified from hA-MSCs isolated from
term placentas of Co- and of Ob-pregnant women using the
mirVana miRNA isolation kit (Ambion) and its concen-
tration was evaluated with the NanoDrop ND-1000 UV-Vis
spectrophotometer (NanoDrop Technologies).
Quantitative real-time PCR of mRNAs
Real-time quantitative PCR (qRT-PCR) was carried out on
the Applied Biosystems 7900HT Sequence Detection system
(Applied Biosystems). cDNAs were synthesized from 2mg of
total RNA using hexamer random primers and M-MuLV
Reverse Transcriptase (New England BioLabs). The PCR was
performed in a 20mL final volume containing cDNA, 1· SYBR
Green PCR mix, and 10mM of each specific primer. Supple-
mentary Table S2 lists the oligonucleotide primers used for
PCR of selected genes: peroxisome proliferator-activated re-
ceptor gamma (PPARg), CD13, protein homologous to myelin
P2 (aP2), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). The PCR conditions for reverse transcription were
stage 1: 50C, 2min; stage 2: 95C, 10min; stage 3: 95C, 15 s;
60C, 1min/40 cycles; and stage 4: 95C, 15 s; 60C, 1min.
Levels of target genes were quantified using specific oligo-
nucleotide primers and normalized for GAPDH expression.
Statistical analysis
The parameters investigated were expressed as mean and
standard error of the mean (SEM) (parametric distributions) or
as the median value and 25th and 75th percentiles (nonpara-
metric distributions). The Student’s t and Mann–Whitney tests
were used to compare parametric and nonparametric data,
respectively. P values< 0.05 were considered statistically sig-
nificant. Correlation analysis was performed with the SPSS
package for Windows (ver. 18; SPSS, Inc.).
Results
The clinical and biochemical characteristics of the mothers
and their newborns are reported in Table 2 (A and B, re-
spectively). Weight gain was lower (P < 0.05) and diastolic
blood pressure was higher (P< 0.05) in Ob- than in Co-
pregnant women. Both the leptin concentration (P < 0.0001)
and the L/A ratio (P < 0.0001) were higher in Ob- than in Co-
pregnant women at delivery. Biometric characteristics did
not differ significantly between Ob- and Co-newborns.
Isolation of hA-MSCs
We isolated hA-MSCs from the mesenchymal layer of
amniotic membranes obtained from our Ob- and Co-pregnant
women at delivery. The fetal origin of all isolated hA-MSCs
was confirmed by STR typing of DNA of the mother and of
the hA-MSCs. Mycoplasma contamination of cultures was
checked and excluded (data not shown). All isolated hA-
MSCs were characterized by a high proliferation potential
and collected after four population doublings. Morphologi-
cally, cultured Ob- and Co-hA-MSCs showed a similar fi-
broblastic-like morphology after four population doublings
(Supplementary Fig. S1).
Immunophenotyping of h-MSCs
The antigenic mosaic displayed by Ob- and Co-hA-MSCs
is shown in Table 3. Seventeen of the 38 antigens investigated
were not expressed on the surface of hA-MSCs (hematopoietic
antigens: CD14, CD15, CD16, CD19, CD28, CD33, CD34,
CD45, and CD117; the endothelial marker PECAM-1/CD31;
and no-lineage markers: thrombospondin receptor/CD36,
Bp50/CD40, Prominin-1/CD133, MDR-1/CD243, NGFR/
CD271, ABCG-2/CD338, and HLA-DR). Both Ob- and Co-
hA-MSCs were positive for the following mesenchymal
markers: CD9, CD10, CD13, CD26, CD29, CD44, CD47,
CD49d, CD54, CD56, CD58, CD71, CD81, CD90, CD99,
CD105, CD151, CD166, CD200, and HLA-ABC. A very weak
positivity for the epithelial antigen E-cadherin/CD324 was
FIG. 1. Expression of CD13 antigen in control (Co-) and obese (Ob-) pregnant women. (A) Ob-Human amniotic mesen-
chymal stem cells (hA-MSCs) expressed significantly higher amounts (at Mann–Whitney test) of CD13 surface antigen
compared with Co-hA-MSCs (P< 0.005); (B) serum levels of CD13 were significantly higher both in Ob- than in Co-not
pregnant women (P < 0.05) and in Ob- than in Co-women at delivery (P < 0.005); (C) serum CD13 levels were correlated with
CD13 surface expression levels in Ob-pregnant women (r2= 0,84; P < 0.0001). The box plots provide a vertical view of the data
expressed as median, 25th percentile, 75th percentile, and extreme values.
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also observed. Interestingly, CD13 expression was signifi-
cantly higher in Ob-hA-MSCs than in Co-hA-MSCs, that is,
MFI: 9,802.0 and 3,950.0, respectively (P< 0.005) (Table 3
and Fig. 1A). The immunophenotype characterization con-
firmed the mesenchymal origin and the higher CD13 ex-
pression in hVAT-MSCs and hUC-MSCs from Ob- than from
Co-women (hVAT-MSCs - MFI: 8,200.0 vs. 1,100.0 and hUC-
MSCs - MFI: 4,965.0 vs. 3,155.0, respectively).
APN/CD13 serum levels
We first measured baseline serum levels of CD13 in a
small group of not pregnant obese and normal weight wo-
men and found significantly higher values in the obese
subset (medians: 6.00 and 1.00U/L, P< 0.05, respectively)
(Fig. 1B). The serum levels of CD13 were also significantly
higher in Ob- than in Co-pregnant women at delivery (me-
dians: 24.00 and 7U/L, P < 0.005, respectively), (Fig. 1B).
CD13 levels were significantly higher in Ob- and Co-preg-
nant women than in not pregnant Ob- and Co-women: four
(P < 0.0005) and seven times (P < 0.005), respectively. Fur-
thermore, in Ob-pregnant women, serum CD13 levels were
significantly correlated to the levels of CD13 on the surface of
hA-MSCs (r2 = 0.84; P < 0.0001) (Fig. 1C).
CD13 h-MSC expression and adipogenic
differentiation
To investigate whether CD13 is involved in adipogenesis,
we cultured Ob- and Co-hA-MSCs for 14 days in the adi-
pogenic induction medium. At the end of incubation, the
adipogenic potential, as measured by PPARg and aP2
mRNA levels, was higher in Ob- than in Co-hA-MSCs. In
fact, as shown in Fig. 2A and B, the mean RQs at day 14 were
0.04 and 0.02, respectively, for PPARg (P < 0.05), and 0.02 and
0.01, respectively, for aP2 (P < 0.05). The same results were
obtained with Oil Red staining; in fact, staining was more
intense in Ob- than in Co-hA-MSCs at day 14 of differenti-
ation [Abs (550 nm) = 0.6 and 0.4, P < 0.05, respectively] (Fig.
2C). During adipogenesis, CD13 mRNA levels remained
higher in Ob- than in Co-hA-MSCs. CD13 silencing by
shRNA in Ob-hA-MSCs resulted in a switch-off of CD13
mRNA expression, as evaluated by RT-PCR (Fig. 3A), and at
the same time, the adipogenic potential of these cells did not
differ from that observed in Co-hA-MSCs, as shown by sim-
ilar PPARg mRNA levels measured in silenced Ob-hA-MSCs
and in Co-hA-MSCs (P= 0.71) (Fig. 3B). In agreement to CD13
involvement in adipogenesis, we overexpressed CD13 in Co-
hA-MSCs (mRNA CD13 mean RQ= 7.23) and observed at day
4 of differentiation that PPARg mRNA levels were higher in
treated (mean RQ= 0.015) than in untreated (mean RQ= 0.001)
Co-hA-MSCs. The adipogenic potential at day 14 was also
higher in Ob- than in Co-hVAT-MSCs isolated from not
pregnant women [aP2: RQs were 0.050 and 0.036; Oil Red O
Abs (550nm): 0.559 and 0.437, respectively].
Upregulation of CD13 h-MSC expression by IFN-c
We next evaluated if CD13 expression could be upregu-
lated in h-MSCs by IFN-g as occurs in murine cellular models
[32]. To this aim, we treated the Co- and Ob-hA-MSCs with
0.8 ng/mL or 12.5 ng/mL IFN-g for 24 h. We found that
CD13 expression was significantly higher on membranes of
Co-hA-MSCs treated with 12.5 ng/mL IFN-g (P < 0.05) than
in untreated cells, whereas there was a slight, not significant,
increase in treated Ob-hA-MSCs (Supplementary Fig. S2)
versus the untreated counterpart cells. In addition, IFN-g
treatment (12.5 ng/mL at 37C for 24 h) induced the increase
of CD13 membrane expression in hVAT-MSCs (Ob- and Co-
MSCs: 39% and 8%, respectively), and in Co-hUC-MSCs (4%)
versus the untreated counterpart cells, but not in Ob-hUC-
MSCs. Our results suggest that high levels of INF-g drive
FIG. 2. Adipogenic potential in Ob-hA-MSCs and in Co-
hA-MSCs. The statistically significant higher mRNA ex-
pression levels of PPARg (P < 0.05) (A) and of aP2 (P < 0.05)
(B) measured 14 days after the adipogenic induction, indi-
cated increased adipogenesis in Ob- versus Co-hA-MSCs. (C)
The higher adipogenesis in Ob- than in Co-hA-MSCs was
also confirmed by Oil Red staining [Abs (550 nm) = 0.6 and
0.4, P < 0.05, respectively].
2294 IAFFALDANO ET AL.
the upregulation of CD13 expression in Co-h-MSCs, irre-
spective of their source and of pregnancy, whereas its
effect on Ob-h-MSC CD13 expression during obesity is
ambiguous.
Discussion
Human amniotic membrane is a readily available source
of abundant fetal MSCs that are free from ethical concerns
[33]. hA-MSCs isolated from normal weight healthy women
at delivery have been characterized [24,34,35], but, to our
knowledge, the features of hA-MSCs from obese women are
largely unknown. In this study, we used flow cytometry to
characterize hA-MSCs isolated at delivery from two groups
of women: prepregnancy normal weight and prepregnancy
severely obese women. The immunophenotypic character-
ization confirmed the mesenchymal origin of the isolated
cells [36]. In particular, the distribution of CD56 was in
agreement with the placental origin of the isolated hA-MSCs.
In fact, this marker is absent from bone marrow [34] and
from adipose tissue-derived mesenchymal stem cells [37].
Similarly, the endothelial marker PECAM-1/CD31, and the
hematopoietic antigens CD14, CD15, CD16, CD19, CD28,
CD33, CD34, CD45, and CD117 were absent from isolated
Ob- and Co-hA-MSCs. Staining for the E-cadherin/CD324
epithelial antigen was very weak in our Ob- and Co-hA-MSC
preparations; the coexpression of epithelial, although at a
low intensity, and mesenchymal markers on our hA-MSCs
was in agreement with previous findings [38,39]. Overall,
our results are similar to those reported by Parolini et al. [24]
and/or Roubelakis [35] regarding the expressed (CD49d,
CD90, HLA-ABC, CD13, CD56, CD105, CD166, CD10, CD29,
CD44, and CD54) and not expressed (PECAM-1/CD31,
HLA-DR, CD14, Prominin-1/CD133, NGFR/CD271, CD34,
and CD45) membrane-bound antigens in hA-MSCs. We
found that the Ob-hA-MSC immunophenotype is character-
ized by a significantly higher expression of the APN/CD13
antigen with respect to the Co-hA-MSC phenotype. Besides
amnion, CD13 was overexpressed in h-MSCs isolated from
the umbilical cord in obese women and in those isolated
from VAT in not pregnant obese women.
Type II metalloprotease APN/CD13 (EC. 3.4.11.2) is a
heavily glycosylated membrane-bound protein (*960aa,
*150kDa) that is encoded by the human ANPEP gene located
on chromosome 15 (q25-q26) [40]. This protein exists also in a
soluble form. APN/CD13 is a ubiquitous enzyme present in a
wide variety of humanorgans, tissues, and cell types, including
the placenta, human umbilical vein endothelial cells, mono-
cytes, lymphocytes T, hypothalamus, and epithelial intestinal
cells [41]. It has various mechanisms of action: enzymatic
cleavage of peptides, endocytosis, and signal transduction [42].
APN/CD13 is involved in inflammation, cellular differentia-
tion and proliferation, apoptosis, cell adhesion, and motility
[42]. Dysregulated expression of membrane and/or soluble
forms of APN/CD13 has been observed in many diseases [43],
but until now, it has never been associated with obesity. Here
we provide the first demonstration that the CD13 antigen is
increased on hA-MSCs during obesity and could play a role in
adipogenesis. In fact, we first detected a higher adipogenic
potential in Ob- than in Co-hA-MSCs after 14 days of adipo-
genic differentiation, and then observed that the adipogenic
potential of Ob-hA-MSCs was comparable to that of Co-hA-
MSCs after CD13 silencing. Conversely, the adipogenic po-
tential increased in Co-hA-MSCs after CD13 overexpression.
Furthermore, we provide evidence that INFg upregulated
CD13 expression in Co-hA-MSCs.
FIG. 3. Role of CD13 in
adipogenesis. (A) mRNA ex-
pression levels of CD13 were
significantly higher in Ob-
than in Co-hA-MSCs at day 0
(P < 0.05), day 2 (P < 0.05),
and day 4 (P < 0.05) when
cultured with the adipogenic
medium. CD13 mRNA ex-
pression was switched-off in
Ob-hA-MSCs after CD13 si-
lencing with shRNA. (B) At
day 4 of adipogenic induction,
PPARg mRNA expression
levels that were significantly
higher in Ob-hA-MSCs than
in Co-hA-MSCs (P< 0.02), de-
creased to the levels detected
in Co-hA-MSCs after CD13
silencing (P= 0.71), which in-
dicates that CD13 enhances
adipogenesis in hA-MSCs.
n.s.: not statistically signifi-
cant difference.
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Intriguingly, in Ob-pregnant women, APN/CD13 serum
levels at delivery were higher than in Co-pregnant women
and correlated with CD13 surface Ob-hA-MSC expression
(r2 = 0.84, P< 0.0001), which support the hypothesis that the
placenta is the major source of the high CD13 levels mea-
sured in maternal serum [44]. We also found that the leptin
concentration and the L/A ratio were increased in Ob-ma-
ternal serum at delivery. This finding confirms the concept
that these two parameters are obesity risk markers [45,46].
In conclusion, this characterization of Ob-hA-MSCs shows
that antigen CD13, by influencing the adipogenic potential of
these cells, could be an in utero risk factor for obesity. Our
data strengthen the hypothesis that high serum CD13 and
mesenchymal stem cell CD13 are markers of obesity.
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